UMAP 1,UMAP 2,index,Metadata_SMILES,Metadata_BROAD_ID,Scaffold,Var1,Metadata_moa.x
10.2841,2.8203998,0,CC(C)NCC(O)COc1ccccc1CC=C,BRD-A00993607,c1ccccc1,BRD-A00993607,adrenergic receptor antagonist
9.27535,5.1972823,1,CCC(C(CC)c1ccc(O)cc1)c2ccc(O)cc2,BRD-A01078468,c1ccc(CCc2ccccc2)cc1,BRD-A01078468,synthetic estrogen
8.31,5.343038,2,CCCN(C/C=C/I)C1CCc2ccc(O)cc2C1,BRD-A01295252,c1ccc2c(c1)CCCC2,BRD-A01295252,dopamine receptor ligand
10.619183,4.1873255,3,CCCCN1CCCCC1C(=O)Nc2c(C)cccc2C,BRD-A01636364,O=C(Nc1ccccc1)C1CCCCN1,BRD-A01636364,sodium channel blocker
2.5236006,0.7515621,4,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)C=CC4(C)C3[C@@H](O)C[C@@]21C,BRD-A01643550,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A01643550,glucocorticoid receptor agonist
10.529804,3.0935113,5,COc1ccccc1N2CCN(CC(O)COc3cccc4ccccc34)CC2,BRD-A01787639,c1ccc(N2CCN(CCCOc3cccc4ccccc34)CC2)cc1,BRD-A01787639,adrenergic receptor antagonist
11.0036745,3.5272558,6,CCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+](=O)[O-])C(=O)OC)C,BRD-A02006392,C1=CC(c2ccccc2)C=CN1,BRD-A02006392,calcium channel blocker
10.089452,5.4994326,7,CC(=C)C1Cc2c(O1)ccc(C(=O)O)c2O,BRD-A02176148,c1ccc2c(c1)CCO2,BRD-A02176148,mitochondrial complex i inhibitor
4.261955,0.93830144,8,C[C@@]12CCC3C(CCc4cc(O)ccc34)C2CC[C@@]1(O)C#C,BRD-A02367930,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A02367930,estrogen receptor agonist|estrogenic component in oral contraceptives
9.427628,4.912915,9,CCC1(CCCCN(C)C1)c2cccc(O)c2,BRD-A02710418,c1ccc(C2CCCCNC2)cc1,BRD-A02710418,opioid receptor agonist
10.258716,2.845796,10,CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1,BRD-A02759312,c1ccc(CCOCC2CC2)cc1,BRD-A02759312,adrenergic receptor antagonist
10.647139,4.224402,11,CN1CCCCC1C(=O)Nc2c(C)cccc2C,BRD-A03216249,O=C(Nc1ccccc1)C1CCCCN1,BRD-A03216249,potassium channel blocker|sodium channel blocker
10.249729,2.8146012,12,COCCc1ccc(OCC(O)CNC(C)C)cc1,BRD-A03623303,c1ccccc1,BRD-A03623303,adrenergic receptor antagonist
13.80557,6.045501,13,C[N+]1(C)C2CC(CC1C3OC32)OC(=O)[C@@H](CO)c4ccccc4,BRD-A03932035,O=C(Cc1ccccc1)OC1CC2[NH2+]C(C1)C1OC21,BRD-A03932035,acetylcholine receptor antagonist
10.66944,8.076424,14,Oc1cc2C(CN(CC=C)CCc2c(Cl)c1O)c3ccccc3,BRD-A04438777,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A04438777,dopamine receptor agonist
12.443401,4.9702454,15,CN(C)CCC(c1ccc(Cl)cc1)c2ccccn2,BRD-A04553218,c1ccc(Cc2ccccn2)cc1,BRD-A04553218,histamine receptor antagonist
9.695207,4.909159,16,CCOC(OCC)P(=O)(O)CCCNCc1ccc(Cl)c(Cl)c1,BRD-A04668240,c1ccccc1,BRD-A04668240,gaba receptor antagonist
10.642788,4.6340275,17,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,BRD-A05186015,c1ccccc1,BRD-A05186015,dopamine uptake inhibitor
10.985253,3.5124454,18,COC(=O)C1=C(C)NC(=C(C1c2ccccc2C(F)(F)F)[N+](=O)[O-])C,BRD-A05457250,C1=CC(c2ccccc2)C=CN1,BRD-A05457250,l-type calcium channel activator
12.160874,6.322998,19,CC(C)(C)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,BRD-A06352418,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1,BRD-A06352418,histamine receptor antagonist
8.80223,4.575273,20,CCCC(=O)Nc1nc2n(cnc2c(=O)[nH]1)C3O[C@H]4COP(=O)(O)O[C@@H]4[C@@H]3OC(=O)CCC,BRD-A06726973,O=c1[nH]cnc2c1ncn2C1CC2O[PH](=O)OCC2O1,BRD-A06726973,cgmp analog
8.295383,3.5372002,21,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]3(C)C2[C@H](O)C[C@H]4/C(=C(/CCC=C(C)C)\\C(=O)O)/[C@H](C[C@@]43C)OC(=O)C,BRD-A06935312,C=C1CCC2C1CCC1C3CCCCC3CCC21,BRD-A06935312,bacterial 30s ribosomal subunit inhibitor
7.7159276,5.5021205,22,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC,BRD-A07207424,O=C1NCC(Cc2ccccc2)N1,BRD-A07207424,phosphodiesterase inhibitor
9.507593,3.8520935,23,CC(CCc1ccccc1)NCC(O)c2ccc(O)c(c2)C(=O)N,BRD-A07440155,c1ccc(CCCNCCc2ccccc2)cc1,BRD-A07440155,adrenergic receptor antagonist
8.593285,7.417034,24,O=C1CC(Oc2ccccc12)c3ccccc3,BRD-A07824748,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A07824748,11-beta hydroxysteroid dehydrogenase inhibitor
12.139223,7.3670874,25,CSc1ccc2Sc3ccccc3CC(N4CCN(C)CC4)c2c1,BRD-A07932845,c1ccc2c(c1)CC(N1CCNCC1)c1ccccc1S2,BRD-A07932845,anti-hcve2
10.090797,4.219924,26,CCC(C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@@H](N)CS,BRD-A07952294,c1ccccc1,BRD-A07952294,farnesyltransferase inhibitor
10.533649,4.8786793,27,CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc2ccccc2,BRD-A08187463,O=C(CCc1ccccc1)NCC(=O)OCc1ccccc1,BRD-A08187463,enkephalinase inhibitor
9.489633,5.6475425,28,CO[C@H](C)C(O)(C(C)C)C(=O)OCC1=CCN2CC[C@H](O)[C@H]21,BRD-A08709697,C1=CC2CCCN2C1,BRD-A08709697,pyrrolizidine alkaloid
8.211809,5.262237,29,COc1cc2nc(nc(N)c2cc1OC)N(C)CCCNC(=O)C3CCCO3,BRD-A09056319,O=C(NCCCNc1ncc2ccccc2n1)C1CCCO1,BRD-A09056319,adrenergic receptor antagonist
10.723513,4.6448073,30,CCC(C)(CN(C)C)OC(=O)c1ccccc1,BRD-A09062839,c1ccccc1,BRD-A09062839,local anesthetic
11.677465,3.8585837,31,CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc2ccc(OC)cc2,BRD-A09467419,O=C(OCCCCNCCc1ccccc1)c1ccccc1,BRD-A09467419,acetylcholine receptor antagonist
11.731099,3.2837846,32,FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2,BRD-A09472452,O=C(NCC1CCCCN1)c1ccccc1,BRD-A09472452,sodium channel blocker
7.693489,5.3477883,33,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2ccc(OC)c(OC)c2)cc1OC,BRD-A09533288,c1ccc(CCCCNCCc2ccccc2)cc1,BRD-A09533288,calcium channel blocker
13.613537,6.1446123,34,CN1C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c3ccccc3,BRD-A09539288,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-A09539288,acetylcholine receptor antagonist
9.715693,3.7597666,35,CCNCC(O)c1cccc(O)c1,BRD-A09925278,c1ccccc1,BRD-A09925278,adrenergic receptor agonist
10.929067,7.390972,36,CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O,BRD-A10420615,O=C1CC(=O)N2CC3Cc4cccc5[nH]cc(c45)C3C12,BRD-A10420615,atpase inhibitor
11.933823,3.1709325,37,CCN1CCC(CNC(=O)c2cc(ccc2OC)S(=O)(=O)N)C1,BRD-A10715913,O=C(NCC1CCNC1)c1ccccc1,BRD-A10715913,dopamine receptor antagonist
10.444138,3.0305464,38,COc1ccccc1OCCNCC(O)COc2cccc3[nH]c4ccccc4c23,BRD-A10977446,c1ccc(OCCNCCCOc2cccc3[nH]c4ccccc4c23)cc1,BRD-A10977446,adrenergic receptor antagonist
8.051355,5.612096,39,COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc3CCC(NC(=O)C)c4cc(=O)c(SC)ccc4-c3c1OC,BRD-A11605036,O=c1cccc2c(c1)CCCc1cc(OC3CCCCO3)ccc1-2,BRD-A11605036,gaba receptor antagonist
13.409859,3.8068714,40,Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1,BRD-A11776908,c1ccc(CCn2ccnc2)cc1,BRD-A11776908,sterol demethylase inhibitor
10.036299,3.1613941,41,CN(CCc1ccc(Cl)c(Cl)c1)CC(O)COc2ccc(NS(=O)(=O)C)cc2,BRD-A11813248,c1ccc(CCNCCCOc2ccccc2)cc1,BRD-A11813248,potassium channel blocker
13.593834,6.2127585,42,CN1C2CCC1CC(C2)NC(=O)c3nn(C)c4ccccc34,BRD-A12016240,O=C(NC1CC2CCC(C1)N2)c1n[nH]c2ccccc12,BRD-A12016240,serotonin receptor antagonist
1.5261462,0.7015014,43,C[C@H]1CC2C3CC[C@](O)(C(=O)C)[C@@]3(C)C[C@H](O)[C@]2(F)C4(C)C=CC(=O)C=C14,BRD-A13133631,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A13133631,glucocorticoid receptor agonist
10.765328,10.072349,44,Cc1onc(c1C(=O)N[C@H]2[C@H]3SC(C)(C)C(N3C2=O)C(=O)O)c4c(F)cccc4Cl,BRD-A13650332,O=C(NC1C(=O)N2CCSC12)c1conc1-c1ccccc1,BRD-A13650332,bacterial cell wall synthesis inhibitor
9.756054,5.3840184,45,CC/1=C(CC(=O)O)c2cc(F)ccc2\\C1=C/c3ccc(cc3)S(=O)C,BRD-A13946108,C1=Cc2ccccc2C1=Cc1ccccc1,BRD-A13946108,cyclooxygenase inhibitor
12.619846,7.4247756,46,CN1CCCCC1CCN2c3ccccc3Sc4ccc(cc24)S(=O)C,BRD-A14395271,c1ccc2c(c1)Sc1ccccc1N2CCC1CCCCN1,BRD-A14395271,dopamine receptor antagonist
1.53344,0.7088977,47,CC(=O)OCC(=O)[C@]12OC(C)(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@@]31C,BRD-A15297126,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-A15297126,glucocorticoid receptor agonist
10.832182,5.3290343,48,OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c3ccc(Cl)cc3,BRD-A15909516,O=C(NCCc1cc(=O)[nH]c2ccccc12)c1ccccc1,BRD-A15909516,free radical scavenger
11.111733,5.1829,49,NC(=O)CS(=O)C(c1ccccc1)c2ccccc2,BRD-A16332958,c1ccc(Cc2ccccc2)cc1,BRD-A16332958,adrenergic receptor agonist
13.412074,3.801435,50,Clc1ccc(CCC(Cn2ccnc2)Sc3c(Cl)cccc3Cl)cc1,BRD-A16665823,c1ccc(CCC(Cn2ccnc2)Sc2ccccc2)cc1,BRD-A16665823,bacterial cell wall synthesis inhibitor
11.5622225,6.444078,51,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC3COc4ccccc4O3,BRD-A17453586,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,BRD-A17453586,serotonin receptor agonist
9.736251,3.5080261,52,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(c1)C(O)CNC(C)(C)C,BRD-A17462676,c1ccccc1,BRD-A17462676,adrenergic receptor agonist
10.449079,7.409779,53,CN1C[C@@]2(C=C)C3CC4OC[C@@H]3[C@@H]1[C@H]2[C@@]45C(=O)Nc6ccccc65,BRD-A17535965,O=C1Nc2ccccc2C12C1CC3C(CO1)C1NCC3C12,BRD-A17535965,acetylcholine receptor antagonist
9.463459,4.5901513,54,CC(C)Cc1ccc(cc1)C(C)C(=O)O,BRD-A17655518,c1ccccc1,BRD-A17655518,cyclooxygenase inhibitor
9.591236,7.0801344,55,CC1(C)C=CC(=O)[C@@]2(C)C1CC(=O)[C@]3(C)C2CC[C@@]4(C)[C@@H](OC(=O)C5OC543)c6ccoc6,BRD-A17819071,O=C1C=CCC2CC(=O)C3C(CCC4C(c5ccoc5)OC(=O)C5OC543)C12,BRD-A17819071,hsp inhibitor
9.410028,5.7969584,56,Cc1c(C)c2OC(C)(CCc2c(C)c1O)C(=O)O,BRD-A17846016,c1ccc2c(c1)CCCO2,BRD-A17846016,antioxidant
10.461187,7.747776,57,CN1C(=O)CC(C1=O)c2ccccc2,BRD-A18043272,O=C1CC(c2ccccc2)C(=O)N1,BRD-A18043272,succinimide antiepileptic
9.168093,4.8244867,58,Nc1ncnc2n(cc(I)c12)C3OC(CO)C(O)C3O,BRD-A18497530,c1ncc2ccn(C3CCCO3)c2n1,BRD-A18497530,adenosine kinase inhibitor|nucleoside transporter inhibitor
9.243678,5.9307604,59,CN(C)CC(O)Cn1c2ccc(Br)cc2c3cc(Br)ccc13,BRD-A18579359,c1ccc2c(c1)[nH]c1ccccc12,BRD-A18579359,neural wiskott-aldrich syndrome protein inhibitor
4.3514686,0.99276894,60,C[C@@]12CCC3C(CCc4cc(O)ccc34)C2C[C@@H](O)[C@@H]1O,BRD-A18620900,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A18620900,estrogen receptor agonist
4.365168,0.9490359,61,C[C@@]12CCC3C(CCc4cc(O)ccc34)C2CC[C@@H]1O,BRD-A18917088,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A18917088,estrogen receptor agonist
9.499526,6.300063,62,CN1C2CCCC1CC(=O)C2,BRD-A19053259,O=C1CC2CCCC(C1)N2,BRD-A19053259,anthelmintic
12.613609,6.9396358,63,CC(CN(C)C)CN1c2ccccc2CCc3ccccc13,BRD-A19195498,c1ccc2c(c1)CCc1ccccc1N2,BRD-A19195498,norepinephrine reuptake inhibitor|tricyclic antidepressant
11.931193,7.3039927,64,CN1CCN2C(C1)c3ccccc3Cc4ccccc24,BRD-A19661776,c1ccc2c(c1)Cc1ccccc1N1CCNCC21,BRD-A19661776,serotonin receptor antagonist
10.463111,7.2168145,65,Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,BRD-A19736161,O=C1c2c([nH]c3ccccc23)CCC1Cn1ccnc1,BRD-A19736161,serotonin receptor antagonist
10.175035,7.3930087,66,Clc1ccc(cc1)[C@H]2CC[C@@H](CC2)C3C(=O)C(=O)c4ccccc4C3=O,BRD-A19795905,O=C1C(=O)C(C2CCC(c3ccccc3)CC2)C(=O)c2ccccc21,BRD-A19795905,mitochondrial electron transport inhibitor
3.2503738,1.0808177,67,C[C@H]1CC2C3CC[C@H](C(=O)C)[C@@]3(C)C[C@H](O)C2[C@@]4(C)CCC(=O)C=C14,BRD-A20126139,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A20126139,glucocorticoid receptor agonist
8.925751,4.8652654,68,CC1(C)[C@@H](O)CC[C@@]2(C)C1CC[C@]3(C)C2C(=O)C=C4[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@]43C)C(=O)O,BRD-A20200672,O=C1C=C2C3CCCCC3CCC2C2CCC3CCCCC3C12,BRD-A20200672,gap junction modulator
10.293812,2.810448,69,CC(C)NCC(O)COc1ccc(CC(=O)N)cc1,BRD-A20239487,c1ccccc1,BRD-A20239487,adrenergic receptor antagonist
10.469171,7.7075253,70,CN1C(c2ccc(Cl)cc2)S(=O)(=O)CCC1=O,BRD-A20348246,O=C1CCS(=O)(=O)C(c2ccccc2)N1,BRD-A20348246,gaba receptor modulator
11.516888,7.461547,71,O=C(C1CCCCC1)N2CC3N(CCc4ccccc34)C(=O)C2,BRD-A21858158,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,BRD-A21858158,anthelmintic
11.010024,3.5363214,72,CCOC(=O)C1=C(COCCN)NC(=C(C1c2ccccc2Cl)C(=O)OC)C,BRD-A22032524,C1=CC(c2ccccc2)C=CN1,BRD-A22032524,calcium channel blocker
7.9426947,5.3318005,73,COc1cc(ccc1c2nc3ncccc3[nH]2)S(=O)C,BRD-A22081593,c1ccc(-c2nc3ncccc3[nH]2)cc1,BRD-A22081593,adenosine receptor antagonist
4.3816433,0.9596904,74,C[C@@]12CCC3C(CCc4cc(OS(=O)(=O)O)ccc34)C2CCC1=O,BRD-A22143024,O=C1CCC2C1CCC1c3ccccc3CCC12,BRD-A22143024,estrogen receptor agonist
8.234358,5.3907447,75,COc1cc2nc(nc(N)c2cc1OC)N3CCN(CC3)C(=O)C4CCCO4,BRD-A22256192,O=C(C1CCCO1)N1CCN(c2ncc3ccccc3n2)CC1,BRD-A22256192,adrenergic receptor antagonist
10.638586,4.729163,76,CC(Cc1cccc(c1)C(F)(F)F)NCCOC(=O)c2ccccc2,BRD-A22305049,O=C(OCCNCCc1ccccc1)c1ccccc1,BRD-A22305049,gluconeogenesis inhibitor
7.7285714,4.9358554,77,COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC,BRD-A22380646,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,BRD-A22380646,atpase inhibitor
9.511245,4.550128,78,CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,BRD-A22684332,O=c1ccc2ccccc2[nH]1,BRD-A22684332,adrenergic receptor agonist
12.215228,6.74968,79,CN1CCCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,BRD-A22769835,c1ccc(C(c2ccccc2)N2CCCNCC2)cc1,BRD-A22769835,antihistamine
10.634857,6.8090086,80,CN1C(C(=O)Nc2ccccn2)C(=O)c3sccc3S1(=O)=O,BRD-A22844106,O=C(Nc1ccccn1)C1NS(=O)(=O)c2ccsc2C1=O,BRD-A22844106,cyclooxygenase inhibitor
9.426516,5.0504537,81,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)C2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,BRD-A23034328,O=C(NCC1CCCCO1)C1CCCN1,BRD-A23034328,protein synthesis inhibitor
12.38505,4.8733096,82,CN(C)CCC(c1ccccc1)c2ccccn2,BRD-A23072235,c1ccc(Cc2ccccn2)cc1,BRD-A23072235,histamine receptor antagonist
4.3743777,0.9805001,83,CC(=O)OC1CCC2C3CCc4cc(O)ccc4C3CCC12C,BRD-A23226398,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A23226398,estrogen receptor agonist
10.478954,4.4149303,84,NCC(CS(=O)(=O)O)c1ccc(Cl)cc1,BRD-A24122750,c1ccccc1,BRD-A24122750,gaba receptor antagonist
9.568974,4.161167,85,CC(C(O)c1ccc(O)cc1)N2CCC(Cc3ccccc3)CC2,BRD-A24191444,c1ccc(CCN2CCC(Cc3ccccc3)CC2)cc1,BRD-A24191444,adrenergic receptor antagonist|glutamate receptor antagonist
8.002211,9.350159,86,CC1COc2c(N3CCN(C)CC3)c(F)cc4c(=O)c(cn1c24)C(=O)O,BRD-A24228527,O=c1ccn2c3c(c(N4CCNCC4)ccc13)OCC2,BRD-A24228527,bacterial dna gyrase inhibitor
10.063841,5.544107,87,CC(=O)CC(c1ccccc1)c2c(O)c3ccccc3oc2=O,BRD-A24514565,O=c1oc2ccccc2cc1Cc1ccccc1,BRD-A24514565,vitamin k antagonist
9.516195,4.3543763,88,CCC(NC(C)C)C(O)c1ccc(O)c(O)c1,BRD-A24587114,c1ccccc1,BRD-A24587114,adrenergic receptor agonist
7.4387927,5.6651454,89,COc1ccc(CC2N(C)CCc3cc(OC)c(OC)cc23)cc1OC,BRD-A24817035,c1ccc(CC2NCCc3ccccc32)cc1,BRD-A24817035,central nervous system
9.723398,6.965287,90,CCC1(CCC(=O)NC1=O)c2ccc(N)cc2,BRD-A25234499,O=C1CCC(c2ccccc2)C(=O)N1,BRD-A25234499,glucocorticoid receptor antagonist
1.3671018,0.5086797,91,CCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C)C(=O)CCl,BRD-A26095496,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A26095496,glucocorticoid receptor agonist
10.464263,3.1768358,92,CCCNCC(O)COc1ccccc1C(=O)CCc2ccccc2,BRD-A26334849,O=C(CCc1ccccc1)c1ccccc1,BRD-A26334849,antiarrhythmic
9.24721,7.138756,93,NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc32,BRD-A26384407,O=C1NC(c2ccccc2)c2ccccc21,BRD-A26384407,carbonic anhydrase inhibitor
11.02159,3.5513387,94,COC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+](=O)[O-])C(=O)OCCN(C)Cc3ccccc3)C,BRD-A26711594,O=C(OCCNCc1ccccc1)C1=CNC=CC1c1ccccc1,BRD-A26711594,calcium channel blocker
11.243411,5.8875484,95,CC(CN1CCCCC1)C(=O)c2ccc(C)cc2,BRD-A27732521,O=C(CCN1CCCCC1)c1ccccc1,BRD-A27732521,sodium channel blocker
2.4854054,0.7361682,96,C[C@@]12C[C@H](O)C3C(CCC4=CC(=O)C=C[C@]34C)C2CC[C@]1(O)C(=O)CO,BRD-A27887842,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A27887842,glucocorticoid receptor agonist
11.245607,7.102682,97,C1CN=C(N1)C2CCCc3ccccc23,BRD-A28856712,c1ccc2c(c1)CCCC2C1=NCCN1,BRD-A28856712,adrenergic receptor agonist
9.1096,4.57525,98,COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)C(O[C@@H]2CO)n3cnc4c(ncnc34)N(C)C)cc1,BRD-A28970875,O=C(CCc1ccccc1)NC1COC(n2cnc3cncnc32)C1,BRD-A28970875,protein synthesis inhibitor
3.9454749,1.6869513,99,C[C@@]12CCC3C(CC[C@@H]4C[C@@H](O)CC[C@@]43C)[C@@]2(O)C[C@H](O)[C@@H]1C5=CC(=O)OC5,BRD-A29082194,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-A29082194,atpase inhibitor
10.275042,2.7815518,100,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(=O)C,BRD-A29260609,c1ccccc1,BRD-A29260609,adrenergic receptor antagonist
11.004078,3.5480182,101,COC(=O)C1=C(C)NC(=C(C1C)C(=O)OCCSc2ccccc2)C,BRD-A29289453,O=C(OCCSc1ccccc1)C1=CNC=CC1,BRD-A29289453,platelet activating factor receptor antagonist
3.335274,1.0660036,102,C[C@@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C2CC[C@@]1(O)CCC(=O)O,BRD-A29322418,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-A29322418,mineralocorticoid receptor antagonist
12.2442465,4.87282,103,CN(C)CCOC(c1ccc(Cl)cc1)c2ccccn2,BRD-A29426959,c1ccc(Cc2ccccn2)cc1,BRD-A29426959,histamine receptor antagonist
10.806557,7.865288,104,CN1CC(c2ccccc2)c3cccc(N)c3C1,BRD-A29644307,c1ccc(C2CNCc3ccccc32)cc1,BRD-A29644307,dopamine uptake inhibitor
3.5332692,1.2033973,105,CCCCCC(=O)O[C@@]1(CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@@]21C)C(=O)C,BRD-A29731977,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A29731977,progesterone receptor agonist
12.108482,4.8624606,106,CC(C)N(CCC(C(=O)N)(c1ccccc1)c2ccccn2)C(C)C,BRD-A29734509,c1ccc(Cc2ccccn2)cc1,BRD-A29734509,sodium channel blocker
9.828151,4.5357347,107,CC(=O)C(C#N)C(=O)Nc1cc(Br)ccc1Br,BRD-A30655177,c1ccccc1,BRD-A30655177,btk inhibitor
11.018728,3.549782,108,CCOC(=O)C1=C(C)NC(=C(C1c2cccc(Cl)c2Cl)C(=O)OC)C,BRD-A30815329,C1=CC(c2ccccc2)C=CN1,BRD-A30815329,calcium channel blocker
10.204797,4.2785954,109,CNCCC(Oc1ccc(cc1)C(F)(F)F)c2ccccc2,BRD-A31159102,c1ccc(COc2ccccc2)cc1,BRD-A31159102,selective serotonin reuptake inhibitor (ssri)
10.431528,3.1899757,110,COc1ccccc1OCC(O)COC(=O)N,BRD-A31521121,c1ccccc1,BRD-A31521121,muscle relaxant
10.653139,5.3981185,111,CCOC(=O)[C@H](CCc1ccccc1)N[C@H](C)C(=O)N2[C@@H](CC3CCCCC32)C(=O)O,BRD-A32505112,O=C(CNCCCc1ccccc1)N1CCC2CCCCC21,BRD-A32505112,angiotensin converting enzyme inhibitor
9.636164,5.591688,112,CC(=O)OC1CN2CCC1CC2,BRD-A32673558,C1CN2CCC1CC2,BRD-A32673558,acetylcholine receptor agonist
9.743483,3.5105953,113,CC(C)NCC(O)c1ccc(NS(=O)(=O)C)cc1,BRD-A33168282,c1ccccc1,BRD-A33168282,adrenergic receptor antagonist
7.508723,6.3567924,114,COc1cc(cc(OC)c1O)[C@H]2[C@@H]3C(COC3=O)C(OC4O[C@@H]5COC(C)O[C@H]5[C@H](O)[C@H]4O)c6cc7OCOc7cc26,BRD-A33280134,O=C1OCC2C(OC3CCC4OCOCC4O3)c3cc4c(cc3C(c3ccccc3)C12)OCO4,BRD-A33280134,topoisomerase inhibitor
7.252879,4.501066,115,COC(=O)Nc1nc2ccc(cc2[nH]1)S(=O)c3ccccc3,BRD-A33447119,O=S(c1ccccc1)c1ccc2nc[nH]c2c1,BRD-A33447119,anthelmintic
12.115552,7.4019194,116,CN1CCCC(CC2c3ccccc3Sc4ccccc24)C1,BRD-A33711280,c1ccc2c(c1)Sc1ccccc1C2CC1CCCNC1,BRD-A33711280,acetylcholine receptor antagonist
9.972034,5.823986,117,CCCCC1C(=O)N(N(C1=O)c2ccc(O)cc2)c3ccccc3,BRD-A33749298,O=C1CC(=O)N(c2ccccc2)N1c1ccccc1,BRD-A33749298,cyclooxygenase inhibitor
8.011262,5.6844335,118,COc1ccc(cc1OC2CCCC2)C3CNC(=O)C3,BRD-A34255068,O=C1CC(c2cccc(OC3CCCC3)c2)CN1,BRD-A34255068,phosphodiesterase inhibitor
3.9689374,1.6693493,119,C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)C4CC[C@]5(C)[C@H](CC[C@]5(O)C4CCC3=C2)c6ccc(=O)oc6)[C@H](O)[C@H](O)[C@H]1O,BRD-A34806832,O=c1ccc(C2CCC3C2CCC2C4CCC(OC5CCCCO5)C=C4CCC23)co1,BRD-A34806832,atpase inhibitor
7.53087,6.3847756,120,COc1cc(cc(OC)c1O)[C@H]2[C@@H]3C(COC3=O)C(O[C@@H]4O[C@@H]5CO[C@H](OC5[C@H](O)[C@H]4O)c6cccs6)c7cc8OCOc8cc27,BRD-A35588707,O=C1OCC2C(OC3CCC4OC(c5cccs5)OCC4O3)c3cc4c(cc3C(c3ccccc3)C12)OCO4,BRD-A35588707,topoisomerase inhibitor
10.277385,7.206194,121,Clc1ccc2NC(=O)CSC(c3ccccc3Cl)c2c1,BRD-A35623999,O=C1CSC(c2ccccc2)c2ccccc2N1,BRD-A35623999,mitochondrial na+/ca2+ exchanger antagonist|sodium/calcium exchange inhibitor
3.4469137,1.153699,122,CC(=O)O[C@@]1(CCC2C3C=C(C)C4=CC(=O)CCC4(C)C3CCC21C)C(=O)C,BRD-A35989968,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-A35989968,progesterone receptor agonist
1.4474758,0.6280907,123,CC(=O)OCC(=O)[C@]12OC3(CCCC3)O[C@@H]2CC4C5CCC6=CC(=O)C=C[C@]6(C)[C@@]5(F)[C@@H](O)C[C@@]41C,BRD-A36010170,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OC3(CCCC3)OC12,BRD-A36010170,glucocorticoid receptor agonist
4.3829684,0.8902143,124,CC12CCC3C(CCc4cc(OC(=O)c5ccccc5)ccc34)C2CCC1O,BRD-A36066264,O=C(Oc1ccc2c(c1)CCC1C2CCC2CCCC21)c1ccccc1,BRD-A36066264,estrogen receptor agonist
10.246244,7.2473254,125,O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4,BRD-A36217750,O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1,BRD-A36217750,uricosuric blocker
11.857213,6.4136724,126,OC(CCN1CCCCC1)(C2C[C@H]3C[C@@H]2C=C3)c4ccccc4,BRD-A36471396,C1=CC2CC1CC2C(CCN1CCCCC1)c1ccccc1,BRD-A36471396,acetylcholine receptor antagonist
13.806665,6.030281,127,CC(C)[N+]1(C)[C@@H]2CC[C@@H]1C[C@H](C2)OC(=O)C(CO)c3ccccc3,BRD-A37432947,O=C(Cc1ccccc1)OC1CC2CCC(C1)[NH2+]2,BRD-A37432947,acetylcholine receptor antagonist
9.875739,3.4264677,128,CC(C)(C)NCC(O)c1ccccc1Cl,BRD-A37441042,c1ccccc1,BRD-A37441042,adrenergic receptor agonist
9.379015,6.269495,129,CC(=C)[C@H]1[C@H]2OC(=O)C1[C@]3(O)CC4O[C@]45C(=O)O[C@H]2[C@@]53C,BRD-A37817666,O=C1OC2CC1C1CC3OC34C(=O)OC2C14,BRD-A37817666,gaba receptor antagonist
4.355757,1.015754,130,C[C@@]12CCC3C(CCc4cc(O)ccc34)C2CCC1=O,BRD-A37959677,O=C1CCC2C1CCC1c3ccccc3CCC12,BRD-A37959677,estrogen receptor agonist|estrogenic hormone
10.515528,3.4123192,131,OCC(O)COC(=O)c1ccccc1Nc2ccnc3cc(Cl)ccc23,BRD-A38076815,c1ccc(Nc2ccnc3ccccc23)cc1,BRD-A38076815,deltaf508-cftr correctors
13.152636,3.969663,132,CC(=O)N1CCN(CC1)c2ccc(OCC3CO[C@@](Cn4ccnc4)(O3)c5ccc(Cl)cc5Cl)cc2,BRD-A38350138,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1,BRD-A38350138,sterol demethylase inhibitor
10.587599,3.5086844,133,NC(=O)OCC(O)COc1ccc(Cl)cc1,BRD-A39230911,c1ccccc1,BRD-A39230911,muscle relaxant
10.697349,7.5209584,134,Clc1ccc(cn1)C2CC3CCC2N3,BRD-A39268308,c1cncc(C2CC3CCC2N3)c1,BRD-A39268308,acetylcholine receptor agonist
3.3889153,1.2170115,135,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)C5CC5[C@]4(C)[C@H]3CC[C@@]21C)C(=O)C,BRD-A39290993,O=C1C=C2C=CC3C4CCCC4CCC3C2C2CC12,BRD-A39290993,androgen receptor antagonist
3.877698,1.1143682,136,C[C@@]12CCC3C(CCC4=CC(=O)CC[C@H]34)C2CC[C@@]1(O)C#C,BRD-A39415247,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A39415247,progesterone receptor agonist
4.3607593,1.0336174,137,CCCCC(=O)O[C@H]1CCC2C3CCc4cc(O)ccc4C3CC[C@]12C,BRD-A39747742,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-A39747742,estrogen receptor agonist
7.934283,9.417892,138,CO/N=C/1\\CN(CC1CN)c2nc3n(cc(C(=O)O)c(=O)c3cc2F)C4CC4,BRD-A40787240,N=C1CCN(c2ccc3c(=O)ccn(C4CC4)c3n2)C1,BRD-A40787240,bacterial dna gyrase inhibitor
8.502082,3.5546575,139,COC(C)(C)CCCC(C)C/C=C/C(=C/C(=O)O)/C,BRD-A41145729,,BRD-A41145729,retinoid receptor agonist
9.391016,7.4262686,140,NS(=O)(=O)c1cc2c(NC(CC3CCCC3)NS2(=O)=O)cc1Cl,BRD-A41250306,O=S1(=O)NC(CC2CCCC2)Nc2ccccc21,BRD-A41250306,thiazide diuretic
8.501859,3.4950714,141,COC(C/C=C/C=C/CC\\C=C/CC(C)\\C=C/C(=C\\C(=O)O)/CC(=O)O)/C(=C\\C=C(/C)\\C(=O)O)/C,BRD-A41301928,,BRD-A41301928,"mitochondrial adp, atp translocase inhibitor"
10.234617,2.8657537,142,CC(C)NCC(O)COc1ccc(NC(=O)C)cc1,BRD-A41304429,c1ccccc1,BRD-A41304429,adrenergic receptor antagonist
10.3315115,5.8969097,143,CCC(C)N(C)C(=O)c1cc2ccccc2c(n1)c3ccccc3Cl,BRD-A41451487,c1ccc(-c2nccc3ccccc23)cc1,BRD-A41451487,benzodiazepine receptor antagonist
9.290308,4.982025,144,OC(CC[C@@H]1[C@H](N(C1=O)c2ccc(F)cc2)c3ccc(O)cc3)c4ccc(F)cc4,BRD-A41519720,O=C1C(CCCc2ccccc2)C(c2ccccc2)N1c1ccccc1,BRD-A41519720,cholesterol inhibitor|niemann-pick c1-like 1 protein antagonist
10.685884,10.005267,145,CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)c3ccccc3)C2=O,BRD-A41698174,O=C(Cc1ccccc1)NC1C(=O)N2CCSC12,BRD-A41698174,bacterial cell wall synthesis inhibitor
7.989421,6.8061376,146,OC[C@H]1OC([C@H](O)[C@@H](O)[C@@H]1O)c2c(O)cc(O)c3c(=O)cc(oc23)c4ccc(O)cc4,BRD-A41941932,O=c1cc(-c2ccccc2)oc2c(C3CCCCO3)cccc12,BRD-A41941932,antioxidant
7.9835005,5.760708,147,COc1cc2N3C4[C@H]5[C@H]6C[C@@H]7N(CC[C@@]74c2cc1OC)CC6=CCOC5CC3=O,BRD-A41995253,O=C1CC2OCC=C3CN4CCC56c7ccccc7N1C5C2C3CC46,BRD-A41995253,glycine receptor antagonist
10.057984,2.9936442,148,CC(C)(C)NCC(O)COc1cccc2NC(=O)CCc12,BRD-A42167015,O=C1CCc2ccccc2N1,BRD-A42167015,adrenergic receptor antagonist
12.356891,6.489097,149,OC(=O)COCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,BRD-A42571354,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-A42571354,histamine receptor antagonist
9.386912,4.7599435,150,CCC(Cc1c(I)cc(I)c(N)c1I)C(=O)O,BRD-A42628519,c1ccccc1,BRD-A42628519,radiopaque medium
9.257926,6.481771,151,Cc1ncc([N+](=O)[O-])n1CC(O)CCl,BRD-A42759514,c1c[nH]cn1,BRD-A42759514,antiprotozoal
8.935121,4.7758155,152,CCCCCc1cc(O)c2C3C=C(CC[C@H]3C(C)(C)Oc2c1)C(=O)O,BRD-A42831637,C1=CC2c3ccccc3OCC2CC1,BRD-A42831637,anti-inflammatory|cannabinoid metabolite
10.315756,2.880894,153,CC(C)NCC(O)COc1ccccc1OCC=C,BRD-A43671941,c1ccccc1,BRD-A43671941,adrenergic receptor antagonist
9.398444,5.461344,154,CCN1C[C@]2(C)CC[C@H](O)[C@]3([C@@H]4C[C@H]5C(O)[C@@H]4[C@](O)(C[C@@H]5OC)[C@H]6C[C@@H]32)C61,BRD-A43849199,C1CC2CNC3C4CC2C3(C1)C1CC2CCC4C1C2,BRD-A43849199,phytotoxin
10.126197,4.872559,155,CC(N/C(=N/C#N)/Nc1ccncc1)C(C)(C)C,BRD-A43882281,c1ccncc1,BRD-A43882281,atp channel activator|potassium channel activator
7.333921,5.789087,156,COc1ccc2CC3N(CCc4cc(OC)c(OC)cc34)Cc2c1OC,BRD-A43940795,c1ccc2c(c1)CC1c3ccccc3CCN1C2,BRD-A43940795,serotonin release inhibitor
10.698696,7.5247216,157,NC1C[C@H]1c2ccccc2,BRD-A43974575,c1ccc(C2CC2)cc1,BRD-A43974575,monoamine oxidase inhibitor
13.725802,6.022063,158,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c3ccccc3,BRD-A43999749,O=C(Cc1ccccc1)OC1CC2CCC(C1)[NH2+]2,BRD-A43999749,acetylcholine receptor antagonist
12.306752,4.9252734,159,CN(C)CCOC(C)(c1ccccc1)c2ccccn2,BRD-A44008656,c1ccc(Cc2ccccn2)cc1,BRD-A44008656,histamine receptor antagonist
9.883378,6.0535746,160,CN1C(=O)COc2c(cc(Cl)cc12)C(=O)NC3CN4CCC3CC4,BRD-A44133049,O=C1COc2c(cccc2C(=O)NC2CN3CCC2CC3)N1,BRD-A44133049,serotonin receptor antagonist
10.606119,5.333081,161,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1,BRD-A44863528,c1ccccc1,BRD-A44863528,cck receptor antagonist
7.103713,5.8709307,162,COc1cc-2c(CC3N(C)CCc4cc(O)c(OC)c2c34)cc1O,BRD-A44966919,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-A44966919,acetylcholine receptor antagonist
11.545594,4.8257923,163,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc3ccc(OC)cc13,BRD-A45889380,c1ccc2nc3ccccc3cc2c1,BRD-A45889380,cytokine production inhibitor|nfkb pathway inhibitor|tp53 activator
10.57552,7.576266,164,C1CN2CC(N=C2S1)c3ccccc3,BRD-A46393198,c1ccc(C2CN3CCSC3=N2)cc1,BRD-A46393198,immunostimulant
9.697409,3.4827306,165,CNCC(O)c1ccc(OC(=O)C(C)(C)C)c(OC(=O)C(C)(C)C)c1,BRD-A47494775,c1ccccc1,BRD-A47494775,adrenergic receptor agonist
10.000857,4.7478266,166,COC[C@H]([C@@H](O)[C@@H](O)C(=O)NCC[C@@H](C)c1nc(/C=C/C[C@H]2OC3(C[C@H](O)[C@H]2C)OC([C@@H](C[C@@H](O)[C@@H](C)[C@@H](O)[C@@H](C)/C=C(\\C)/C(=C/C=C/C(=C\\C#N)/C)/C)OC)[C@@H](OP(=O)(O)O)C3(C)C)co1)N(C)C,BRD-A47513740,C(=Cc1cocn1)CC1CCCC2(CCCO2)O1,BRD-A47513740,protein phosphatase inhibitor
9.814788,5.3508415,167,CO[C@]12[C@@H]3NC3CN2C4=C([C@@H]1COC(=O)N)C(=O)C(=C(C)C4=O)N,BRD-A48237631,O=C1C=CC(=O)C2=C1CC1C3NC3CN21,BRD-A48237631,dna alkylating|dna synthesis inhibitor
12.011196,4.6316833,168,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,BRD-A48430263,O=C1NC(=O)C(Cc2ccc(OCCc3ccccn3)cc2)S1,BRD-A48430263,insulin sensitizer|ppar receptor agonist
3.5065365,1.1705042,169,CCC(=O)O[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,BRD-A48720949,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A48720949,androgen receptor agonist
9.233868,4.8359513,170,CNC(=O)[C@H]1O[C@H](C(O)[C@H]1O)n2cnc3c(NCc4cccc(I)c4)ncnc23,BRD-A48809242,c1ccc(CNc2ncnc3c2ncn3C2CCCO2)cc1,BRD-A48809242,adenosine receptor agonist
11.711253,6.065162,171,OC(=O)C1CCCN(CCC=C(c2ccccc2)c3ccccc3)C1,BRD-A49046702,C(CCN1CCCCC1)=C(c1ccccc1)c1ccccc1,BRD-A49046702,gaba uptake inhibitor
7.7895255,4.940348,172,Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F,BRD-A49172652,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,BRD-A49172652,atpase inhibitor
11.065899,4.53848,173,CC(C)(Oc1ccc(cc1)C2CC2(Cl)Cl)C(=O)O,BRD-A49358627,c1ccc(C2CC2)cc1,BRD-A49358627,ppar receptor agonist
10.436007,3.1621742,174,COc1cc(=O)n(C)c2c(OCC(O)C(C)(C)O)cccc12,BRD-A49734948,O=c1ccc2ccccc2[nH]1,BRD-A49734948,plant alkaloid
2.0866036,0.845486,175,CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)CC[C@]5(C)C4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,BRD-A49765801,O=C1C=C2CCC3C(CCC4C3CC3OCOC34)C2CC1,BRD-A49765801,glucocorticoid receptor agonist
13.833868,5.988171,176,C[N+]1([O-])[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@H]32)OC(=O)[C@H](CO)c4ccccc4,BRD-A49906757,O=C(Cc1ccccc1)OC1CC2[NH2+]C(C1)C1OC21,BRD-A49906757,acetylcholine receptor antagonist
9.701987,3.4580739,177,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,BRD-A50157456,c1ccccc1,BRD-A50157456,adrenergic receptor agonist
12.278284,6.619471,178,Cc1cccc(CN2CCN(CC2)C(c3ccccc3)c4ccc(Cl)cc4)c1,BRD-A50311610,c1ccc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1,BRD-A50311610,car agonist
9.764048,6.6602416,179,Nc1c(S(=O)C(F)(F)F)c(C#N)nn1c2c(Cl)cc(cc2Cl)C(F)(F)F,BRD-A50675702,c1ccc(-n2cccn2)cc1,BRD-A50675702,chloride channel blocker|gaba gated chloride channel blocker
10.603937,8.141853,180,Oc1ccc(cc1)C2CNCCc3c(Cl)c(O)c(O)cc23,BRD-A50684349,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A50684349,dopamine receptor agonist
11.587141,6.4374495,181,O=C1CC2(CCCC2)CC(=O)N1CCNCC3COc4ccccc4O3,BRD-A50764878,O=C1CC2(CCCC2)CC(=O)N1CCNCC1COc2ccccc2O1,BRD-A50764878,serotonin receptor antagonist
11.926682,4.513842,182,COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2,BRD-A51714012,c1ccc(CC2CCCCC2)cc1,BRD-A51714012,adrenergic inhibitor|norepinephrine reuptake inhibitor|serotonin reuptake inhibitor
13.422056,3.790767,183,Clc1ccc(COC(Cn2ccnc2)c3ccc(Cl)cc3Cl)cc1,BRD-A51820102,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1,BRD-A51820102,lanosterol demethylase inhibitor|sterol demethylase inhibitor
11.896965,6.865719,184,OC(CN1CCN(CC1)c2cccc(Cl)c2)C(c3ccccc3)c4ccccc4,BRD-A51829654,c1ccc(C(CCN2CCN(c3ccccc3)CC2)c2ccccc2)cc1,BRD-A51829654,serotonin receptor antagonist
7.738214,5.3791246,185,COc1ccc(CCN(C)CCCC(C#N)(C(C)C)c2cc(OC)c(OC)c(OC)c2)cc1OC,BRD-A52922642,c1ccc(CCCCNCCc2ccccc2)cc1,BRD-A52922642,l-type calcium channel blocker
2.4098382,0.74816394,186,C[C@H]1CC2C3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)C2[C@@]4(C)C=CC(=O)C=C14,BRD-A53176877,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A53176877,glucocorticoid receptor agonist
10.553678,4.205463,187,CCCNC(C)C(=O)Nc1ccccc1C,BRD-A53952395,c1ccccc1,BRD-A53952395,local anesthetic
10.072525,4.1261177,188,CNC(C)C(O)c1ccccc1,BRD-A54236247,c1ccccc1,BRD-A54236247,adrenergic receptor agonist
10.795802,7.358606,189,Cc1ccc2n3CCNC4CCCc(c43)c2c1,BRD-A54490543,c1ccc2c(c1)c1c3n2CCNC3CCC1,BRD-A54490543,monoamine oxidase inhibitor
11.926028,3.1235955,190,CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N,BRD-A55272860,O=C(NCC1CCCN1)c1ccccc1,BRD-A55272860,dopamine receptor antagonist
3.5790365,1.1493042,191,C[C@@]12CCC3C(CCC4=CC(=O)CC[C@]34C)C2CC[C@@H]1O,BRD-A55393291,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A55393291,androgen receptor agonist
10.60265,7.4192204,192,O=c1cccc2C3CNC[C@@H](C3)Cn21,BRD-A55579717,O=c1cccc2n1CC1CNCC2C1,BRD-A55579717,acetylcholine receptor agonist
11.090039,7.161447,193,CC1CNCCN1S(=O)(=O)c2cccc3cnccc23,BRD-A55756846,O=S(=O)(c1cccc2cnccc12)N1CCNCC1,BRD-A55756846,pka inhibitor
8.892019,5.477411,194,CC(/C=C/c1cccc(Oc2ccc(F)cc2)c1)N(O)C(=O)N,BRD-A55946879,c1ccc(Oc2ccccc2)cc1,BRD-A55946879,lipoxygenase inhibitor
7.748582,4.8935604,195,COc1ccc2nc([nH]c2c1)S(=O)Cc3ncc(C)c(OC)c3C,BRD-A55962179,O=S(Cc1ccccn1)c1nc2ccccc2[nH]1,BRD-A55962179,atpase inhibitor
9.489238,5.438251,196,CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](C(C)CC)C(=O)N2CCC[C@H]2C(=O)OC,BRD-A56020723,O=C(NCC(=O)N1CCCC1)C1CO1,BRD-A56020723,cathepsin inhibitor|antiamyloidogenic
9.374108,7.4529443,197,NS(=O)(=O)c1cc2c(NC(CSCC=C)NS2(=O)=O)cc1Cl,BRD-A56675431,O=S1(=O)NCNc2ccccc21,BRD-A56675431,diuretic
10.97536,3.538382,198,COCCOC(=O)C1=C(C)NC(=C(C1c2cccc(c2)[N+](=O)[O-])C(=O)OC(C)C)C,BRD-A58048407,C1=CC(c2ccccc2)C=CN1,BRD-A58048407,calcium channel blocker
9.494235,4.0699205,199,CC(NCCc1ccc(O)cc1)C(O)c2ccc(O)cc2,BRD-A59174698,c1ccc(CCNCCc2ccccc2)cc1,BRD-A59174698,adrenergic receptor agonist
11.992341,6.3210335,200,CN1C(CC(O)c2ccccc2)CCCC1CC(O)c3ccccc3,BRD-A59215453,c1ccc(CCC2CCCC(CCc3ccccc3)N2)cc1,BRD-A59215453,acetylcholine receptor antagonist
9.410519,7.3820567,201,CCC1NC(=O)c2cc(c(Cl)cc2N1)S(=O)(=O)N,BRD-A59303141,O=C1NCNc2ccccc21,BRD-A59303141,thiazide diuretic
8.929079,7.9360266,202,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,BRD-A61154809,O=C(NN1CC2CCCC2C1)NS(=O)(=O)c1ccccc1,BRD-A61154809,atp channel blocker|insulin secretagogue
3.448104,1.2049582,203,C[C@H]1CC2C3CC[C@](OC(=O)C)(C(=O)C)[C@@]3(C)CCC2[C@@]4(C)CCC(=O)C=C14,BRD-A61221616,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A61221616,progesterone receptor agonist
9.468207,7.4407,204,CC1Nc2cc(Cl)c(cc2C(=O)N1c3ccccc3C)S(=O)(=O)N,BRD-A61793559,O=C1c2ccccc2NCN1c1ccccc1,BRD-A61793559,carbonic anhydrase inhibitor
9.336547,5.83878,205,CN/C(=N\\c1ccc(cc1)C2=NNC(=O)CC2C)/NC#N,BRD-A62071884,O=C1CCC(c2ccccc2)=NN1,BRD-A62071884,phosphodiesterase inhibitor
12.346749,6.631044,206,OCCOCCN1CCN(CC1)C(c2ccccc2)c3ccc(Cl)cc3,BRD-A62428732,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-A62428732,antihistamine
2.6155567,0.7844973,207,C[C@@]12CC(=O)C3C(CCC4=CC(=O)C=C[C@]34C)C2CC[C@]1(O)C(=O)CO,BRD-A62525898,O=C1C=CC2C(=C1)CCC1C3CCCC3CC(=O)C21,BRD-A62525898,glucocorticoid receptor agonist
1.3371189,0.5116575,208,CCC(=O)OC1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C)C(=O)CCl,BRD-A63894585,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A63894585,glucocorticoid receptor agonist
10.390122,4.296901,209,CC(N)COc1c(C)cccc1C,BRD-A64092382,c1ccccc1,BRD-A64092382,sodium channel blocker
9.667527,6.512232,210,OC[C@H]1OC(C[C@@H]1O)n2cc(c(=O)[nH]c2=O)C(F)(F)F,BRD-A64485570,O=c1ccn(C2CCCO2)c(=O)[nH]1,BRD-A64485570,dna polymerase inhibitor|thymidylate synthase inhibitor
10.448616,3.0656967,211,OC(COc1cccc2[nH]c(C#N)cc12)CN3CCN(CC3)C(c4ccccc4)c5ccccc5,BRD-A64553394,c1ccc(C(c2ccccc2)N2CCN(CCCOc3cccc4[nH]ccc34)CC2)cc1,BRD-A64553394,sodium channel activator
11.6461115,4.5567517,212,CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2,BRD-A65013509,c1ccc(CC2CCCCC2)cc1,BRD-A65013509,acetylcholine receptor antagonist
10.111266,5.37238,213,CC(=O)CC(c1ccc(cc1)[N+](=O)[O-])c2c(O)c3ccccc3oc2=O,BRD-A65051990,O=c1oc2ccccc2cc1Cc1ccccc1,BRD-A65051990,vitamin k antagonist
11.917875,8.920638,214,CC(C)[C@@]1(NC(=O)[C@@H]2CC3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C1=O,BRD-A65076780,O=C(NC1OC2C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O)C1CNC2Cc3c[nH]c4cccc(c34)C2C1,BRD-A65076780,adrenergic receptor antagonist|prolactin inhibitor
9.638349,6.2192187,215,CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,BRD-A65280694,O=C1c2cc[nH]c2CCC1CN1CCOCC1,BRD-A65280694,dopamine receptor antagonist
9.632532,3.6487253,216,CC(C)NCC(O)c1ccc(N)c(C#N)c1,BRD-A65440446,c1ccccc1,BRD-A65440446,adrenergic receptor agonist
2.1120079,0.79907763,217,CC1(C)O[C@@H]2CC3C4C[C@H](F)C5=CC(=O)C=CC5(C)C4C(O)CC3(C)[C@@]2(O1)C(=O)CO,BRD-A65449987,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-A65449987,cytochrome p450 inhibitor
10.423098,5.9558644,218,CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)c5ccccc5c6nnn[nH]6,BRD-A65671304,O=C(OCOC(=O)c1cccc2ncn(Cc3ccc(-c4ccccc4-c4nnn[nH]4)cc3)c12)OC1CCCCC1,BRD-A65671304,angiotensin receptor antagonist
2.8293548,0.9075739,219,CC(=O)OCC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3[C@@H](O)C[C@@]21C,BRD-A65767837,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A65767837,glucocorticoid receptor agonist
10.703565,10.096355,220,CC(Oc1ccccc1)C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O,BRD-A66025870,O=C(COc1ccccc1)NC1C(=O)N2CCSC12,BRD-A66025870,bacterial cell wall synthesis inhibitor
4.323401,1.8920838,221,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)C5CC[C@]43C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](COC7O[C@H](CO)[C@@H](OC8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O,BRD-A66199457,O=C(OC1CCCC(COC2CCC(OC3CCCCO3)CO2)O1)C12CCCCC1C1=CCC3C4CCCCC4CCC3C1CC2,BRD-A66199457,antineoplastic
3.5617435,1.2307303,222,CC(=O)[C@H]1CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,BRD-A67479912,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A67479912,progesterone receptor agonist
11.74979,4.192871,223,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc2cccc3ccccc23,BRD-A67862938,c1ccc2c(CCCC3CCCO3)cccc2c1,BRD-A67862938,adrenergic receptor antagonist
8.319865,7.4075255,224,COc1ccc(cc1)C2CC(=O)c3ccc(OC)cc3O2,BRD-A68039575,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A68039575,aromatase inhibitor
9.821337,3.9252682,225,CCCCCC(O)c1cccc(OCc2ccc3ccccc3n2)c1,BRD-A68281735,c1ccc(OCc2ccc3ccccc3n2)cc1,BRD-A68281735,leukotriene receptor antagonist|lipoxygenase inhibitor
12.424768,4.9069886,226,CN(C)CCC(c1ccc(Br)cc1)c2ccccn2,BRD-A68723818,c1ccc(Cc2ccccn2)cc1,BRD-A68723818,histamine receptor antagonist
4.0422344,1.7980622,227,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)C4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)C4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O,BRD-A68930007,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCCCO5)CC4CCC23)CO1,BRD-A68930007,atpase inhibitor
12.363615,4.7947035,228,COc1ccc(cc1)C2Sc3ccccc3N(CCN(C)C)C(=O)C2OC(=O)C,BRD-A69636825,O=C1CC(c2ccccc2)Sc2ccccc2N1,BRD-A69636825,calcium channel blocker
7.9784627,9.367979,229,CC1CCc2cc(F)cc3c(=O)c(cn1c23)C(=O)O,BRD-A69777949,O=c1ccn2c3c(cccc13)CCC2,BRD-A69777949,topoisomerase inhibitor
13.588171,6.014098,230,CC1C(CCC(C)(C)N1C)OC(=O)C(O)c2ccccc2,BRD-A69786436,O=C(Cc1ccccc1)OC1CCCNC1,BRD-A69786436,acetylcholine receptor antagonist
8.45418,3.946958,231,CCC1NC(=O)C(C(O)C(C)C/C=C/C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,BRD-A69815203,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1,BRD-A69815203,calcineurin inhibitor
9.348231,6.257685,232,CC(O)Cn1c(C)ncc1[N+](=O)[O-],BRD-A70083328,c1c[nH]cn1,BRD-A70083328,acetylcholinesterase inhibitor|microtubule inhibitor
10.463668,4.203994,233,CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,BRD-A70514680,c1ccsc1,BRD-A70514680,local anesthetic
9.261597,5.5284963,234,C/C(=C(/CCO)\\SSCC1CCCO1)/N(Cc2cnc(C)nc2N)C=O,BRD-A71157293,C(=CSSCC1CCCO1)NCc1cncnc1,BRD-A71157293,vitamin b
10.823089,4.930742,235,FC(C(F)(F)F)C(F)(F)Oc1cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)cc1Cl,BRD-A71774530,O=C(NC(=O)c1ccccc1)Nc1ccccc1,BRD-A71774530,chitin inhibitor
9.675787,5.0411177,236,CCC(C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)C12,BRD-A71816415,C1=CC2=CCCCC2CC1,BRD-A71816415,hmgcr inhibitor
12.753435,5.9395804,237,O=C1NCN(c2ccccc2)C31CCN(CC4COc5ccccc5O4)CC3,BRD-A72483914,O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccccc3O1)CC2,BRD-A72483914,serotonin receptor antagonist
13.36956,3.8380024,238,COc1ccc(CCCOC(Cn2ccnc2)c3ccc(OC)cc3)cc1,BRD-A72703248,c1ccc(CCCOC(Cn2ccnc2)c2ccccc2)cc1,BRD-A72703248,calcium channel blocker|cytochrome p450 inhibitor
9.963894,4.8183813,239,CC(C(=O)O)c1ccc(s1)C(=O)c2ccccc2,BRD-A72988804,O=C(c1ccccc1)c1cccs1,BRD-A72988804,cyclooxygenase inhibitor
12.19904,6.3149586,240,CC(C)(C(=O)O)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,BRD-A73368467,c1ccc(CCCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)cc1,BRD-A73368467,histamine receptor antagonist
11.783705,8.657413,241,CC(CO)NC(=O)C1CN(C)C2Cc3c[nH]c4cccc(C2=C1)c34,BRD-A73581086,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-A73581086,adrenergic receptor agonist
10.571585,5.74518,242,CCc1cccc2c3CCOC(CC)(CC(=O)O)c3[nH]c12,BRD-A74667430,c1ccc2c3c([nH]c2c1)COCC3,BRD-A74667430,cyclooxygenase inhibitor
9.077055,4.855485,243,OC[C@H]1O[C@H](C(O)[C@H]1O)n2cnc3cc(Cl)c(Cl)cc23,BRD-A74904029,c1ccc2c(c1)ncn2C1CCCO1,BRD-A74904029,casein kinase inhibitor
7.9492984,9.40256,244,COc1c(N2CCNC(C)C2)c(F)cc3c(=O)c(cn(C4CC4)c13)C(=O)O,BRD-A74980173,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12,BRD-A74980173,bacterial dna gyrase inhibitor
2.8120563,0.8798856,245,C[C@@]12C[C@H](O)C3C(CCC4=CC(=O)CC[C@]34C)C2CC[C@]1(O)C(=O)CO,BRD-A75172220,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-A75172220,glucocorticoid receptor agonist
10.593752,6.866257,246,CN1C(C(=O)Nc2cc(C)on2)C(=O)c3ccccc3S1(=O)=O,BRD-A75552914,O=C(Nc1ccon1)C1NS(=O)(=O)c2ccccc2C1=O,BRD-A75552914,cyclooxygenase inhibitor
9.759861,3.4487603,247,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,BRD-A75726477,c1ccccc1,BRD-A75726477,adrenergic receptor agonist
10.290998,7.490367,248,Cc1ccc2N=C3N(CCC3(O)C(=O)c2c1)c4ccccc4,BRD-A75817871,O=C1c2ccccc2N=C2C1CCN2c1ccccc1,BRD-A75817871,atpase inhibitor
7.9714074,9.379008,249,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,BRD-A75850590,O=c1cc[nH]c2cc(N3CCNCC3)ccc12,BRD-A75850590,bacterial dna gyrase inhibitor
11.867325,4.450755,250,CN(C)CCOC(=O)C(c1ccccc1)C2(O)CCCC2,BRD-A77291778,c1ccc(CC2CCCC2)cc1,BRD-A77291778,acetylcholine receptor antagonist
9.166908,5.177584,251,CC[C@H]1CN2CCC1C[C@H]2[C@H](O)c3ccnc4ccc(OC)cc34,BRD-A78295502,c1ccc2c(CC3CC4CCN3CC4)ccnc2c1,BRD-A78295502,anti-arrhythmia
13.77847,6.0398993,252,CN1C2CC[C@@H]1C[C@H](C2)OC(=O)[C@H](CO)c3ccccc3,BRD-A78303415,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-A78303415,acetylcholine receptor antagonist
9.42147,4.025471,253,CC(CCc1ccc(O)cc1)NCCc2ccc(O)c(O)c2,BRD-A78322124,c1ccc(CCCNCCc2ccccc2)cc1,BRD-A78322124,adrenergic receptor agonist
11.733869,7.2818103,254,CN1CCOC(c2ccccc2)c3ccccc3C1,BRD-A78877355,c1ccc(C2OCCNCc3ccccc32)cc1,BRD-A78877355,cyclooxygenase inhibitor
13.645017,6.2191443,255,CN1[C@H]2CC[C@@H]1CC(C2)OC(=O)C3C=Nc4ccccc34,BRD-A79226577,O=C(OC1CC2CCC(C1)N2)C1C=Nc2ccccc21,BRD-A79226577,serotonin receptor antagonist|polarization inhibitor|sodium channel blocker
11.311694,5.0809436,256,CCN(Cc1ccncc1)C(=O)C(CO)c2ccccc2,BRD-A79672927,O=C(Cc1ccccc1)NCc1ccncc1,BRD-A79672927,acetylcholine receptor antagonist
8.777996,5.2924294,257,COc1ccc(OC)c(c1)C(O)CNC(=O)CN,BRD-A79981887,c1ccccc1,BRD-A79981887,adrenergic receptor agonist
9.366524,7.5166364,258,NS(=O)(=O)c1cc2c(NC(Cc3ccccc3)NS2(=O)=O)cc1C(F)(F)F,BRD-A80017228,O=S1(=O)NC(Cc2ccccc2)Nc2ccccc21,BRD-A80017228,sodium/potassium/chloride transporter inhibitor
11.899504,8.898911,259,CC(C)CC1N2C(=O)[C@](NC(=O)C3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(OC2(O)[C@@H]7CCCN7C1=O)C(C)C,BRD-A80151636,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-A80151636,dopamine receptor agonist
1.2843987,0.47883898,260,CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(O)C[C@@]21C)C(=O)CO,BRD-A80594172,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A80594172,glucocorticoid receptor agonist
9.524485,4.6450143,261,CC(N)Cc1ccc(O)cc1,BRD-A80871782,c1ccccc1,BRD-A80871782,trace amine associated receptor agonist
10.974633,7.034932,262,CN(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)C(=O)N4CCN(CC4)c5ccccc5)S(=O)(=O)c6cccc7cnccc67,BRD-A81177136,O=C(C(Cc1ccc(OS(=O)(=O)c2cccc3cnccc23)cc1)NS(=O)(=O)c1cccc2cnccc12)N1CCN(c2ccccc2)CC1,BRD-A81177136,calcium/calmodulin dependent protein kinase inhibitor|purinergic receptor antagonist
13.429238,3.7926915,263,Clc1ccc(COC(Cn2ccnc2)c3ccc(Cl)cc3Cl)c(Cl)c1,BRD-A82396632,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1,BRD-A82396632,bacterial cell wall synthesis inhibitor
9.555846,5.1211896,264,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)C(CCC3C[C@@H](O)CC(=O)O3)[C@@H]12,BRD-A83177971,O=C1CCCC(CCC2CC=CC3=CCCCC32)O1,BRD-A83177971,hmgcr inhibitor
10.133692,6.8008313,265,CCC1(NC(=O)N(C)C1=O)c2ccccc2,BRD-A83937277,O=C1NC(=O)C(c2ccccc2)N1,BRD-A83937277,hydantoin antiepileptic
10.599602,6.8814545,266,CN1C(C(=O)Nc2ncc(C)s2)C(=O)c3ccccc3S1(=O)=O,BRD-A84174393,O=C(Nc1nccs1)C1NS(=O)(=O)c2ccccc2C1=O,BRD-A84174393,cyclooxygenase inhibitor
10.875049,4.6233883,267,NCC(CC(=O)O)c1ccc(Cl)cc1,BRD-A84174873,c1ccccc1,BRD-A84174873,benzodiazepine receptor agonist
13.611707,6.182003,268,CN1C2CCC1CC(C2)OC(=O)c3cc(C)cc(C)c3,BRD-A84389633,O=C(OC1CC2CCC(C1)N2)c1ccccc1,BRD-A84389633,serotonin receptor antagonist
10.211059,7.338443,269,Clc1ccc(cc1)C2CCC(CC2)C3C(=O)C(=O)c4ccccc4C3=O,BRD-A84493640,O=C1C(=O)C(C2CCC(c3ccccc3)CC2)C(=O)c2ccccc21,BRD-A84493640,mitochondrial electron transport inhibitor
13.579296,6.1831646,270,CN1C2CCC1CC(C2)OC(=O)c3cc(Cl)cc(Cl)c3,BRD-A85587465,O=C(OC1CC2CCC(C1)N2)c1ccccc1,BRD-A85587465,serotonin receptor antagonist
8.779994,5.244447,271,COc1ccc2cc(ccc2c1)C(C)C(=O)O,BRD-A87719232,c1ccc2ccccc2c1,BRD-A87719232,cyclooxygenase inhibitor
9.660427,3.467076,272,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,BRD-A88254928,c1ccccc1,BRD-A88254928,adrenergic receptor agonist
10.753315,8.032168,273,Oc1cc2CCNCC(c3ccccc3)c2cc1O,BRD-A88548664,c1ccc(C2CNCCc3ccccc32)cc1,BRD-A88548664,dopamine receptor agonist
10.757388,7.382855,274,OC(C1CCCCN1)c2cc(nc3c(cccc23)C(F)(F)F)C(F)(F)F,BRD-A89585551,c1ccc2c(CC3CCCCN3)ccnc2c1,BRD-A89585551,adenosine receptor antagonist|hemoglobin antagonist
10.086628,4.1109614,275,C[C@H](NC[C@H](O)CP(=O)(O)Cc1ccccc1)c2ccc(Cl)c(Cl)c2,BRD-A89672324,O=[PH](CCCNCc1ccccc1)Cc1ccccc1,BRD-A89672324,gaba receptor antagonist
2.1961954,0.70212376,276,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@H](C)CC2C3[C@H](Cl)CC4=CC(=O)C=C[C@]4(C)C3[C@@H](O)C[C@@]21C,BRD-A90131694,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A90131694,glucocorticoid receptor agonist
10.389914,3.1272404,277,COc1ccccc1OCC(O)CO,BRD-A90515964,c1ccccc1,BRD-A90515964,expectorant
10.969217,3.5617044,278,COC(=O)C1=C(C)NC(=C(C1c2cccc3nonc23)C(=O)OC(C)C)C,BRD-A90799790,C1=CC(c2cccc3nonc23)C=CN1,BRD-A90799790,calcium channel blocker
4.4044228,1.0060558,279,C[C@@]12CCC3C(CCc4cc(O)ccc34)C2CC[C@@H]1OC(=O)CCC5CCCC5,BRD-A91452556,O=C(CCC1CCCC1)OC1CCC2C1CCC1c3ccccc3CCC12,BRD-A91452556,estrogen receptor agonist
1.4466016,0.58529866,280,CC1(C)O[C@@H]2CC3C4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,BRD-A92439610,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-A92439610,glucocorticoid receptor agonist
3.8027194,1.0723432,281,C[C@@]12CCC3C(CCC4=Cc5oncc5C[C@]34C)C2CC[C@@]1(O)C#C,BRD-A92537424,C1=C2CCC3C4CCCC4CCC3C2Cc2cnoc21,BRD-A92537424,estrogen receptor antagonist|progesterone receptor agonist
9.488706,6.267514,282,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5OC1[C@]2(CCN3CC6CCC6)c54,BRD-A92651262,c1cc2c3c(c1)OC1CCCC4C(C2)N(CC2CCC2)CCC314,BRD-A92651262,opioid receptor agonist
10.446582,4.285426,283,CC(N)C(=O)Nc1c(C)cccc1C,BRD-A92670106,c1ccccc1,BRD-A92670106,sodium channel blocker
9.61135,6.7439656,284,O=C1CCCC2C3CC(CN21)[C@@H]4CCCCN4C3,BRD-A92826379,O=C1CCCC2C3CC(CN12)C1CCCCN1C3,BRD-A92826379,sodium channel blocker
12.0372505,4.703512,285,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1,BRD-A93000692,O=C1NC(=O)C(Cc2ccc(OCC3CCCCC3)cc2)S1,BRD-A93000692,ppar receptor agonist
4.025409,1.8139948,286,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@@H]2[C@@H](C)O[C@H](C[C@@H]2O)O[C@@H]3[C@@H](C)O[C@H](C[C@@H]3O)O[C@H]4CC[C@@]5(C)[C@H](CCC6C5CC[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4,BRD-A93236127,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCC(OC6CCC(OC7CCCCO7)CO6)CO5)CC4CCC23)CO1,BRD-A93236127,atpase inhibitor
13.42363,3.7929149,287,Clc1ccc(C(Cn2ccnc2)OCc3c(Cl)cccc3Cl)c(Cl)c1,BRD-A93353767,c1ccc(COC(Cn2ccnc2)c2ccccc2)cc1,BRD-A93353767,lanosterol demethylase inhibitor
1.3485054,0.5778774,288,C[C@@H]1CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C,BRD-A93424738,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-A93424738,glucocorticoid receptor agonist
11.319784,6.0514946,289,c1cn(cn1)C(c2ccccc2)c3ccc(cc3)c4ccccc4,BRD-A94543220,c1ccc(-c2ccc(C(c3ccccc3)n3ccnc3)cc2)cc1,BRD-A94543220,sterol demethylase inhibitor
8.879309,4.6116724,290,CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]3O[C@@H]4COP(=O)(O)O[C@H]4[C@H]3OC(=O)CCC,BRD-A94624445,O=[PH]1OCC2OC(n3cnc4cncnc43)CC2O1,BRD-A94624445,adenosine receptor agonist|camp stimulant
8.17507,7.4048767,291,Oc1ccc(cc1)C2CC(=O)c3c(O)cc(O)cc3O2,BRD-A94669766,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-A94669766,aromatase inhibitor
9.254141,6.2391014,292,Cc1cc(C)cc(OCC2CNC(=O)O2)c1,BRD-A94709349,O=C1NCC(COc2ccccc2)O1,BRD-A94709349,muscle relaxant
4.0296197,1.7836381,293,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@@H]2[C@@H](C)O[C@H](C[C@@H]2O)O[C@@H]3[C@@H](C)O[C@H](C[C@@H]3O)O[C@H]4CC[C@@]5(C)[C@H](CCC6C5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4,BRD-A94756469,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCC(OC6CCC(OC7CCCCO7)CO6)CO5)CC4CCC23)CO1,BRD-A94756469,atpase inhibitor
11.785643,7.2014117,294,Fc1ccc(cc1)N2CCN(CCC3OCCc4ccccc34)CC2,BRD-A95096829,c1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1,BRD-A95096829,dopamine receptor antagonist
3.3826294,1.2761235,295,CC(=O)O[C@@]1(CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)C3CC[C@@]21C)C(=O)C,BRD-A95207036,O=C1C=C2C=CC3C4CCCC4CCC3C2C2CC12,BRD-A95207036,androgen receptor antagonist
8.388184,6.0876226,296,Oc1ccc2C3Oc4cc5OCOc5cc4C3COc2c1,BRD-A95445494,c1ccc2c(c1)OCC1c3cc4c(cc3OC21)OCO4,BRD-A95445494,interleukin synthesis inhibitor|sodium/glucose cotransporter inhibitor
3.7543752,1.0615209,297,C[C@@]12CCC3C(CCC4=CC(=O)C=C[C@]34C)C2CCC1=O,BRD-A95513702,O=C1C=CC2C(=C1)CCC1C2CCC2C(=O)CCC21,BRD-A95513702,aromatase inhibitor
9.529335,7.356345,298,CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(=O)(=O)N,BRD-A95869247,O=C(NN1CCc2ccccc21)c1ccccc1,BRD-A95869247,thiazide diuretic
13.3944025,3.8215554,299,Clc1ccc(C(Cn2ccnc2)OCc3csc4c(Cl)cccc34)c(Cl)c1,BRD-A95939040,c1ccc(C(Cn2ccnc2)OCc2csc3ccccc23)cc1,BRD-A95939040,sterol demethylase inhibitor
10.65659,5.3628235,300,CCOC(=O)C1CN(Cc2ccccc2)C(=O)C1=O,BRD-A96485169,O=C1CCN(Cc2ccccc2)C1=O,BRD-A96485169,aldose reductase inhibitor
3.7713394,1.1012648,301,CC12CC=C3C(CCC4=CC(=O)C=CC43C)C2CC[C@@H]1C(=O)CN5CCN(CC5)c6cc(nc(n6)N7CCCC7)N8CCCC8,BRD-A96897502,O=C1C=CC2C(=C1)CCC1C2=CCC2C(C(=O)CN3CCN(c4cc(N5CCCC5)nc(N5CCCC5)n4)CC3)CCC12,BRD-A96897502,lipid peroxidase inhibitor
9.506077,3.7438428,302,CC(Cc1ccc(O)cc1)NCC(O)c2cc(O)cc(O)c2,BRD-A97104540,c1ccc(CCNCCc2ccccc2)cc1,BRD-A97104540,adrenergic receptor agonist
12.164637,4.694501,303,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,BRD-A97437073,O=C1NC(=O)C(Cc2ccc(OCCNc3ccccn3)cc2)S1,BRD-A97437073,insulin sensitizer|ppar receptor agonist
13.521144,6.013575,304,CCN1CCCC(C1)OC(=O)C(c2ccccc2)c3ccccc3,BRD-A97479839,O=C(OC1CCCNC1)C(c1ccccc1)c1ccccc1,BRD-A97479839,acetylcholine receptor antagonist
10.555177,3.2043731,305,COc1ccccc1OCC(O)CN2CCN(CC(=O)Nc3c(C)cccc3C)CC2,BRD-A97674275,O=C(CN1CCN(CCCOc2ccccc2)CC1)Nc1ccccc1,BRD-A97674275,sodium channel blocker
10.324376,2.8475835,306,CC(C)NCC(O)COc1cccc2[nH]ccc12,BRD-A97701745,c1ccc2[nH]ccc2c1,BRD-A97701745,adrenergic receptor antagonist|serotonin receptor antagonist
10.425827,4.977448,307,CC(CNC1CCCCC1)OC(=O)c2ccccc2,BRD-A97730597,O=C(OCCNC1CCCCC1)c1ccccc1,BRD-A97730597,sodium channel blocker
9.837035,4.694985,308,CC(C(=O)O)c1cccc(c1)C(=O)c2ccccc2,BRD-A97739905,O=C(c1ccccc1)c1ccccc1,BRD-A97739905,cyclooxygenase inhibitor
10.647326,7.2201033,309,Nc1c2C(O)CCCc2nc3ccccc13,BRD-A98299281,c1ccc2nc3c(cc2c1)CCCC3,BRD-A98299281,calcium channel activator
9.425448,5.4378204,310,CCN1C[C@]2(C)CC[C@H](OC)[C@@]34[C@@H]2[C@H](OC(=O)C)[C@@]5(OCO[C@]65C[C@H](OC)[C@H]7C[C@]4(O)[C@@H]6[C@H]7OC)C13,BRD-A99177642,C1CC2CNC3C4(C1)C2CC31OCOC12CCC1CC4C2C1,BRD-A99177642,acetylcholine receptor antagonist
10.659982,10.149844,311,CCOc1ccc2ccccc2c1NC(=O)[C@H]3[C@H]4SC(C)(C)C(N4C3=O)C(=O)O,BRD-A99402294,O=C(Nc1cccc2ccccc12)C1C(=O)N2CCSC12,BRD-A99402294,bacterial cell wall synthesis inhibitor
10.708844,7.062153,312,COc1c2CC(Oc2nc3ccccc13)C(C)(O)CO,BRD-A99571536,c1ccc2nc3c(cc2c1)CCO3,BRD-A99571536,anti-epileptic
9.415722,7.063384,313,Cc1coc-2c1C(=O)C(=O)c3c4CCCC(C)(C)c4ccc23,BRD-K00141480,O=C1C(=O)c2c(ccc3c2CCCC3)-c2occc21,BRD-K00141480,anti-inflammatory|interleukin inhibitor
10.969931,6.4264145,314,O=Cc1c2[nH]c3ccccc3c2cc4[nH]c5ccccc5c14,BRD-K00184207,c1ccc2c(c1)[nH]c1cc3c(cc12)[nH]c1ccccc13,BRD-K00184207,aryl hydrocarbon receptor ligand
7.988932,5.6169376,315,COc1cc2CC[C@H](NC(=O)C)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC,BRD-K00259736,O=c1cccc2c(c1)CCCc1ccccc1-2,BRD-K00259736,microtubule inhibitor
11.807628,7.130261,316,Clc1ccccc1CN2CCc3sccc3C2,BRD-K00603606,c1ccc(CN2CCc3sccc3C2)cc1,BRD-K00603606,purinergic receptor antagonist|platelet aggregation inhibitor
10.598986,7.1343093,317,Cc1nnc2ccc(nn12)c3cccc(c3)C(F)(F)F,BRD-K00662280,c1ccc(-c2ccc3nncn3n2)cc1,BRD-K00662280,gaba receptor agonist
9.307118,7.0549765,318,NC(=Nc1nc(CSCC/C(=N\\S(=O)(=O)N)/N)cs1)N,BRD-K00673382,c1cscn1,BRD-K00673382,histamine receptor antagonist
2.1195602,0.857764,319,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO,BRD-K00824317,O=C1C=C2CCC3C(CCC4C3CC3OCOC34)C2CC1,BRD-K00824317,glucocorticoid receptor agonist
3.606243,1.1848841,320,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,BRD-K01095011,O=C1C=CC2C(CCC3C4CCCC4CCC23)N1,BRD-K01095011,5 alpha reductase inhibitor
10.724352,10.115556,321,Cc1onc(c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4ccccc4Cl,BRD-K01244426,O=C(NC1C(=O)N2CCSC12)c1conc1-c1ccccc1,BRD-K01244426,bacterial cell wall synthesis inhibitor
12.645312,5.9690967,322,Fc1ccc(cc1)C(CCCN2CCC(CC2)n3c(=O)[nH]c4ccccc34)c5ccc(F)cc5,BRD-K01292756,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccccc2)c2ccccc2)CC1,BRD-K01292756,dopamine receptor antagonist
10.419219,5.703227,323,O=C(CC(=O)c1ccccc1)c2ccccc2,BRD-K01555864,O=C(CC(=O)c1ccccc1)c1ccccc1,BRD-K01555864,antineoplastic
8.4355,3.4133275,324,CC/C=C\\C/C=C\\C/C=C\\CCCCCCCCCCCC(=O)O,BRD-K01624546,,BRD-K01624546,ltb4 inhibitor
11.874935,7.0881333,325,CN1CCc2c(Cc3ccccc3CC1)[nH]c4ccccc24,BRD-K01648091,c1ccc2c(c1)CCNCCc1c([nH]c3ccccc13)C2,BRD-K01648091,dopamine receptor antagonist
11.9732065,6.232053,326,OC(CCCN1CCCCC1)(c2ccccc2)c3ccccc3,BRD-K01663662,c1ccc(C(CCCN2CCCCC2)c2ccccc2)cc1,BRD-K01663662,muscarinic antagonist
11.046366,6.5339913,327,OCc1c[nH]c2ccccc12,BRD-K01815685,c1ccc2[nH]ccc2c1,BRD-K01815685,"aryl hydrocarbon receptor agonist|indoleamine 2,3-dioxygenase inhibitor"
9.1880455,6.445527,328,CCCn1c(=O)n(CCC)c2[nH]c(nc2c1=O)C3CCCC3,BRD-K01824921,O=c1[nH]c(=O)c2nc(C3CCCC3)[nH]c2[nH]1,BRD-K01824921,adenosine receptor antagonist
11.971105,3.8120053,329,COc1cc(N)c(Cl)cc1C(=O)OCCCN2CCCCC2,BRD-K01868942,O=C(OCCCN1CCCCC1)c1ccccc1,BRD-K01868942,serotonin receptor antagonist
10.788517,4.5808115,330,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C,BRD-K01902415,c1ccc(Nc2ccncn2)cc1,BRD-K01902415,ppar receptor agonist
11.639264,7.671283,331,Clc1ccc2Oc3ccccc3N=C(N4CCNCC4)c2c1,BRD-K02265150,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1O2,BRD-K02265150,norepinephrine reuptake inhibitor
10.552165,9.351078,332,CN(C)CCn1nnnc1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)Cc4csc(N)n4)C3=O)C(=O)O,BRD-K02275692,O=C(Cc1cscn1)NC1C(=O)N2C=C(CSc3nnn[nH]3)CSC12,BRD-K02275692,bacterial cell wall synthesis inhibitor
10.661619,9.524733,333,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)CSc4nnnn4C)c5ccc(O)cc5)C(=O)C1=O,BRD-K02292852,O=C1NCCN(C(=O)NC(C(=O)NC2C(=O)N3C=C(CSc4nnn[nH]4)CSC23)c2ccccc2)C1=O,BRD-K02292852,bacterial cell wall synthesis inhibitor
9.078481,6.5459146,334,Cn1cnc2n(C)c(=O)n(C)c(=O)c12,BRD-K02404261,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K02404261,adenosine receptor antagonist|phosphodiesterase inhibitor
7.265024,4.523818,335,CCCCc1ccc2[nH]c(NC(=O)OC)nc2c1,BRD-K02407574,c1ccc2[nH]cnc2c1,BRD-K02407574,tubulin polymerization inhibitor
7.1061244,5.8501754,336,COc1cc2CC[N+](C)(C)[C@@H]3Cc4ccc(O)c(Oc5cc6[C@H](Cc7cccc(Oc(c1O)c32)c7)N(C)CCc6cc5OC)c4,BRD-K02607075,c1cc2cc(c1)Oc1ccc3c(c1)C(Cc1cccc(c1)Oc1cccc4c1C(C2)[NH2+]CC4)NCC3,BRD-K02607075,acetylcholine receptor antagonist
9.20357,7.678283,337,Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F,BRD-K02637541,c1ccc(-c2ccnn2-c2ccccc2)cc1,BRD-K02637541,cyclooxygenase inhibitor
7.206843,5.9228063,338,COc1ccc2[C@H](OC(=O)c2c1OC)[C@@H]3N(C)CCc4cc5OCOc5cc34,BRD-K02715688,O=C1OC(C2NCCc3cc4c(cc32)OCO4)c2ccccc21,BRD-K02715688,tyrosine hydroxylase inhibitor
7.241199,4.4686656,339,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,BRD-K02764365,c1ccc2[nH]cnc2c1,BRD-K02764365,anthelmintic
11.787221,6.713298,340,Cc1cc(nnc1NCCN2CCOCC2)c3ccccc3,BRD-K02867583,c1ccc(-c2ccc(NCCN3CCOCC3)nn2)cc1,BRD-K02867583,serotonin reuptake inhibitor
8.119404,7.3360496,341,C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc3cc(O)c4C(=O)C[C@H](Oc4c3)c5ccc(O)cc5)[C@H](O)[C@H](O)[C@H]1O,BRD-K02953697,O=C1CC(c2ccccc2)Oc2cc(OC3OCCCC3OC3CCCCO3)ccc21,BRD-K02953697,cytochrome p450 inhibitor
7.449352,5.579347,342,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]4NCCc5cc(OC)c(OC)cc45,BRD-K03067624,c1ccc2c(c1)CCNC2CC1CCN2CCc3ccccc3C2C1,BRD-K03067624,protein synthesis inhibitor
11.388995,5.985215,343,CNCCC[C@]1(CC[C@H]2c3ccccc31)c4ccccc24,BRD-K03319035,c1ccc2c(c1)C1CCC2c2ccccc21,BRD-K03319035,norepinephrine reuptake inhibitor
10.282366,7.092534,344,CC(=C)[C@H]1O[C@H]2CC[C@]3(C)[C@]4(C)[C@@H](CC[C@@]3(O)[C@@]52O[C@@H]5[C@H]1O)[C@@H]6OC(C)(C)[C@H]7C[C@@H]8C(=C)Cc9c(Cl)cc%10[nH]c4c6c%10c9[C@@]87O,BRD-K03842655,C=C1Cc2ccc3[nH]c4c5c3c2C2C(COC5C3CCC5C(CCC6OCCC7OC675)C43)CC12,BRD-K03842655,potassium channel blocker
3.7091658,1.1603702,345,C[C@@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]2CC[C@@]1(O)C#C,BRD-K03981224,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K03981224,progestogen hormone
8.49225,3.3210237,346,CCCCC[C@H](O)/C=C/[C@H]1C=CC(=O)[C@@H]1CCCCCCC(=O)O,BRD-K04010869,O=C1C=CCC1,BRD-K04010869,hsp inducer|nfkb pathway inhibitor
11.992513,3.029509,347,CCN1CCC[C@H]1CNC(=O)c2c(O)c(Cl)cc(Cl)c2OC,BRD-K04111260,O=C(NCC1CCCN1)c1ccccc1,BRD-K04111260,dopamine receptor antagonist
11.7866535,3.9429348,348,CCCCOc1cc(ccc1N)C(=O)OCCN(CC)CC,BRD-K04185004,c1ccccc1,BRD-K04185004,local anesthetic
9.586516,6.9239717,349,[O-][N+](=O)c1cccc2cn[nH]c12,BRD-K04430056,c1ccc2[nH]ncc2c1,BRD-K04430056,nitric oxide synthase inhibitor
11.739153,6.393876,350,Clc1ccc(Cn2c(CN3CCCC3)nc4ccccc24)cc1,BRD-K04704168,c1ccc(Cn2c(CN3CCCC3)nc3ccccc32)cc1,BRD-K04704168,hcv inhibitor
7.9472437,9.412141,351,OC(=O)c1cn(C2CC2)c3cc(N4CCNCC4)c(F)cc3c1=O,BRD-K04804440,O=c1ccn(C2CC2)c2cc(N3CCNCC3)ccc12,BRD-K04804440,bacterial dna gyrase inhibitor
9.937679,4.3042607,352,CSCC[C@H](NC(=O)[C@H](Cc1ccccc1)NC[C@@H](NC[C@@H](N)CS)C(C)C)C(=O)O,BRD-K04877770,c1ccccc1,BRD-K04877770,farnesyltransferase inhibitor
11.324267,6.4790416,353,OC1(CCN(Cc2c[nH]c3ccccc23)CC1)c4ccc(Cl)cc4,BRD-K05181463,c1ccc(C2CCN(Cc3c[nH]c4ccccc34)CC2)cc1,BRD-K05181463,dopamine receptor antagonist
8.017919,6.846912,354,Oc1cc(O)c2c(=O)cc(oc2c1)c3ccc(O)c(O)c3,BRD-K05236810,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K05236810,glucosidase inhibitor
10.945825,7.6686144,355,CN1CCC[C@H]1c2cccnc2,BRD-K05395900,c1cncc(C2CCCN2)c1,BRD-K05395900,acetylcholine receptor agonist
10.959798,6.7256784,356,NC(=N)NCCNS(=O)(=O)c1cccc2cnccc12,BRD-K05434375,c1ccc2cnccc2c1,BRD-K05434375,calcium channel blocker
11.442459,6.4869385,357,Clc1ccc(cc1)N2CCN(Cc3c[nH]c4ncccc34)CC2,BRD-K05528470,c1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1,BRD-K05528470,dopamine receptor antagonist
9.831875,3.8619013,358,CCCCCCCCCC(=O)N[C@H](CN1CCOCC1)[C@H](O)c2ccccc2,BRD-K05653692,c1ccc(CCCN2CCOCC2)cc1,BRD-K05653692,glucosyltransferase inhibitor
10.763026,10.131601,359,Cc1onc(c1C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4c(Cl)cccc4Cl,BRD-K05673000,O=C(NC1C(=O)N2CCSC12)c1conc1-c1ccccc1,BRD-K05673000,bacterial cell wall synthesis inhibitor
11.730669,8.532878,360,CCN(CC)C(=O)N[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(C)C1,BRD-K05901394,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K05901394,dopamine receptor agonist
9.456956,5.9768486,361,OC(Cn1cncn1)(Cn2cncn2)c3ccc(F)cc3F,BRD-K05977355,c1ccc(C(Cn2cncn2)Cn2cncn2)cc1,BRD-K05977355,sterol demethylase inhibitor
11.974357,7.3331985,362,CN1CCN(CC(=O)N2c3c(C)scc3C(=O)Nc4ccccc24)CC1,BRD-K06147391,O=C1Nc2ccccc2N(C(=O)CN2CCNCC2)c2cscc21,BRD-K06147391,acetylcholine receptor antagonist
11.835312,4.282342,363,CCN(CC)CCOCCOC(=O)C1(CCCC1)c2ccccc2,BRD-K06181161,c1ccc(C2CCCC2)cc1,BRD-K06181161,acetylcholine receptor antagonist
7.691126,5.4921856,364,COc1ccc(CCN(C)CCc2ccc(OC)c(OC)c2)cc1OC,BRD-K06208435,c1ccc(CCNCCc2ccccc2)cc1,BRD-K06208435,calcium channel blocker
10.85803,6.6738815,365,Cn1cc(C2=C(C(=O)NC2=O)c3cn(CCCSC(=N)N)c4ccccc34)c5ccccc15,BRD-K06543683,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,BRD-K06543683,pkc inhibitor|glycogen synthase kinase inhibitor|leucine rich repeat kinase inhibitor|sirt inhibitor
10.083768,5.225908,366,CC1(C)CCC(C)(C)c2cc(ccc21)C(=O)Nc3ccc(cc3)C(=O)O,BRD-K06854232,O=C(Nc1ccccc1)c1ccc2c(c1)CCCC2,BRD-K06854232,retinoid receptor agonist
11.093303,7.6903043,367,Nc1cc(nc(N)[n+]1[O-])N2CCCCC2,BRD-K06902185,c1cc(N2CCCCC2)nc[nH+]1,BRD-K06902185,katp activator|kir6 channel (katp) activator|vasodilator
7.76752,5.42758,368,COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,BRD-K07208025,c1ccc(Cc2cncnc2)cc1,BRD-K07208025,dihydrofolate reductase inhibitor
12.32718,6.558459,369,C(/C=C/c1ccccc1)N2CCN(CC2)C(c3ccccc3)c4ccccc4,BRD-K07220430,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,BRD-K07220430,calcium channel blocker
8.462789,5.655771,370,COc1cc(/C=C/C(=O)CC(=O)\\C=C\\c2ccc(O)c(OC)c2)ccc1O,BRD-K07572174,O=C(C=Cc1ccccc1)CC(=O)C=Cc1ccccc1,BRD-K07572174,cyclooxygenase inhibitor|histone acetyltransferase inhibitor|lipoxygenase inhibitor|nfkb pathway inhibitor
11.532923,4.035165,371,CCN(CC)CCNC(=O)c1ccc(NC(=O)C)cc1,BRD-K07753030,c1ccccc1,BRD-K07753030,polarization inhibitor
8.436825,5.9063478,372,C[C@@]1(C[C@@H](O)[C@]2(O)C=CO[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)[C@H]12)OC(=O)/C=C/c4ccccc4,BRD-K07996107,O=C(C=Cc1ccccc1)OC1CCC2C=COC(OC3CCCCO3)C21,BRD-K07996107,acetylcholinesterase inhibitor
9.461807,5.13411,373,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@@H]([C@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O,BRD-K08033334,O=C(NCC1CCCCO1)C1CCCN1,BRD-K08033334,bacterial 30s ribosomal subunit inhibitor
7.1841598,5.7525086,374,COc1cc2CCN(C)[C@H]3Cc4ccc(OC)c(Oc5ccc(C[C@@H]6N(C)CCc7cc(OC)c(Oc(c1OC)c32)cc67)cc5)c4,BRD-K08078237,c1cc2cc(c1)Oc1ccc(cc1)CC1NCCc3ccc(cc31)Oc1cccc3c1C(C2)NCC3,BRD-K08078237,calcium channel blocker
10.04369,6.8648577,375,Oc1c(c2cccc(Oc3ccccc3)c2)c(=O)[nH]c4cc(Cl)ccc14,BRD-K08109516,O=c1[nH]c2ccccc2cc1-c1cccc(Oc2ccccc2)c1,BRD-K08109516,glutamate receptor antagonist
10.902665,4.864643,376,OC(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl,BRD-K08252256,c1ccc(Nc2ccccc2)cc1,BRD-K08252256,cyclooxygenase inhibitor
8.282485,5.824782,377,COC1=CC(=O)C[C@@H](C)[C@@]21Oc3c(C2=O)c(OC)cc(OC)c3Cl,BRD-K08273968,O=C1C=CC2(CC1)Oc1ccccc1C2=O,BRD-K08273968,tubulin polymerization inhibitor
9.332468,5.9057026,378,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,BRD-K08303368,c1ccncc1,BRD-K08303368,acetylcholinesterase inhibitor
9.409161,5.363235,379,CCCSP(=O)(OCC)SCCC,BRD-K08556791,,BRD-K08556791,acetylcholinesterase inhibitor
12.588572,7.493834,380,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3N(CCCN4CCN(C)CC4)c2c1,BRD-K08619574,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K08619574,dopamine receptor antagonist
8.227417,7.36484,381,Oc1ccc(cc1)[C@@H]2CC(=O)c3c(O)cc(O)cc3O2,BRD-K08832567,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-K08832567,aromatase inhibitor|trpv antagonist
8.443464,3.422124,382,CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)O,BRD-K08973992,,BRD-K08973992,oxidative stress inducer
11.154143,7.6251836,383,NC1CCN(CC1)c2cccc(Cl)n2,BRD-K09397065,c1ccc(N2CCCCC2)nc1,BRD-K09397065,serotonin receptor agonist
9.628674,5.150244,384,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,BRD-K09416995,O=C1CCCC(CCC2CC=CC3=CCCCC32)O1,BRD-K09416995,hmgcr inhibitor
10.417539,7.5753984,385,COC1=CC(=O)O[C@H](C1)/C=C/c2ccccc2,BRD-K09497549,O=C1C=CCC(C=Cc2ccccc2)O1,BRD-K09497549,calcium channel modulator|mtor inhibitor|sodium channel blocker
9.949234,4.002332,386,CCCCCCCCCCCCCC(=O)N[C@@H](C)[C@H](O)c1ccccc1,BRD-K09635134,c1ccccc1,BRD-K09635134,negative control for d-erythro-mapp
10.435591,6.721266,387,c1ccc2c(c1)cc3ccc4cccc5ccc2c3c45,BRD-K09668667,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34,BRD-K09668667,carcinogen
11.131248,6.2005563,388,CCCCCCN(CCCCCC)C(=O)Cc1c([nH]c2ccccc12)c3ccc(F)cc3,BRD-K09778810,c1ccc(-c2cc3ccccc3[nH]2)cc1,BRD-K09778810,inositol monophosphatase inhibitor
10.496237,5.5007935,389,CC[N+](C)(CC)CCOC(=O)C1c2ccccc2Oc3ccccc13,BRD-K09859624,c1ccc2c(c1)Cc1ccccc1O2,BRD-K09859624,acetylcholine receptor antagonist
10.349488,4.5374017,390,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(=O)N)NC(=O)c4ccc5ccccc5n4,BRD-K09963420,O=C(CNC(=O)c1ccc2ccccc2n1)NC(CCN1CCC2CCCCC2C1)Cc1ccccc1,BRD-K09963420,hiv protease inhibitor
11.680239,7.6483393,391,Clc1ccc2Nc3ccccc3C(=Nc2c1)N4CCNCC4,BRD-K10042277,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,BRD-K10042277,cetylcholine receptor agonist|dopamine receptor agonist|dopamine receptor antagonist|dopamine receptor partial agonist|serotonin receptor antagonist|serotonin receptor inverse agonist
9.066706,7.008356,392,Oc1cccc2C(=O)c3cccc(O)c3C(=O)c12,BRD-K10065684,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K10065684,laxative
10.026648,6.819703,393,Oc1c(C(=O)C2CC2)c(=O)[nH]c3cc(Cl)ccc13,BRD-K10176267,O=C(c1cc2ccccc2[nH]c1=O)C1CC1,BRD-K10176267,glutamate receptor antagonist
11.778355,4.470566,394,CN(C)CCOC(=O)COc1ccc(Cl)cc1,BRD-K10314788,c1ccccc1,BRD-K10314788,nootropic
9.265378,8.2386,395,OC(=O)c1cc(/N=N/c2ccc(cc2)S(=O)(=O)Nc3ccccn3)ccc1O,BRD-K10670311,O=S(=O)(Nc1ccccn1)c1ccc(N=Nc2ccccc2)cc1,BRD-K10670311,antirheumatic drug|nfkb pathway inhibitor
9.264351,8.258373,396,Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2c3ccccc3,BRD-K10671814,O=S(=O)(Nc1ccnn1-c1ccccc1)c1ccccc1,BRD-K10671814,dihydropteroate synthetase inhibitor
8.720432,5.876071,397,Oc1ccc(/C=C(/C#N)\\C(=O)OC\\C=C\\c2ccccc2)cc1O,BRD-K10870738,O=C(C=Cc1ccccc1)OCC=Cc1ccccc1,BRD-K10870738,lipoxygenase inhibitor
12.615566,7.424282,398,OCCN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,BRD-K10995081,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K10995081,dopamine receptor antagonist
10.584567,5.2763343,399,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,BRD-K11129031,c1ccccc1,BRD-K11129031,lipoprotein lipase activator
7.991947,9.398714,400,CCn1cc(C(=O)O)c(=O)c2cc(F)c(cc12)N3CCNCC3,BRD-K11196887,O=c1cc[nH]c2cc(N3CCNCC3)ccc12,BRD-K11196887,bacterial dna gyrase inhibitor
11.326708,5.137726,401,NC(=N)NC(=N)NCCc1ccccc1,BRD-K11399644,c1ccccc1,BRD-K11399644,ampk activator
9.2507,8.15688,402,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1,BRD-K11640013,O=S(=O)(Nc1ncccn1)c1ccccc1,BRD-K11640013,paba antagonist
10.044212,5.6595163,403,CCc1oc2ccccc2c1C(=O)c3cc(Br)c(O)c(Br)c3,BRD-K11717138,O=C(c1ccccc1)c1coc2ccccc12,BRD-K11717138,chloride channel blocker
11.393057,5.979915,404,Cc1ccc(cc1)/C(=C\\CN2CCCC2)/c3ccccn3,BRD-K11742128,C(CN1CCCC1)=C(c1ccccc1)c1ccccn1,BRD-K11742128,histamine receptor antagonist
9.80562,7.3925548,405,[O-][N+](=O)c1ccc(/C=N/N2CCOC2=O)o1,BRD-K11756522,O=C1OCCN1N=Cc1ccco1,BRD-K11756522,bacterial dna inhibitor
10.930126,5.160333,406,O=C(CCNNC(=O)c1ccncc1)NCc2ccccc2,BRD-K12102668,O=C(CCNNC(=O)c1ccncc1)NCc1ccccc1,BRD-K12102668,monoamine oxidase inhibitor
8.877246,7.969858,407,Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,BRD-K12219985,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCNC(=O)c2cnccn2)cc1,BRD-K12219985,sulfonylurea
8.389818,5.5334487,408,COc1cc(O)c(C(=O)C)c(OC)c1,BRD-K12260308,c1ccccc1,BRD-K12260308,antifungal
10.706729,5.635402,409,OC(=O)CCC(=O)c1ccc(cc1)c2ccccc2,BRD-K12513978,c1ccc(-c2ccccc2)cc1,BRD-K12513978,cyclooxygenase inhibitor
10.437955,7.5481424,410,CN(C)c1c(C)n(C)n(c2ccccc2)c1=O,BRD-K12568846,O=c1cc[nH]n1-c1ccccc1,BRD-K12568846,analgesic
11.325685,5.1028543,411,N/C(=N\\C(=O)c1nc(Cl)c(N)nc1N)/NCc2ccc(Cl)cc2Cl,BRD-K12906962,O=C(N=CNCc1ccccc1)c1cnccn1,BRD-K12906962,sodium/calcium exchange inhibitor
9.563862,7.538405,412,Cc1onc(c1c2ccc(cc2)S(=O)(=O)N)c3ccccc3,BRD-K12994359,c1ccc(-c2conc2-c2ccccc2)cc1,BRD-K12994359,cyclooxygenase inhibitor
11.918945,5.9034557,413,Cc1c(noc1c2ccc(Cl)cc2)C3CCN(CCc4ccccc4)CC3,BRD-K13211965,c1ccc(CCN2CCC(c3cc(-c4ccccc4)on3)CC2)cc1,BRD-K13211965,dopamine receptor antagonist
11.121904,7.747352,414,CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21,BRD-K13261168,c1ncc2c(n1)CC1CCCNC1C2,BRD-K13261168,dopamine receptor agonist
8.448346,3.9369748,415,CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C/C=C/C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C,BRD-K13533483,O=C1CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CN1,BRD-K13533483,calcineurin inhibitor|cyclophilin inhibitor|immunosuppressant|insulin expression inhibitor|t cell inhibitor
7.0059276,5.989077,416,CCCN1CCc2cccc-3c2[C@H]1Cc4ccc(O)c(O)c43,BRD-K13544237,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K13544237,dopamine receptor agonist|antiamyloidogenic
11.493718,7.3581834,417,C1CN2Cc3ccccc3N=C2C1,BRD-K13819402,c1ccc2c(c1)CN1CCCC1=N2,BRD-K13819402,acetylcholinesterase inhibitor|monoamine oxidase inhibitor
9.594912,6.645677,418,CCCc1nc(C)c2c(=O)[nH]c(nn12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(CC)CC4,BRD-K13926615,O=c1[nH]c(-c2cccc(S(=O)(=O)N3CCNCC3)c2)nn2cncc12,BRD-K13926615,phosphodiesterase inhibitor
10.328941,2.865546,419,CC(C)NC[C@H](O)COc1cccc2ccccc12,BRD-K13994703,c1ccc2ccccc2c1,BRD-K13994703,adrenergic receptor antagonist
9.923736,5.7810717,420,CN/C(=C/[N+](=O)[O-])/NCCSCc1ccc(CN(C)C)o1,BRD-K14204120,c1ccoc1,BRD-K14204120,histamine receptor antagonist
11.731279,7.1284733,421,Nc1ccc(CCN2CCN(CC2)c3cccc(c3)C(F)(F)F)cc1,BRD-K14282469,c1ccc(CCN2CCN(c3ccccc3)CC2)cc1,BRD-K14282469,serotonin receptor antagonist
11.900673,8.907407,422,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C,BRD-K14496212,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-K14496212,dopamine receptor agonist
8.496507,5.8973503,423,COc1ccc(/C=C/c2cc(O)cc(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1,BRD-K14536225,C(=Cc1cccc(OC2CCCCO2)c1)c1ccccc1,BRD-K14536225,glucosidase inhibitor
10.522335,5.9998465,424,CCn1nc(C(=O)O)c(=O)c2cc3OCOc3cc12,BRD-K14704277,O=c1cn[nH]c2cc3c(cc12)OCO3,BRD-K14704277,topoisomerase inhibitor
9.255179,8.259088,425,Nc1ccc(cc1)S(=O)(=O)Nc2nccs2,BRD-K14705039,O=S(=O)(Nc1nccs1)c1ccccc1,BRD-K14705039,dihydropteroate synthase inhibitor
7.5340185,5.9147644,426,COc1ccc2cc3-c4cc5OCOc5cc4CC[n+]3cc2c1OC,BRD-K14796088,c1ccc2c[n+]3c(cc2c1)-c1cc2c(cc1CC3)OCO2,BRD-K14796088,ldl receptor activator
8.976575,6.075139,427,FC(F)(F)Oc1ccc(NN=C(C#N)C#N)cc1,BRD-K14821540,c1ccccc1,BRD-K14821540,mitochondrial oxidative phosphorylation uncoupler
11.155419,7.698326,428,Nc1cc(nc(=N)n1O)N2CCCCC2,BRD-K14888893,N=c1nc(N2CCCCC2)cc[nH]1,BRD-K14888893,katp activator
9.114715,7.5593767,429,Cc1ccc(cc1)S(=O)(=O)/C=C/C#N,BRD-K15025317,c1ccccc1,BRD-K15025317,nfkb pathway inhibitor
10.421513,6.963052,430,C1CCN(CC1)C2(CCCCC2)c3cc4ccccc4s3,BRD-K15519488,c1ccc2sc(C3(N4CCCCC4)CCCCC3)cc2c1,BRD-K15519488,dopamine receptor agonist
8.7997265,5.133846,431,Oc1ccc(CCC(=O)c2c(O)cc(O)cc2O)cc1,BRD-K15563106,O=C(CCc1ccccc1)c1ccccc1,BRD-K15563106,sodium/glucose cotransporter inhibitor
7.6695323,5.4513364,432,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC,BRD-K15567136,c1ccc(Cc2nccc3ccccc23)cc1,BRD-K15567136,phosphodiesterase inhibitor
11.896335,7.625618,433,CN1CCN(CC1)C2=Nc3cc(F)ccc3Cc4ccccc24,BRD-K15715913,c1ccc2c(c1)Cc1ccccc1C(N1CCNCC1)=N2,BRD-K15715913,dopamine receptor antagonist|serotonin receptor antagonist
11.913843,3.7826643,434,CCN(CC)CCOC(=O)c1cc(Cl)c(N)cc1OC,BRD-K15868788,c1ccccc1,BRD-K15868788,serotonin receptor antagonist
9.863971,5.9728065,435,CCCN(CCC)CCc1cccc2NC(=O)Cc21,BRD-K15933101,O=C1Cc2ccccc2N1,BRD-K15933101,dopamine receptor agonist|dopamine receptor modulator
11.234033,6.860311,436,Cc1cc(c(O)c(C)c1CC2=NCCN2)C(C)(C)C,BRD-K16195444,c1ccc(CC2=NCCN2)cc1,BRD-K16195444,adrenergic receptor agonist
9.992885,4.793607,437,CC(=O)Nc1cccc(O)c1,BRD-K16474819,c1ccccc1,BRD-K16474819,analgesic
10.408187,7.657701,438,CN1C(=O)CN=C(c2ccccc2)c3cc(Cl)ccc13,BRD-K16508793,O=C1CN=C(c2ccccc2)c2ccccc2N1,BRD-K16508793,benzodiazepine receptor agonist
10.261734,6.6321425,439,CCCOc1ccccc1c2nc3[nH]nnc3c(=O)[nH]2,BRD-K16542329,O=c1[nH]c(-c2ccccc2)nc2[nH]nnc12,BRD-K16542329,phosphodiesterase inhibitor
10.71268,7.099758,440,Cn1c2CCNCCc2c3ccccc13,BRD-K16551401,c1ccc2c3c([nH]c2c1)CCNCC3,BRD-K16551401,serotonin receptor agonist
7.006547,6.0153522,441,CCCN1CCc2cc(O)cc-3c2[C@H]1Cc4ccc(O)c(O)c43,BRD-K16604360,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K16604360,antiamyloidogenic|dopamine receptor agonist
4.366729,1.012005,442,C[C@@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]2C[C@@H](O)[C@@H]1O,BRD-K17016787,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-K17016787,estrogen receptor agonist
11.941446,3.6363122,443,COc1cc(N)c(Cl)cc1C(=O)NC2CCN(Cc3ccccc3)CC2,BRD-K17294426,O=C(NC1CCN(Cc2ccccc2)CC1)c1ccccc1,BRD-K17294426,dopamine receptor antagonist
11.4044285,3.8121722,444,COc1ccccc1N2CCN(CCCCNC(=O)c3ccc4ccccc4c3)CC2,BRD-K17378184,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc2ccccc2c1,BRD-K17378184,dopamine receptor agonist
11.987765,6.234774,445,OC(CCN1CCCCC1)(c2ccccc2)c3ccccc3,BRD-K17565903,c1ccc(C(CCN2CCCCC2)c2ccccc2)cc1,BRD-K17565903,muscle relaxant
1.4988593,0.74360543,446,C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)C)C(=O)COC(=O)C,BRD-K17674993,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K17674993,corticosteroid agonist
10.501343,7.0791907,447,CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n3c4ccccc4c5c6CNC(=O)c6c7c8ccccc8n2c7c35,BRD-K17953061,O=C1NCc2c1c1c3ccccc3n3c1c1c2c2ccccc2n1C1CCCC3O1,BRD-K17953061,pkc inhibitor
8.570904,3.4604697,448,CCCCC/C=C\\C/C=C\\C/C=C\\CCCCC(=O)O,BRD-K18059238,,BRD-K18059238,cyclooxygenase inhibitor|prostanoid receptor stimulant|thromboxane synthase stimulant
11.797836,3.9160283,449,CCCOc1cc(N)ccc1C(=O)OCCN(CC)CC,BRD-K18250272,c1ccccc1,BRD-K18250272,local anesthetic
3.973189,1.715912,450,C[C@@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@@]43C)[C@@]2(O)CC[C@@H]1C5=CC(=O)OC5,BRD-K18518344,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-K18518344,atpase inhibitor
8.316487,6.509962,451,COc1c(O)cc2C(=O)O[C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]3c2c1O,BRD-K18550767,O=C1OC2CCCOC2c2ccccc21,BRD-K18550767,interleukin inhibitor
10.494542,6.4042563,452,N/C(=C(/C#N)\\C(=C(/N)\\Sc1ccccc1N)\\C#N)/Sc2ccccc2N,BRD-K18787491,C(C=CSc1ccccc1)=CSc1ccccc1,BRD-K18787491,mek inhibitor
4.3696737,0.9843822,453,C[C@@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]2CC[C@@H]1O,BRD-K18910433,c1ccc2c(c1)CCC1C2CCC2CCCC21,BRD-K18910433,estrogen receptor agonist
9.583433,5.733449,454,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,BRD-K18922609,c1ccccc1,BRD-K18922609,acetylcholinesterase inhibitor
11.183797,4.6752214,455,CC(C)(Oc1ccc(Cl)cc1)C(=O)O,BRD-K19111024,c1ccccc1,BRD-K19111024,ppar receptor agonist
9.117543,7.0059524,456,Oc1ccc(cc1)C2(OC(=O)c3ccccc32)c4ccc(O)cc4,BRD-K19227686,O=C1OC(c2ccccc2)(c2ccccc2)c2ccccc21,BRD-K19227686,indicator dye
9.367145,5.7907457,457,CC(C)c1c(O)c(O)c(C=O)c2c(O)c(c(C)cc12)c3c(C)cc4c(C(C)C)c(O)c(O)c(C=O)c4c3O,BRD-K19295594,c1ccc2cc(-c3ccc4ccccc4c3)ccc2c1,BRD-K19295594,bcl inhibitor|mcl1 inhibitor
11.985972,6.835235,458,C(CN1CCOCC1)Nc2cc3CCCc4ccccc4-c3nn2,BRD-K19309090,c1ccc2c(c1)CCCc1cc(NCCN3CCOCC3)nnc1-2,BRD-K19309090,acetylcholine receptor agonist
12.588516,7.4490457,459,CN1CCN(CCCN2c3ccccc3Sc4ccc(Cl)cc24)CC1,BRD-K19352500,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K19352500,dopamine receptor antagonist
11.86182,8.841103,460,CC(C)[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C,BRD-K19360254,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-K19360254,dopamine receptor agonist
9.960608,5.292994,461,N[C@@H](CC(=O)N1CCn2c(nnc2C1)C(F)(F)F)Cc3cc(F)c(F)cc3F,BRD-K19416115,O=C(CCCc1ccccc1)N1CCn2cnnc2C1,BRD-K19416115,dipeptidyl peptidase inhibitor
9.609762,6.9721813,462,[O-][N+](=O)c1cc2[nH]c(=O)c(=O)[nH]c2cc1C#N,BRD-K19438463,O=c1[nH]c2ccccc2[nH]c1=O,BRD-K19438463,glutamate receptor antagonist
11.881878,4.118106,463,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1,BRD-K19462402,O=C(CCCN1CCCC1)c1ccccc1,BRD-K19462402,adrenergic receptor antagonist|calcium channel blocker
11.241657,7.5872536,464,Clc1cncc(n1)N2CCNCC2,BRD-K19554809,c1cnc(N2CCNCC2)cn1,BRD-K19554809,serotonin receptor agonist
10.601817,9.39,465,N[C@@H](C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)Cl)c3ccccc3,BRD-K20338176,O=C(Cc1ccccc1)NC1C(=O)N2C=CCSC12,BRD-K20338176,bacterial cell wall synthesis inhibitor
11.637232,7.354076,466,CC(C)(C)[C@]1(O)CCN2C[C@@H]3c4c(cccc4CCc5ccccc35)[C@@H]2C1,BRD-K20620780,c1ccc2c(c1)CCc1cccc3c1C2CN1CCCCC31,BRD-K20620780,dopamine receptor antagonist
11.775481,4.0610905,467,CCN(CC)CCNC(=O)COc1ccc(OC)cc1,BRD-K20655524,c1ccccc1,BRD-K20655524,psychoactive drug
10.02052,6.0090456,468,Cn1cc(C(=O)C(=O)N[C@H]2CN3CCC2CC3)c4ccccc14,BRD-K20714604,O=C(NC1CN2CCC1CC2)C(=O)c1c[nH]c2ccccc12,BRD-K20714604,serotonin receptor partial agonist
11.9499655,3.6356418,469,COc1cc(COc2cc(N)c(Cl)cc2C(=O)CCC3CCN(CCNS(=O)(=O)C)CC3)cc(OC)c1,BRD-K20742498,O=C(CCC1CCNCC1)c1ccccc1OCc1ccccc1,BRD-K20742498,serotonin receptor antagonist
9.279618,6.575617,470,Nc1nc2ccc(OC(F)(F)F)cc2s1,BRD-K21283037,c1ccc2scnc2c1,BRD-K21283037,glutamate inhibitor
11.2990675,5.128058,471,Nc1nc(N)c(nc1Cl)C(=O)NC(=N)Nc2ccccc2,BRD-K21350491,N=C(NC(=O)c1cnccn1)Nc1ccccc1,BRD-K21350491,acid sensing ion channel blocker|sodium channel blocker|trpp3 channel inhibitor|trpv modulator
10.264963,5.1752896,472,CCOC(=O)Nc1ccc2Sc3ccccc3N(C(=O)CCN4CCOCC4)c2c1,BRD-K21548250,O=C(CCN1CCOCC1)N1c2ccccc2Sc2ccccc21,BRD-K21548250,sodium channel blocker
10.557246,4.152044,473,Cc1cccc(C)c1NC2=NCCCS2,BRD-K21565985,c1ccc(NC2=NCCCS2)cc1,BRD-K21565985,adrenergic receptor agonist
8.968319,6.9301662,474,OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12,BRD-K21680192,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K21680192,topoisomerase inhibitor
9.841486,7.511543,475,CS(=O)(=O)c1ccc(cc1)C2=C(C(=O)OC2)c3ccccc3,BRD-K21733600,O=C1OCC(c2ccccc2)=C1c1ccccc1,BRD-K21733600,cyclooxygenase inhibitor
9.467782,5.7773027,476,OC(=O)c1cc(ccc1O)c2ccc(F)cc2F,BRD-K22031190,c1ccc(-c2ccccc2)cc1,BRD-K22031190,prostanoid receptor antagonist
8.590143,5.5258465,477,COc1ccc(C(=O)c2ccccc2O)c(O)c1,BRD-K22193694,O=C(c1ccccc1)c1ccccc1,BRD-K22193694,topical sunscreen
12.300107,6.8643274,478,CN1CCC(CC1)OC(c2ccccc2)c3ccccc3,BRD-K22936972,c1ccc(C(OC2CCNCC2)c2ccccc2)cc1,BRD-K22936972,dopamine uptake inhibitor
9.960814,4.1918826,479,OC[C@H](NC(=O)C(Cl)Cl)[C@H](O)c1ccc(cc1)[N+](=O)[O-],BRD-K22969690,c1ccccc1,BRD-K22969690,bacterial 50s ribosomal subunit inhibitor
4.022832,1.7716504,480,C[C@H]1O[C@H](C[C@H](O)[C@@H]1O)O[C@@H]2[C@@H](C)O[C@H](C[C@@H]2O)O[C@@H]3[C@@H](C)O[C@H](C[C@@H]3O)O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]7(C)[C@H](CC[C@]67O)C8=CC(=O)OC8)C4,BRD-K23478508,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCC(OC6CCC(OC7CCCCO7)CO6)CO5)CC4CCC23)CO1,BRD-K23478508,atpase inhibitor
9.350552,5.6668763,481,OC(=O)c1cc(ccc1O)N(Cc2ccccc2O)Cc3cc(O)ccc3O,BRD-K23583188,c1ccc(CN(Cc2ccccc2)c2ccccc2)cc1,BRD-K23583188,egfr inhibitor|tyrosine kinase inhibitor
10.35401,6.9618754,482,Clc1oc(=O)c2ccccc2c1Cl,BRD-K23704908,O=c1occc2ccccc12,BRD-K23704908,serine protease inhibitor
10.076009,6.932452,483,O=c1ccc2ccccc2o1,BRD-K23913458,O=c1ccc2ccccc2o1,BRD-K23913458,vitamin k antagonist
9.063464,6.536057,484,Cn1cnc2[nH]c(=O)n(C)c(=O)c12,BRD-K24084088,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K24084088,adenosine receptor antagonist
8.429237,5.661884,485,COc1cc(/C=C/C(=O)N2CCC=CC2=O)cc(OC)c1OC,BRD-K24132293,O=C1C=CCCN1C(=O)C=Cc1ccccc1,BRD-K24132293,glutathione transferase inhibitor
9.120697,6.583155,486,NC[C@@H]1O[C@@H](Cc2c(O)c(O)ccc12)C3(CC4CC5CC(C4)C3)C5,BRD-K24396733,c1ccc2c(c1)COC(C13CC4CC(CC(C4)C1)C3)C2,BRD-K24396733,dopamine receptor agonist
11.677589,4.0896583,487,CCN(CC)CCOC(=O)c1ccc(N)cc1,BRD-K24616672,c1ccccc1,BRD-K24616672,hmgcr inhibitor
10.7528925,6.07264,488,O=C(N1CCCCC1)c2ccc3OCOc3c2,BRD-K25140590,O=C(c1ccc2c(c1)OCO2)N1CCCCC1,BRD-K25140590,glutamate receptor modulator
12.318551,5.717742,489,Cc1nc2ccccn2c(=O)c1CCN3CCC(CC3)C(=O)c4ccc(F)cc4,BRD-K25224017,O=C(c1ccccc1)C1CCN(CCc2cnc3ccccn3c2=O)CC1,BRD-K25224017,serotonin receptor antagonist
10.909052,5.581832,490,OC(=O)CCc1nc(c(o1)c2ccccc2)c3ccccc3,BRD-K25394294,c1ccc(-c2ncoc2-c2ccccc2)cc1,BRD-K25394294,cyclooxygenase inhibitor
8.8203125,5.868763,491,CNC(=O)Oc1ccc2N(C)[C@H]3N(C)CC[C@@]3(C)c2c1,BRD-K25650355,c1ccc2c(c1)NC1NCCC21,BRD-K25650355,cholinesterase inhibitor
7.865659,5.987595,492,COc1ccc2c(OC)c3ccoc3nc2c1OC,BRD-K25741894,c1ccc2nc3occc3cc2c1,BRD-K25741894,acetylcholinesterase inhibitor
11.257848,6.5506563,493,CN(C)Cc1c[nH]c2ccccc12,BRD-K26005076,c1ccc2[nH]ccc2c1,BRD-K26005076,norepinephrine reuptake inhibitor
11.1541,7.7997017,494,CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@H]21,BRD-K26548821,c1[nH]nc2c1CC1NCCCC1C2,BRD-K26548821,dopamine receptor agonist
7.99442,6.832524,495,COc1ccc(cc1O)c2cc(=O)c3c(O)cc(O)cc3o2,BRD-K26862302,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K26862302,aryl hydrocarbon receptor agonist
10.604271,9.398806,496,Cn1nnnc1SCC2=C(N3[C@H](SC2)[C@H](NC(=O)[C@H](O)c4ccccc4)C3=O)C(=O)O,BRD-K27130738,O=C(Cc1ccccc1)NC1C(=O)N2C=C(CSc3nnn[nH]3)CSC12,BRD-K27130738,bacterial cell wall synthesis inhibitor
10.284901,6.9433384,497,O=c1cc(oc2c(cccc12)c3ccccc3)N4CCOCC4,BRD-K27305650,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12,BRD-K27305650,mtor inhibitor|pi3k inhibitor|dna dependent protein kinase inhibitor|phosphodiesterase inhibitor|plk inhibitor
9.383232,6.249422,498,C[C@H](CCCC(C)(C)O)[C@H]1CC[C@H]2/C(=C/C=C\\3/C[C@@H](O)C[C@H](O)C3=C)/CCC[C@]12C,BRD-K27316855,C=C1CCCCC1=CC=C1CCCC2CCCC12,BRD-K27316855,vitamin d receptor agonist
3.4985282,1.2214648,499,CC(=O)O[C@@]1(CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C)C(=O)C,BRD-K27351809,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-K27351809,progesterone receptor agonist
8.939679,5.0040383,500,CCCCCC[C@@H]([C@@H](C)O)n1cnc2c(N)ncnc12,BRD-K27450477,c1ncc2nc[nH]c2n1,BRD-K27450477,adenosine deaminase inhibitor
8.487017,3.283733,501,CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2C/C(=C\\CCCC(=O)O)/C[C@H]12,BRD-K27499107,C=C1CC2CCCC2C1,BRD-K27499107,ip receptor activator
10.307961,6.807076,502,O=C1CCc2c(O1)ccc3ccccc23,BRD-K27710560,O=C1CCc2c(ccc3ccccc23)O1,BRD-K27710560,sirt inhibitor
11.867908,6.857151,503,COC(=O)[C@@H](N1CCc2sccc2C1)c3ccccc3Cl,BRD-K27721098,c1ccc(CN2CCc3sccc3C2)cc1,BRD-K27721098,purinergic receptor antagonist
10.719514,6.7091236,504,Brc1ccc(/C=C/CNCCNS(=O)(=O)c2cccc3cnccc23)cc1,BRD-K27737647,O=S(=O)(NCCNCC=Cc1ccccc1)c1cccc2cnccc12,BRD-K27737647,pka inhibitor
12.168393,7.3990803,505,CN1CCC(=C2c3ccccc3C=Cc4ccccc24)CC1,BRD-K28143534,C1=Cc2ccccc2C(=C2CCNCC2)c2ccccc21,BRD-K28143534,histamine receptor antagonist
11.172604,4.996651,506,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,BRD-K28183345,c1ccccc1,BRD-K28183345,dihydrofolate reductase inhibitor
10.266798,4.3504953,507,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(c1)C(F)(F)F,BRD-K28307902,c1ccccc1,BRD-K28307902,androgen receptor antagonist
11.853917,4.2613015,508,CCN(CC)CCOC(=O)C1(CCCC1)c2ccc(cc2)[N+](=O)[O-],BRD-K28453807,c1ccc(C2CCCC2)cc1,BRD-K28453807,cholinergic receptor antagonist
11.974814,5.1294327,509,CN(C)CCCOc1nn(Cc2ccccc2)c3ccccc13,BRD-K28542495,c1ccc(Cn2ncc3ccccc32)cc1,BRD-K28542495,prostanoid receptor antagonist
13.5968075,6.1895704,510,COc1cc(ccc1O)C(=O)O[C@@H]2C[C@@H]3CC[C@H](C2)N3C,BRD-K28667196,O=C(OC1CC2CCC(C1)N2)c1ccccc1,BRD-K28667196,increases arterial blood pressure
10.981166,6.2877417,511,COC(=O)c1cc2c(cn1)[nH]c3ccccc32,BRD-K28680267,c1ccc2c(c1)[nH]c1cnccc12,BRD-K28680267,cck receptor antagonist
10.233937,5.0260015,512,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,BRD-K28761891,c1cc2c(c3c1CCC3)CCO2,BRD-K28761891,melatonin receptor agonist
11.399434,6.5292377,513,Ic1ccc(cc1)N2CCN(Cc3c[nH]c4ncccc34)CC2,BRD-K28806945,c1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1,BRD-K28806945,dopamine receptor antagonist
12.170297,7.4538236,514,CN1CCC(=C2c3ccsc3C(=O)Cc4ccccc24)CC1,BRD-K28936863,O=C1Cc2ccccc2C(=C2CCNCC2)c2ccsc21,BRD-K28936863,histamine receptor agonist|leukotriene receptor antagonist|phosphodiesterase inhibitor
13.077848,4.0291376,515,CC(=O)N1CCN(CC1)c2ccc(OC[C@H]3CO[C@@](Cn4ccnc4)(O3)c5ccc(Cl)cc5Cl)cc2,BRD-K29113274,c1ccc(C2(Cn3ccnc3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1,BRD-K29113274,sterol demethylase inhibitor
8.51352,3.3488667,516,OC(=O)CCC/C=C\\C[C@@H]1CO[C@@H](O[C@@H]1c2ccccc2O)C(F)(F)F,BRD-K29133151,c1ccc(C2CCOCO2)cc1,BRD-K29133151,thromboxane receptor antagonist
10.334775,7.1416407,517,O=c1n([se]c2ccccc12)c3ccccc3,BRD-K29359156,O=c1c2ccccc2[se]n1-c1ccccc1,BRD-K29359156,cyclooxygenase inhibitor|glutathione peroxidase agonist|h+/k+-atpase inhibitor|nitric oxide synthase inhibitor
9.433861,4.353348,518,OC(=O)CCCc1ccc(cc1)N(CCCl)CCCl,BRD-K29458283,c1ccccc1,BRD-K29458283,dna inhibitor
12.32506,6.540558,519,Fc1ccc(cc1)C(N2CCN(C/C=C/c3ccccc3)CC2)c4ccc(F)cc4,BRD-K29582677,C(=Cc1ccccc1)CN1CCN(C(c2ccccc2)c2ccccc2)CC1,BRD-K29582677,calcium channel blocker
11.835903,4.4473267,520,CCN(CC)CCOc1ccc(cc1)/C(=C(\\Cl)/c2ccccc2)/c3ccccc3,BRD-K29950728,C(=C(c1ccccc1)c1ccccc1)c1ccccc1,BRD-K29950728,estrogen receptor antagonist
11.173093,6.3556385,521,COc1ccc2[nH]cc(CCN)c2c1,BRD-K30197592,c1ccc2[nH]ccc2c1,BRD-K30197592,serotonin receptor agonist
12.03173,6.1833262,522,CN1CCC[C@@H]1CCO[C@](C)(c2ccccc2)c3ccc(Cl)cc3,BRD-K30240666,c1ccc(C(OCCC2CCCN2)c2ccccc2)cc1,BRD-K30240666,histamine receptor antagonist
8.560718,5.594985,523,COc1cc(O)c(C(=O)/C=C/c2ccccc2)c(OC)c1,BRD-K30296925,O=C(C=Cc1ccccc1)c1ccccc1,BRD-K30296925,antineoplastic
9.847745,3.2789252,524,CC(C)(C)NC[C@@H](O)COc1nsnc1N2CCOCC2,BRD-K30421593,c1nsnc1N1CCOCC1,BRD-K30421593,adrenergic receptor antagonist
10.256083,4.8224783,525,CC(C)NC(=O)NS(=O)(=O)c1cnccc1Nc2cccc(C)c2,BRD-K30480208,c1ccc(Nc2ccncc2)cc1,BRD-K30480208,electrolyte reabsorption inhibitor|thromboxane receptor antagonist
9.441558,4.554566,526,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,BRD-K30685142,c1ccc(Oc2ccccc2)cc1,BRD-K30685142,thyroid hormone stimulant
11.410636,4.4138927,527,COc1ccc(NC(=O)c2ccc(cc2)c3ccc(cc3C)c4noc(C)n4)cc1OCCN(C)C,BRD-K30867024,O=C(Nc1ccccc1)c1ccc(-c2ccc(-c3ncon3)cc2)cc1,BRD-K30867024,serotonin receptor antagonist
11.146449,6.6103296,528,CN(C)CCCn1cc(C2=C(C(=O)NC2=O)c3c[nH]c4ccccc34)c5ccccc15,BRD-K31342827,O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12,BRD-K31342827,pkc inhibitor
11.229068,5.172851,529,NC(=N)NC(=N)Nc1ccccc1,BRD-K31491153,c1ccccc1,BRD-K31491153,serotonin receptor agonist
8.405549,3.3520596,530,O[C@@H](COc1cccc(c1)C(F)(F)F)/C=C/[C@H]2[C@H](O)C[C@H](O)[C@@H]2C/C=C\\CCCC(=O)O,BRD-K31611373,C(=CC1CCCC1)CCOc1ccccc1,BRD-K31611373,prostanoid receptor agonist
2.4747097,0.7358405,531,CCC(=O)[C@@]1(C)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,BRD-K31627533,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K31627533,glucocorticoid receptor agonist
9.029209,7.8294024,532,Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CCCCCC2,BRD-K32164935,O=C(NN1CCCCCC1)NS(=O)(=O)c1ccccc1,BRD-K32164935,atp channel blocker
10.183062,6.6355605,533,CCC1(C(=O)NCNC1=O)c2ccccc2,BRD-K32247306,O=C1NCNC(=O)C1c1ccccc1,BRD-K32247306,gaba receptor antagonist
12.337047,6.2493825,534,Fc1ccc(cc1)C(OCCN2CCN(CCCc3ccccc3)CC2)c4ccc(F)cc4,BRD-K32501161,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1,BRD-K32501161,dopamine uptake inhibitor
10.409626,5.7096868,535,OC(=O)c1ccc2nc(c3ccccc3)c(nc2c1)c4ccccc4,BRD-K32584078,c1ccc(-c2nc3ccccc3nc2-c2ccccc2)cc1,BRD-K32584078,akt inhibitor|hcv ns5b rdrp inhibitor
9.387057,5.4544506,536,CCN(CC)C(=S)SSC(=S)N(CC)CC,BRD-K32744045,,BRD-K32744045,aldehyde dehydrogenase inhibitor|dna methyltransferase inhibitor|trpv agonist
8.885258,5.603782,537,CO[C@H]1[C@H](O)C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)O,BRD-K32755366,c1ccc2c3c([nH]c2c1)C1CC2CCCCC2CN1CC3,BRD-K32755366,norepinephrine transporter inhibitor
9.103803,6.6657495,538,Cn1cnc([N+](=O)[O-])c1Sc2[nH]cnc3ncnc23,BRD-K32821942,c1nc2nc[nH]c(Sc3cnc[nH]3)c-2n1,BRD-K32821942,dehydrogenase inhibitor
7.300082,5.945905,539,CN1Cc2c3OCOc3ccc2[C@H]4[C@@H](O)Cc5cc6OCOc6cc5[C@H]41,BRD-K32828673,c1c2c(cc3c1OCO3)C1NCc3c(ccc4c3OCO4)C1CC2,BRD-K32828673,tubulin polymerization inhibitor
11.190556,5.0759864,540,NC(=N)NC(=O)Cc1c(Cl)cccc1Cl,BRD-K32830106,c1ccccc1,BRD-K32830106,adrenergic receptor agonist
8.784448,6.067393,541,NC(=C(C#N)C#N)/C(=C/c1ccc2[nH]ccc2c1)/C#N,BRD-K33204703,c1ccc2[nH]ccc2c1,BRD-K33204703,pdgfr receptor inhibitor
8.868656,6.140516,542,COc1ccc2C[C@H]3[C@H]4CCCC[C@@]4(CCN3C)c2c1,BRD-K33211335,c1ccc2c(c1)CC1NCCC23CCCCC13,BRD-K33211335,glutamate receptor antagonist|sigma receptor agonist
8.429324,3.4113474,543,CC/C=C\\C/C=C\\C/C=C\\CCCCCCCC(=O)O,BRD-K33396764,,BRD-K33396764,omega 3 fatty acid stimulant
10.147506,6.931786,544,C[C@@H]1CN(CC[C@]1(C(=O)O)c2ccccc2)[C@H]3CC[C@](CC3)(C#N)c4ccc(F)cc4,BRD-K33453211,c1ccc(C2CCC(N3CCC(c4ccccc4)CC3)CC2)cc1,BRD-K33453211,histamine receptor antagonist
8.587523,5.6654315,545,Oc1ccc(/C=C/C(=O)c2ccc(O)cc2O)cc1,BRD-K33583600,O=C(C=Cc1ccccc1)c1ccccc1,BRD-K33583600,guanylate cyclase activator
9.284497,5.3597403,546,CCc1cc(ccn1)C(=S)N,BRD-K33710385,c1ccncc1,BRD-K33710385,mycolic synthesis inhibitor
8.551971,3.381039,547,CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCc1ccc(O)c(OC)c1,BRD-K34092021,c1ccccc1,BRD-K34092021,trpv agonist|cannabinoid receptor agonist
10.043553,4.5825763,548,CCCCNc1c(C(=O)OCC)c(C)nc2n(CC)ncc12,BRD-K34154330,c1cnc2[nH]ncc2c1,BRD-K34154330,gaba receptor modulator
11.014795,5.778253,549,CN/C(=N\\C#N)/NCCSCc1nc[nH]c1C,BRD-K34157611,c1c[nH]cn1,BRD-K34157611,histamine receptor antagonist
11.526134,4.3790336,550,COc1cc(cc(OC)c1OC)C(=O)NCc2ccc(OCCN(C)C)cc2,BRD-K34415467,O=C(NCc1ccccc1)c1ccccc1,BRD-K34415467,histamine receptor antagonist
11.780671,8.659556,551,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,BRD-K34685430,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K34685430,dopamine receptor antagonist|serotonin receptor antagonist
8.876253,8.001831,552,CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O,BRD-K34776109,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCNC(=O)N2CC=CC2=O)cc1,BRD-K34776109,insulin secretagogue
9.400438,5.5111227,553,CNC(=O)N(C)c1nnc(s1)C(C)(C)C,BRD-K34820100,c1nncs1,BRD-K34820100,photosynthesis inhibitor
3.8864245,1.0984516,554,CC[C@@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]2CC[C@@]1(O)C#C,BRD-K35189033,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K35189033,estrogen receptor agonist|glucocorticoid receptor antagonist|progesterone receptor agonist|progesterone receptor antagonist
2.3856382,0.7355801,555,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]4(C)C=CC(=O)C=C14,BRD-K35240538,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K35240538,glucocorticoid receptor agonist
10.268618,7.4694586,556,CC1=NN(C(=O)C1)c2ccccc2,BRD-K35458079,O=C1CC=NN1c1ccccc1,BRD-K35458079,nootropic
9.881281,5.3191676,557,CCOC(=O)/N=c\\1/c[n+]([n-]o1)N2CCOCC2,BRD-K35531059,N=c1c[n+](N2CCOCC2)[n-]o1,BRD-K35531059,guanylyl cyclase activator
11.017357,6.501987,558,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@H]12,BRD-K35586044,c1ccc2c3c([nH]c2c1)C1CC2CCCCC2CN1CC3,BRD-K35586044,adrenergic receptor antagonist
4.0288053,1.7869228,559,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)C6=CC(=O)OC6)[C@H](O)[C@H](O)[C@H]1O,BRD-K35708212,O=C1C=C(C2CCC3C2CCC2C4CCC(OC5CCCCO5)CC4CCC23)CO1,BRD-K35708212,atpase inhibitor
11.694081,8.622229,560,CC[C@@H](CO)NC(=O)[C@H]1CN(C)[C@@H]2Cc3cn(C)c4cccc(C2=C1)c34,BRD-K35941380,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K35941380,serotonin receptor antagonist
10.377899,4.9059815,561,Oc1ccc(Cl)cc1C(=O)Nc2ccc(cc2Cl)[N+](=O)[O-],BRD-K35960502,O=C(Nc1ccccc1)c1ccccc1,BRD-K35960502,dna replication inhibitor|stat inhibitor
9.11205,4.589717,562,COc1ccc(C[C@H](N)C(=O)N[C@H]2[C@@H](O)[C@@H](O[C@@H]2CO)n3cnc4c(ncnc34)N(C)C)cc1,BRD-K36007650,O=C(CCc1ccccc1)NC1COC(n2cnc3cncnc32)C1,BRD-K36007650,protein synthesis inhibitor
9.381617,6.3027387,563,C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC2CC(=O)NC(=O)C2,BRD-K36055864,O=C1CC(CCC2CCCCC2=O)CC(=O)N1,BRD-K36055864,protein synthesis inhibitor
9.667587,6.5072656,564,CCC1(CC)C(=O)NC=CC1=O,BRD-K36116267,O=C1C=CNC(=O)C1,BRD-K36116267,psychoactive drug
8.572838,6.6576023,565,CC(C)(O)[C@@H]1Cc2cc3ccc(=O)oc3cc2O1,BRD-K36377456,O=c1ccc2cc3c(cc2o1)OCC3,BRD-K36377456,angiogenesis inhibitor
10.866737,7.562702,566,C1CC[C@@H](NC1)c2cccnc2,BRD-K36638830,c1cncc(C2CCCCN2)c1,BRD-K36638830,acetylcholine receptor agonist
9.370256,7.4486246,567,NS(=O)(=O)c1cc2c(NCNS2(=O)=O)cc1C(F)(F)F,BRD-K36862742,O=S1(=O)NCNc2ccccc21,BRD-K36862742,sodium/potassium/chloride transporter inhibitor
8.84477,7.950322,568,COc1ccc(Cl)cc1C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3,BRD-K36927236,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCNC(=O)c2ccccc2)cc1,BRD-K36927236,atp channel blocker|insulin secretagogue|sulfonylurea
11.178692,5.2441373,569,NC(=N)NC(=N)Nc1cccc(Cl)c1,BRD-K36965586,c1ccccc1,BRD-K36965586,serotonin receptor agonist
12.004166,6.3821135,570,COc1ccc(CCN2CCC(CC2)Nc3nc4ccccc4n3Cc5ccc(F)cc5)cc1,BRD-K37249724,c1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccccc3)CC2)cc1,BRD-K37249724,histamine receptor antagonist
3.799633,1.1193584,571,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@@]21C)c5ccc(cc5)N(C)C,BRD-K37270826,O=C1C=C2CCC3C(=C2CC1)C(c1ccccc1)CC1CCCC13,BRD-K37270826,glucocorticoid receptor antagonist|progesterone receptor antagonist
11.839927,7.6476383,572,CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24,BRD-K37289225,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1N2,BRD-K37289225,dopamine receptor antagonist|serotonin receptor antagonist
7.236291,5.8955564,573,COc1c2OCOc2cc3CCN(C)Cc13,BRD-K37447567,c1c2c(cc3c1OCO3)CNCC2,BRD-K37447567,opioid receptor antagonist
7.8663015,5.498254,574,COc1cc(ccc1OC(F)F)c2ccc(=O)[nH]n2,BRD-K37561857,O=c1ccc(-c2ccccc2)n[nH]1,BRD-K37561857,phosphodiesterase inhibitor
7.9891315,9.356024,575,CCn1cc(C(=O)O)c(=O)c2cnc(nc12)N3CCCC3,BRD-K37682401,O=c1cc[nH]c2nc(N3CCCC3)ncc12,BRD-K37682401,bacterial dna gyrase inhibitor
11.620241,6.062399,576,Clc1ccc(OCC(=O)N2CCN(Cc3ccc4OCOc4c3)CC2)cc1,BRD-K37688416,O=C(COc1ccccc1)N1CCN(Cc2ccc3c(c2)OCO3)CC1,BRD-K37688416,psychoactive drug
13.00157,7.1423545,577,CN(C)CC/C=C\\1/c2ccccc2COc3ccccc13,BRD-K37694030,C=C1c2ccccc2COc2ccccc21,BRD-K37694030,histamine receptor antagonist
7.5039363,6.362691,578,COc1cc(cc(OC)c1O)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](O[C@@H]4O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]4O)c6cc7OCOc7cc26,BRD-K37798499,O=C1OCC2C(OC3CCC4OCOCC4O3)c3cc4c(cc3C(c3ccccc3)C12)OCO4,BRD-K37798499,topoisomerase inhibitor
11.023356,6.5663586,579,C(c1c[nH]c2ccccc12)c3c[nH]c4ccccc34,BRD-K37846922,c1ccc2c(Cc3c[nH]c4ccccc34)c[nH]c2c1,BRD-K37846922,"chk inhibitor|cytochrome p450 activator|indoleamine 2,3-dioxygenase inhibitor"
10.578719,9.370087,580,NCc1ccccc1CC(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)CSc4nnnn4CC(=O)O,BRD-K37848908,O=C(Cc1ccccc1)NC1C(=O)N2C=C(CSc3nnn[nH]3)CSC12,BRD-K37848908,penicillin binding protein inhibitor
1.4988205,0.7055593,581,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)COC(=O)C(C)(C)C,BRD-K38003476,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K38003476,steroid
8.462273,5.3710866,582,CCN(CC)C(=O)c1ccc(O)c(OC)c1,BRD-K38055836,c1ccccc1,BRD-K38055836,respiratory stimulant
10.378585,5.7801166,583,CCCCNc1cc(cc(c1Oc2ccccc2)S(=O)(=O)N)C(=O)O,BRD-K38197229,c1ccc(Oc2ccccc2)cc1,BRD-K38197229,solute carrier family member inhibitor
10.769276,6.9909587,584,CC(C)(O)[C@H]1O[C@H]2CC[C@]3(C)[C@]4(C)[C@H](Cc5c4[nH]c6ccccc56)CC[C@@]3(O)C2=CC1=O,BRD-K38251852,O=C1C=C2C(CCC3C2CCC2Cc4c([nH]c5ccccc45)C23)OC1,BRD-K38251852,abc transporter expression enhancer|high conductance calcium activated potassium blocker|lxr agonist|potassium channel blocker
12.680704,6.0059905,585,Clc1ccc2n(C3CCN(CCCn4c(=O)[nH]c5ccccc45)CC3)c(=O)[nH]c2c1,BRD-K38305202,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1,BRD-K38305202,dopamine receptor antagonist
10.145577,4.69605,586,CCOc1ccc(NC(=O)C)cc1,BRD-K38323065,c1ccccc1,BRD-K38323065,cyclooxygenase inhibitor
9.091084,6.6747518,587,Cn1c(=O)n(C)c2[nH]c(nc2c1=O)C3CCCC3,BRD-K38347298,O=c1[nH]c(=O)c2nc(C3CCCC3)[nH]c2[nH]1,BRD-K38347298,adenosine receptor antagonist
12.639846,7.0619254,588,CN(C)CCCN1c2ccccc2CCc3ccccc13,BRD-K38436528,c1ccc2c(c1)CCc1ccccc1N2,BRD-K38436528,norepinephrine reuptake inhibitor|serotonin reuptake inhibitor
9.877231,6.967309,589,C/C=C\\1/CC(=C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@H]32,BRD-K38449220,C=C1CC(=C)C(=O)OC2CCN3CC=C(COC(=O)C1)C23,BRD-K38449220,cytochrome p450 inhibitor
1.334162,0.5981642,590,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BRD-K38775274,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K38775274,glucocorticoid receptor agonist
8.159387,7.3706393,591,COc1ccc(cc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2,BRD-K38903228,O=C1CC(c2ccccc2)Oc2cc(OC3CCCC(COC4CCCCO4)O3)ccc21,BRD-K38903228,flavanone glycoside
7.0418124,5.948462,592,CN1CCc2cc(O)cc-3c2[C@H]1Cc4ccc(O)c(O)c43,BRD-K39187410,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K39187410,antiamyloidogenic
1.365824,0.54937834,593,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BRD-K39188321,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K39188321,glucocorticoid receptor agonist
8.93381,5.8820233,594,COc1cc(C)nn1c2nc(C)cc(OC)n2,BRD-K39339537,c1cnc(-n2cccn2)nc1,BRD-K39339537,cyclooxygenase inhibitor
3.7812707,1.3268661,595,CC(=O)[C@H]1[C@@H](C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C#N,BRD-K39356024,C1=C2CCCCC2C2CCC3CCCC3C2C1,BRD-K39356024,acetylcholine release enhancer|dopamine release enhancer|gaba receptor negative allosteric modulator|glutamate receptor modulator|progesterone receptor agonist|steroid hormone inhibitor of cyp17a1 and sult2b1
9.628925,6.0645638,596,CC(C)[C@@]12O[C@H]2[C@@H]3O[C@]34[C@]5(O[C@H]5C[C@H]6C7=C(CC[C@@]64C)C(=O)OC7)[C@@H]1O,BRD-K39484304,O=C1OCC2=C1CCC1C2CC2OC23CC2OC2C2OC123,BRD-K39484304,rna polymerase inhibitor
11.812538,7.630609,597,CN1CCN(CC1)C2=Nc3ccccc3Oc4ccc(Cl)cc24,BRD-K39915878,c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1O2,BRD-K39915878,dopamine receptor antagonist|serotonin receptor antagonist
8.535482,3.6626709,598,CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCC(=O)O,BRD-K39965020,,BRD-K39965020,ppar receptor agonist
12.2983465,4.995208,599,CC(=O)Oc1ccc(cc1)C(c2ccc(OC(=O)C)cc2)c3ccccn3,BRD-K39987650,c1ccc(C(c2ccccc2)c2ccccn2)cc1,BRD-K39987650,laxative
10.814715,6.707917,600,CC[C@]1(CCCN2CCc3c4[C@@H]21)CC(=O)n4c5ccccc35,BRD-K40227168,O=C1CC2CCCN3CCc4c(n1c1ccccc41)C23,BRD-K40227168,adrenergic receptor antagonist
13.7487335,6.082602,601,CN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)[C@H](CO)c3ccccc3,BRD-K40530731,O=C(Cc1ccccc1)OC1CC2CCC(C1)N2,BRD-K40530731,acetylcholine receptor inhibitor
12.284866,5.7668824,602,Cc1nc2sccn2c(=O)c1CCN3CCC(=C(c4ccc(F)cc4)c5ccc(F)cc5)CC3,BRD-K40887525,O=c1c(CCN2CCC(=C(c3ccccc3)c3ccccc3)CC2)cnc2sccn12,BRD-K40887525,serotonin receptor antagonist
11.13223,5.3802476,603,CN(C)CCCSc1ccccc1NC(=O)/C=C/c2ccccc2,BRD-K40901640,O=C(C=Cc1ccccc1)Nc1ccccc1,BRD-K40901640,serotonin receptor antagonist
10.898925,4.992249,604,NC(=O)NC(=O)Cc1ccccc1,BRD-K40905133,c1ccccc1,BRD-K40905133,sodium channel blocker
10.452798,5.041052,605,CC(=O)OCOC(=O)CN(CC(=O)OCOC(=O)C)c1ccccc1OCCOc2ccccc2N(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C,BRD-K40919711,c1ccc(OCCOc2ccccc2)cc1,BRD-K40919711,potassium channel blocker
10.231549,2.9677317,606,CC(C)(C)NC[C@H](O)COc1cccc2[nH]c(C#N)cc12,BRD-K40965114,c1ccc2[nH]ccc2c1,BRD-K40965114,adrenergic receptor antagonist
9.248933,8.231199,607,Nc1ccc(cc1)S(=O)(=O)Nc2ccccn2,BRD-K41406082,O=S(=O)(Nc1ccccn1)c1ccccc1,BRD-K41406082,paba antagonist
8.517535,3.2763126,608,CCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](CO)NC(=O)C,BRD-K41707108,,BRD-K41707108,phosphoenolpyruvate carboxylase activator
11.951873,5.4821744,609,Cc1cccc(CCN2CCC(CC2)C(=O)c3ccc(NS(=O)(=O)C)cc3)n1,BRD-K41713976,O=C(c1ccccc1)C1CCN(CCc2ccccn2)CC1,BRD-K41713976,potassium channel blocker
8.259836,6.7057734,610,Oc1ccc2sc(=O)oc2c1,BRD-K41876534,O=c1oc2ccccc2s1,BRD-K41876534,carbonic anhydrase inhibitor
8.75443,5.861007,611,COc1ccc(C=C(C#N)C#N)cc1,BRD-K41996876,c1ccccc1,BRD-K41996876,egfr inhibitor
8.023507,6.7708325,612,Oc1ccc(cc1)c2coc3cc(O)ccc3c2=O,BRD-K42095107,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K42095107,estrogen receptor agonist
9.855254,6.9402575,613,C/C=C\\1/C[C@@H](C)[C@](O)(CO)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@H]32,BRD-K42142750,C=C1CCCC(=O)OCC2=CCN3CCC(OC1=O)C23,BRD-K42142750,antimitotic
10.848436,5.704167,614,OC(=O)C1=CCCN(CCON=C(c2ccccc2)c3ccccc3)C1,BRD-K42221274,C1=CCN(CCON=C(c2ccccc2)c2ccccc2)CC1,BRD-K42221274,gat inhibitor
12.915611,7.1780157,615,CN(C)CCC=C1c2ccccc2C=Cc3ccccc13,BRD-K42348709,C=C1c2ccccc2C=Cc2ccccc21,BRD-K42348709,adrenergic receptor agonist|serotonin receptor agonist
8.535107,3.3493001,616,CCCCC/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)NCCO,BRD-K42352790,,BRD-K42352790,cannabinoid receptor agonist
11.495265,5.283044,617,CCN(CC)CCc1nc(no1)c2ccccc2,BRD-K42596464,c1ccc(-c2ncon2)cc1,BRD-K42596464,antitussive
9.645635,4.12181,618,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1,BRD-K42635745,c1ccccc1,BRD-K42635745,adrenergic receptor antagonist
8.065799,6.868178,619,Oc1cc(O)c2c(=O)c(O)c(oc2c1)c3cc(O)c(O)c(O)c3,BRD-K43149758,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K43149758,androgen receptor agonist|cytochrome p450 inhibitor
10.406453,4.8147273,620,CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc2ccccc2)C=O,BRD-K43245338,O=C(CNC(=O)OCc1ccccc1)NCCc1ccccc1,BRD-K43245338,calpain inhibitor|cathepsin inhibitor
9.249823,8.238954,621,CNc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(NC)n1,BRD-K43290182,O=S(=O)(Nc1ccncn1)c1ccccc1,BRD-K43290182,serotonin receptor antagonist
9.144357,6.81247,622,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)C,BRD-K43389675,O=C1c2ccccc2C(=O)c2cc3c(cc21)CCCC3OC1CCCCO1,BRD-K43389675,rna synthesis inhibitor|topoisomerase inhibitor
2.8550563,0.8814103,623,C[C@@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]2CC[C@]1(O)C(=O)CO,BRD-K43736954,O=C1C=C2CCC3C4CCCC4CC(=O)C3C2CC1,BRD-K43736954,glucocorticoid receptor agonist
8.057696,6.765835,624,Oc1ccc(cc1)c2coc3cc(O)cc(O)c3c2=O,BRD-K43797669,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K43797669,tyrosine kinase inhibitor
11.219933,5.2628345,625,NC(=N)NCc1cccc(I)c1,BRD-K43860855,c1ccccc1,BRD-K43860855,antineoplastic
10.727995,10.154873,626,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,BRD-K43966364,O=C(COc1ccccc1)NC1C(=O)N2CCSC12,BRD-K43966364,bacterial cell wall synthesis inhibitor
10.641289,4.7420597,627,OC(=O)c1ccccc1Nc2cccc(c2)C(F)(F)F,BRD-K44067360,c1ccc(Nc2ccccc2)cc1,BRD-K44067360,chloride channel blocker
9.526648,5.8905635,628,CN(C(=S)Oc1ccc2ccccc2c1)c3cccc(C)c3,BRD-K44273375,S=C(Nc1ccccc1)Oc1ccc2ccccc2c1,BRD-K44273375,fungal squalene epoxidase inhibitor
11.0944805,4.794156,629,Oc1cc2CCCN(Cc2cc1O)C(=S)NCCc3ccc(Cl)cc3,BRD-K44849676,S=C(NCCc1ccccc1)N1CCCc2ccccc2C1,BRD-K44849676,trpv agonist
10.52199,5.577315,630,CN(C)C(=O)Cc1c(nc2ccc(C)cn12)c3ccc(C)cc3,BRD-K44876623,c1ccc(-c2cn3ccccc3n2)cc1,BRD-K44876623,benzodiazepine receptor agonist
11.168567,4.613186,631,NCCNC(=O)c1ccc(Cl)cc1,BRD-K44899736,c1ccccc1,BRD-K44899736,monoamine oxidase inhibitor
9.585397,4.9286866,632,CC(=O)OCC(CCn1cnc2cnc(N)nc12)COC(=O)C,BRD-K45033733,c1ncc2nc[nH]c2n1,BRD-K45033733,dna polymerase inhibitor
11.560612,4.1277275,633,CCCCNc1ccc(cc1)C(=O)OCCN(C)C,BRD-K45071273,c1ccccc1,BRD-K45071273,membrane integrity inhibitor
10.587688,5.377163,634,CCCCC(=O)N(Cc1ccc(cc1)c2ccccc2c3nn[nH]n3)[C@@H](C(C)C)C(=O)O,BRD-K45158365,c1ccc(-c2ccccc2-c2nn[nH]n2)cc1,BRD-K45158365,angiotensin receptor antagonist
9.001203,4.844108,635,CC(=C)[C@@H]1CC[C@@]2(CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12)C(=O)O,BRD-K45401373,C1CCC2C(C1)CCC1C2CCC2C3CCCC3CCC21,BRD-K45401373,apoptosis stimulant
10.803939,7.9602532,636,CN1CCc2cc(Cl)c(O)cc2[C@H](C1)c3ccccc3,BRD-K45435259,c1ccc(C2CNCCc3ccccc32)cc1,BRD-K45435259,dopamine receptor antagonist
11.994212,6.35873,637,C(COc1ccc2OCOc2c1)CN3CCN(CC3)c4ccccc4,BRD-K45479396,c1ccc(N2CCN(CCCOc3ccc4c(c3)OCO4)CC2)cc1,BRD-K45479396,serotonin receptor agonist
9.553232,5.4720592,638,CCN(CC)C(=O)N1CCN(C)CC1,BRD-K45542189,C1CNCCN1,BRD-K45542189,lipoxygenase inhibitor
12.652057,5.814311,639,Fc1ccc(cc1)C(=O)CCCN2CCC3(CC2)N(CN(Cc4cccc(F)c4)C3=O)c5ccccc5,BRD-K45662124,O=C(CCCN1CCC2(CC1)C(=O)N(Cc1ccccc1)CN2c1ccccc1)c1ccccc1,BRD-K45662124,dopamine receptor ligand
12.63162,5.7371893,640,Fc1ccc(cc1)C(=O)CCCN2CCN(CC2)c3ccccn3,BRD-K45861246,O=C(CCCN1CCN(c2ccccn2)CC1)c1ccccc1,BRD-K45861246,dopamine receptor antagonist
11.250153,4.6106157,641,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O,BRD-K46018455,O=C(NCCc1ccccc1)c1ccccc1,BRD-K46018455,ppar receptor agonist
8.289381,6.6873045,642,Cc1cc(=O)c2c(O)c(C)c(O)cc2o1,BRD-K46068882,O=c1ccoc2ccccc12,BRD-K46068882,bacterial quorum sensing inhibitor
2.5404773,0.65812004,643,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C)C(=O)COC(=O)CC,BRD-K46137903,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K46137903,phospholipase activator
11.227888,6.8546333,644,C(C1=NCCN1)c2ccccc2,BRD-K46211610,c1ccc(CC2=NCCN2)cc1,BRD-K46211610,adrenergic receptor antagonist
11.755531,4.25832,645,CCCC(C(=O)OCCN(CC)CC)(c1ccccc1)c2ccccc2,BRD-K46317332,c1ccc(Cc2ccccc2)cc1,BRD-K46317332,nitric oxide synthase inhibitor
9.564239,4.7475514,646,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc12,BRD-K46435977,O=c1[nH]cnc2[nH]cnc12,BRD-K46435977,dna polymerase inhibitor
10.296726,4.9288206,647,CN(C)CCCc1cc(ccc1O)C(=O)Nc2ccc(cc2)c3ccncc3,BRD-K46441700,O=C(Nc1ccc(-c2ccncc2)cc1)c1ccccc1,BRD-K46441700,serotonin receptor antagonist
3.4020748,1.1168509,648,C[C@@]12CC[C@H]3[C@@H](C=CC4=CC(=O)CC[C@]34C)[C@@H]2CC[C@@]1(O)CCC(=O)O,BRD-K46556543,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-K46556543,mineralocorticoid receptor antagonist
10.316867,7.4719415,649,Cc1cc(=O)n(c2ccccc2)n1C,BRD-K46937689,O=c1cc[nH]n1-c1ccccc1,BRD-K46937689,cyclooxygenase inhibitor
10.265858,6.35592,650,Oc1ccc(Cl)c2cccnc12,BRD-K46982791,c1ccc2ncccc2c1,BRD-K46982791,potassium channel activator
8.72855,5.8914785,651,Oc1ccc(/C=C(\\C#N)/C(=O)NCc2ccccc2)cc1O,BRD-K47105409,O=C(C=Cc1ccccc1)NCc1ccccc1,BRD-K47105409,jak inhibitor
8.481621,3.5122297,652,CC/C=C\\C/C=C\\C/C=C\\C/C=C\\C/C=C\\CCCC(=O)O,BRD-K47192521,,BRD-K47192521,platelet aggregation inhibitor
12.116419,4.891145,653,CN(C)CCOC(c1ccccc1)c2ccccc2,BRD-K47278471,c1ccc(Cc2ccccc2)cc1,BRD-K47278471,histamine receptor antagonist
12.375178,4.888075,654,CN(C)CCN(Cc1cccs1)c2ccccn2,BRD-K47323024,c1ccc(NCc2cccs2)nc1,BRD-K47323024,histamine receptor antagonist
9.857788,4.3975077,655,NCCCC[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O,BRD-K47328134,O=C(CCc1ccccc1)NCCc1ccccc1,BRD-K47328134,heparin activation inhibitor
9.475103,7.105027,656,Cc1ccc(cc1)c2nn(c3ncnc(N)c23)C(C)(C)C,BRD-K47598052,c1ccc(-c2n[nH]c3ncncc23)cc1,BRD-K47598052,src inhibitor
10.35433,5.1933193,657,CC(=O)Oc1cccc(C(=O)O)c1OC(=O)C,BRD-K47608922,c1ccccc1,BRD-K47608922,chelating
9.784519,6.431556,658,CN(Cc1cc(Br)cc(Br)c1N)C2CCCCC2,BRD-K47631482,c1ccc(CNC2CCCCC2)cc1,BRD-K47631482,mucolytic
1.3500917,0.5631018,659,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COC(=O)C,BRD-K47635719,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K47635719,glucocorticoid receptor agonist
11.88491,5.888316,660,Cc1c(oc2c(cccc2c1=O)C(=O)OCCN3CCCCC3)c4ccccc4,BRD-K47639036,O=C(OCCN1CCCCC1)c1cccc2c(=O)cc(-c3ccccc3)oc12,BRD-K47639036,acetylcholine receptor antagonist
7.954636,5.937116,661,COc1c(OC[C@@H](O)C(C)(C)O)ccc2c(OC)c3ccoc3nc12,BRD-K47693913,c1ccc2nc3occc3cc2c1,BRD-K47693913,furoquinoline alkaloid
7.450932,6.265731,662,COc1cc(cc(OC)c1OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](O)c4cc5OCOc5cc24,BRD-K47869605,O=C1OCC2Cc3cc4c(cc3C(c3ccccc3)C12)OCO4,BRD-K47869605,microtubule inhibitor|tubulin polymerization inhibitor
11.634502,6.203502,663,C(N1CCN(CC1)c2ncccn2)c3ccc4OCOc4c3,BRD-K47936004,c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1,BRD-K47936004,dopamine receptor agonist
9.437212,6.2277207,664,CCCc1cc(=O)[nH]c(=S)[nH]1,BRD-K48168960,O=c1cc[nH]c(=S)[nH]1,BRD-K48168960,thyroid peroxidase inhibitor
11.744341,3.9419062,665,COc1cc(cc(OC)c1OC)C(=O)OCCCN2CCCN(CCCOC(=O)c3cc(OC)c(OC)c(OC)c3)CC2,BRD-K48722258,O=C(OCCCN1CCCN(CCCOC(=O)c2ccccc2)CC1)c1ccccc1,BRD-K48722258,adenosine reuptake inhibitor
10.967355,6.2967243,666,CCOC(=O)c1cc2c(cn1)[nH]c3ccccc32,BRD-K49061529,c1ccc2c(c1)[nH]c1cnccc12,BRD-K49061529,gaba benzodiazepine site receptor inverse agonist
9.684808,6.6614504,667,O=C1O[C@]2(C[C@H]3C=CC2=C1)[C@H]4CCCCN34,BRD-K49071277,O=C1C=C2C=CC3CC2(O1)C1CCCCN31,BRD-K49071277,gaba receptor antagonist|tp53 activator
11.870032,7.0557804,668,COc1ccc2CN(C)CC[C@]34C=C[C@H](O)C[C@@H]4Oc1c23,BRD-K49481516,C1=CC23CCNCc4cccc(c42)OC3CC1,BRD-K49481516,acetylcholinesterase inhibitor
12.529503,5.828602,669,Fc1ccc(cc1)C(=O)C2CCN(CCn3c(=O)[nH]c4ccccc4c3=O)CC2,BRD-K49671696,O=C(c1ccccc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1,BRD-K49671696,serotonin receptor antagonist
10.052751,5.446187,670,C/C(=C\\c1ccc(cc1)C(=O)O)/c2ccc3c(c2)C(C)(C)CCC3(C)C,BRD-K49685476,C(=Cc1ccc2c(c1)CCCC2)c1ccccc1,BRD-K49685476,retinoid receptor agonist
10.685589,5.406934,671,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]2CCc3ccccc3N(CC(=O)O)C2=O,BRD-K49807096,O=C1Nc2ccccc2CCC1NCCCc1ccccc1,BRD-K49807096,angiotensin converting enzyme inhibitor
10.816131,4.684907,672,Cc1c(Cl)cccc1Nc2ccccc2C(=O)O,BRD-K50133271,c1ccc(Nc2ccccc2)cc1,BRD-K50133271,cyclooxygenase inhibitor|prostanoid receptor antagonist
12.277955,6.30343,673,C(CN1CCN(CCOC(c2ccccc2)c3ccccc3)CC1)Cc4ccccc4,BRD-K50135270,c1ccc(CCCN2CCN(CCOC(c3ccccc3)c3ccccc3)CC2)cc1,BRD-K50135270,dopamine uptake inhibitor
10.380359,7.084268,674,Nc1ccc2C(=O)NC(=O)c3cccc1c32,BRD-K50214219,O=C1NC(=O)c2cccc3cccc1c23,BRD-K50214219,parp inhibitor
11.076095,4.525773,675,CC(C)OC(=O)C(C)(C)Oc1ccc(cc1)C(=O)c2ccc(Cl)cc2,BRD-K50388907,O=C(c1ccccc1)c1ccccc1,BRD-K50388907,ppar receptor agonist
10.8447695,4.7457433,676,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl,BRD-K50398167,c1ccc(Nc2ccccc2)cc1,BRD-K50398167,cyclooxygenase inhibitor|prostanoid receptor antagonist
11.518936,5.046256,677,CCN(CC)CCNc1ccc(CO)c2sc3ccccc3c(=O)c12,BRD-K50406511,O=c1c2ccccc2sc2ccccc12,BRD-K50406511,rna synthesis inhibitor
11.933355,3.104579,678,CCN1CCC[C@H]1CNC(=O)c2c(O)c(CC)cc(Cl)c2OC,BRD-K50417881,O=C(NCC1CCCN1)c1ccccc1,BRD-K50417881,dopamine receptor antagonist
9.931832,6.1332955,679,Cc1ncsc1CCCl,BRD-K50422030,c1cscn1,BRD-K50422030,gaba receptor antagonist|gaba receptor modulator
9.238439,8.2159,680,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,BRD-K50859149,O=S(=O)(Nc1ccno1)c1ccccc1,BRD-K50859149,bacterial antifolate
11.383035,3.831366,681,COc1ccccc1N2CCN(CCCCNC(=O)c3ccc(cc3)c4ccc(cc4)C(=O)C)CC2,BRD-K50891186,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(-c2ccccc2)cc1,BRD-K50891186,dopamine receptor antagonist
11.159915,6.312254,682,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1,BRD-K50938287,c1ccc2[nH]ccc2c1,BRD-K50938287,serotonin receptor agonist
7.1824975,4.455275,683,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1,BRD-K51318897,c1ccc(Sc2ccc3nc[nH]c3c2)cc1,BRD-K51318897,tubulin polymerization inhibitor
9.568239,4.107033,684,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c2ccc(O)cc2,BRD-K51465424,c1ccc(CCNCCc2ccccc2)cc1,BRD-K51465424,adrenergic receptor agonist
11.912965,3.131791,685,CCN1CCC[C@H]1CNC(=O)c2cc(ccc2OC)S(=O)(=O)N,BRD-K51671335,O=C(NCC1CCCN1)c1ccccc1,BRD-K51671335,dopamine receptor antagonist
3.6677096,1.3762593,686,CC(=O)OCC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C,BRD-K51751936,O=C1CC2CCCC2C2CCC3CCCCC3C12,BRD-K51751936,benzodiazepine receptor agonist
8.485875,3.4739869,687,C/C=C/C\\C=C\\CCC(=O)[C@H]1O[C@H]1C(=O)N,BRD-K52075040,C1CO1,BRD-K52075040,fatty acid synthase inhibitor
7.1975093,4.5202384,688,CCCOc1ccc2nc(NC(=O)OC)[nH]c2c1,BRD-K52075715,c1ccc2[nH]cnc2c1,BRD-K52075715,tubulin inhibitor
12.468099,5.889524,689,CCNC(=O)N1CCN(CCCC(c2ccc(F)cc2)c3ccc(F)cc3)CC1,BRD-K52397688,c1ccc(C(CCCN2CCNCC2)c2ccccc2)cc1,BRD-K52397688,dopamine receptor antagonist|faah inhibitor|serotonin receptor antagonist
10.68658,4.1595774,690,CCN(CC)CC(=O)Nc1c(C)cccc1C,BRD-K52662033,c1ccccc1,BRD-K52662033,histamine receptor agonist
8.77303,6.132955,691,CC1(C)Oc2ccc(C#N)cc2[C@@H](OC3=CC(=O)CC3)[C@@H]1O,BRD-K52721684,O=C1C=C(OC2CCOc3ccccc32)CC1,BRD-K52721684,potassium channel activator
12.720392,7.094333,692,CN(C)CCCN1c2ccccc2CCc3ccc(Cl)cc13,BRD-K52989797,c1ccc2c(c1)CCc1ccccc1N2,BRD-K52989797,serotonin transporter (sert) inhibitor
10.19762,5.41558,693,OC(=O)/C=C/c1ccc(Cn2ccnc2)cc1,BRD-K53061490,c1ccc(Cn2ccnc2)cc1,BRD-K53061490,thromboxane synthase inhibitor
9.503107,7.0478983,694,[O-][N+](=O)c1cnc(s1)N2CCNC2=O,BRD-K53123955,O=C1NCCN1c1nccs1,BRD-K53123955,phosphofructokinase inhibitor
10.757105,6.4699435,695,CCOC(=O)C1=C[C@]2(CC)CCCN3CCc4c([C@@H]32)n1c5ccccc45,BRD-K53318339,C1=Cn2c3c(c4ccccc42)CCN2CCCC1C32,BRD-K53318339,phosphodiesterase inhibitor|sodium channel blocker
9.878018,4.980678,696,COCCCC/C(=N\\OCCN)/c1ccc(cc1)C(F)(F)F,BRD-K53517854,c1ccccc1,BRD-K53517854,selective serotonin reuptake inhibitor (ssri)
12.906427,7.194628,697,CN(C)CCC=C1c2ccccc2CCc3ccccc13,BRD-K53737926,C=C1c2ccccc2CCc2ccccc21,BRD-K53737926,norepinephrine inhibitor|norepinephrine reuptake inhibitor|serotonin receptor antagonist|serotonin reuptake inhibitor
12.178764,5.843903,698,Cc1nc2CCCCn2c(=O)c1CCN3CCC(CC3)c4noc5cc(F)ccc45,BRD-K53857191,O=c1c(CCN2CCC(c3noc4ccccc34)CC2)cnc2n1CCCC2,BRD-K53857191,dopamine receptor antagonist|serotonin receptor antagonist
11.942283,3.0820832,699,CCN1CCC[C@H]1CNC(=O)c2c(OC)ccc(Br)c2OC,BRD-K54094468,O=C(NCC1CCCN1)c1ccccc1,BRD-K54094468,dopamine receptor antagonist
11.201787,6.8549724,700,C(Oc1ccccc1C2CC2)C3=NCCN3,BRD-K54142781,c1ccc(C2CC2)c(OCC2=NCCN2)c1,BRD-K54142781,adrenergic receptor agonist
9.009219,6.3724456,701,Oc1ccc(cc1n2c(=O)[nH]c3cc(ccc23)C(F)(F)F)C(F)(F)F,BRD-K54210043,O=c1[nH]c2ccccc2n1-c1ccccc1,BRD-K54210043,calcium channel activator|large conductance potassium channel activator
9.227636,5.7936497,702,Oc1ccc(cc1)c2nc(c([nH]2)c3ccncc3)c4ccc(F)cc4,BRD-K54330070,c1ccc(-c2nc(-c3ccccc3)c(-c3ccncc3)[nH]2)cc1,BRD-K54330070,p38 mapk inhibitor
7.9566402,6.5673122,703,COc1ccc(cc1)c2c(O)c3c(OC)c4C=CC(C)(C)Oc4cc3oc2=O,BRD-K54411430,O=c1oc2cc3c(cc2cc1-c1ccccc1)C=CCO3,BRD-K54411430,camp inhibitor
9.619273,5.497765,704,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,BRD-K54529596,C1CCNC1,BRD-K54529596,angiotensin converting enzyme inhibitor
12.876173,7.2080173,705,CN(C)CC/C=C/1\\c2ccccc2CSc3ccccc13,BRD-K54759182,C=C1c2ccccc2CSc2ccccc21,BRD-K54759182,norepinephrine reuptake inhibitor|serotonin reuptake inhibitor|tricyclic antidepressant
8.724331,3.6394224,706,C[C@H](CCC(=O)NCC(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C,BRD-K54771420,C1CCC2C(C1)CCC1C3CCCC3CCC21,BRD-K54771420,cholesterol inhibitor
8.620705,6.753565,707,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1,BRD-K54790157,O=c1ccc2cc3ccoc3cc2o1,BRD-K54790157,dna synthesis inhibitor
8.002381,9.339229,708,CCn1cc(C(=O)O)c(=O)c2cc(F)c(cc12)N3CCN(C)CC3,BRD-K55034111,O=c1cc[nH]c2cc(N3CCNCC3)ccc12,BRD-K55034111,bacterial dna gyrase inhibitor
10.711401,10.0727415,709,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,BRD-K55044200,O=C(Cc1ccccc1)NC1C(=O)N2CCSC12,BRD-K55044200,penicillin binding protein inhibitor
12.635639,7.432888,710,OCCN1CCN(CCCN2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1,BRD-K55127134,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K55127134,dopamine receptor antagonist
10.71501,10.072847,711,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,BRD-K55191674,O=C(Cc1ccccc1)NC1C(=O)N2CCSC12,BRD-K55191674,penicillin binding protein inhibitor
9.2656555,8.260135,712,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,BRD-K55250441,O=S(=O)(Nc1ccncn1)c1ccccc1,BRD-K55250441,dihydropteroate synthase inhibitor
11.0487175,7.508807,713,Clc1cccc(SC2CCNCC2)n1,BRD-K55424922,c1ccc(SC2CCNCC2)nc1,BRD-K55424922,serotonin receptor agonist
12.764341,5.918079,714,Fc1ccc(cc1)C(=O)CCCN2CCC3(CC2)N(CNC3=O)c4ccccc4,BRD-K55468218,O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccccc1,BRD-K55468218,dopamine receptor antagonist
10.7609625,5.4015293,715,OC(=O)c1cc2cc(Cc3cccnc3)ccc2o1,BRD-K55529781,c1cncc(Cc2ccc3occc3c2)c1,BRD-K55529781,thromboxane synthase inhibitor
7.947807,6.616045,716,COc1ccc(cc1)c2coc3cc(O)ccc3c2=O,BRD-K55567017,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K55567017,alcohol dehydrogenase inhibitor
10.024077,7.030714,717,O=C1NC(=O)C(N1)(c2ccccc2)c3ccccc3,BRD-K55930204,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,BRD-K55930204,hydantoin antiepileptic
13.444581,3.7617877,718,Clc1ccc(CO/N=C(\\Cn2ccnc2)/c3ccc(Cl)cc3Cl)c(Cl)c1,BRD-K56104152,c1ccc(CON=C(Cn2ccnc2)c2ccccc2)cc1,BRD-K56104152,bacterial cell wall synthesis inhibitor
9.928171,6.383635,719,Nc1c(Br)cc(Br)cc1CN[C@H]2CC[C@H](O)CC2,BRD-K56558538,c1ccc(CNC2CCCCC2)cc1,BRD-K56558538,sodium channel blocker
10.578021,4.2826757,720,CC[N+](CC)(CC)CC(=O)Nc1c(C)cccc1C,BRD-K56596464,c1ccccc1,BRD-K56596464,sodium channel blocker
11.638082,8.464206,721,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@H]3[C@H]1Cc4cn(C)c5cccc3c45,BRD-K56699285,O=C(NCC1CNC2Cc3c[nH]c4cccc(c34)C2C1)OCc1ccccc1,BRD-K56699285,dopamine receptor agonist|serotonin receptor antagonist
11.214023,5.2559676,722,NC(=N)N/N=C\\c1c(Cl)cccc1Cl,BRD-K56800335,c1ccccc1,BRD-K56800335,adrenergic receptor agonist
12.34084,4.9055195,723,CN(C)CCN(Cc1ccccc1)c2ccccn2,BRD-K57033106,c1ccc(CNc2ccccn2)cc1,BRD-K57033106,histamine receptor antagonist
11.871521,3.646788,724,CCN(CC)CCNC(=O)c1cc(ccc1OC)S(=O)(=O)C,BRD-K57432881,c1ccccc1,BRD-K57432881,dopamine receptor antagonist
7.9533386,6.7048354,725,COc1cc(O)c2c(=O)c(coc2c1)c3ccc(O)cc3,BRD-K57546357,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K57546357,breast cancer resistance protein inhibitor
8.56692,4.1535025,726,CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O,BRD-K57569181,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K57569181,phosphodiesterase inhibitor
1.5201936,0.73845375,727,CC(=O)OCC(=O)[C@]12OC(C)(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@@]31C,BRD-K57886322,O=C1C=CC2C(=C1)CCC1C2CCC2C1CC1OCOC12,BRD-K57886322,glucocorticoid receptor agonist
11.763301,3.9077518,728,CCN(CC)CCCCCCCCOC(=O)c1cc(OC)c(OC)c(OC)c1,BRD-K58220566,c1ccccc1,BRD-K58220566,pkc inhibitor|sodium channel blocker|calcium channel blocker
9.322272,7.2141833,729,Cc1cc2CCCS(=O)(=O)c2cc1S(=O)(=O)N,BRD-K58265391,O=S1(=O)CCCc2ccccc21,BRD-K58265391,diuretic
7.64069,5.707085,730,COc1ccc2cc3-c4cc(OC)c(OC)cc4CC[n+]3cc2c1OC,BRD-K58466253,c1ccc2c(c1)CC[n+]1cc3ccccc3cc1-2,BRD-K58466253,serotonin release inhibitor
8.649256,6.9432254,731,Cc1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,BRD-K58685305,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K58685305,11-beta hydroxysteroid dehydrogenase inhibitor
8.237067,7.444996,732,O[C@H]1Cc2c(O)cc(O)cc2O[C@@H]1c3ccc(O)c(O)c3,BRD-K58736316,c1ccc(C2CCc3ccccc3O2)cc1,BRD-K58736316,fatty acid synthase inhibitor
10.875479,7.41322,733,C[C@@]1(N[C@@H]2Cc3ccccc31)c4ccccc24,BRD-K58930050,c1ccc2c(c1)CC1NC2c2ccccc21,BRD-K58930050,glutamate receptor antagonist
4.1955085,1.2990794,734,C[C@@H]1[C@@H]2NC[C@@H](C)C[C@H]2O[C@@]31CC[C@H]4[C@@H]5CC=C6C[C@@H](O)CC[C@]6(C)[C@H]5CC4=C3C,BRD-K58938839,C1=C2CC3C4CCCCC4=CCC3C2CCC12CC1NCCCC1O2,BRD-K58938839,smoothened receptor antagonist|hedgehog pathway inhibitor
12.959921,7.2923374,735,CN(C)CC/C=C/1\\c2ccccc2Sc3ccc(Cl)cc13,BRD-K59058766,C=C1c2ccccc2Sc2ccccc21,BRD-K59058766,dopamine receptor antagonist
8.866593,5.266342,736,COc1ccc2cc(ccc2c1)[C@H](C)C(=O)O,BRD-K59197931,c1ccc2ccccc2c1,BRD-K59197931,cyclooxygenase inhibitor
11.2926235,4.288578,737,CCOC(=O)c1ccc(OC(=O)CCCCCNC(=N)N)cc1,BRD-K59256312,c1ccccc1,BRD-K59256312,serine protease inhibitor
8.576625,3.9857557,738,CCCn1cnc2n(C)c(=O)n(CCCCC(=O)C)c(=O)c12,BRD-K59273480,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K59273480,adenosine reuptake inhibitor|phosphodiesterase inhibitor
8.8655815,6.9440727,739,Cc1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1,BRD-K59284035,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K59284035,egfr inhibitor
8.945646,5.95962,740,CC(C)(C)c1cc(/C=C(\\C#N)/C(=S)N)cc(c1O)C(C)(C)C,BRD-K59469039,c1ccccc1,BRD-K59469039,angiogenesis inhibitor
9.936888,4.432498,741,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O,BRD-K59574735,c1ccccc1,BRD-K59574735,leukotriene synthesis inhibitor
10.690176,5.3469095,742,OC(=O)CCc1c([nH]c2cc(Cl)cc(Cl)c12)C(=O)O,BRD-K59753853,c1ccc2[nH]ccc2c1,BRD-K59753853,glutamate receptor antagonist
10.700095,7.305354,743,CN1CC[C@]23[C@@H]4Nc5ccccc5[C@]3(CCN4C)[C@@H]1Nc6ccccc62,BRD-K59851896,c1ccc2c(c1)NC1NCCC23C2NCCC13c1ccccc1N2,BRD-K59851896,gaba release inhibitor
9.172755,8.048153,744,Nc1ccc(cc1)S(=O)(=O)NC(=O)c2ccccc2,BRD-K59983611,O=C(NS(=O)(=O)c1ccccc1)c1ccccc1,BRD-K59983611,bacterial antifolate
9.386218,5.339516,745,CN(C)c1ccc(cc1)C(=C2C=CC(=[N+](C)C)C=C2)c3ccc(cc3)N(C)C,BRD-K60025295,[N+]=C1C=CC(=C(c2ccccc2)c2ccccc2)C=C1,BRD-K60025295,antibiotic
10.3223095,6.1470766,746,CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)c4ccccc4c5nnn[nH]5,BRD-K60038276,O=C1N(Cc2ccc(-c3ccccc3-c3nnn[nH]3)cc2)C=NC12CCCC2,BRD-K60038276,angiotensin receptor antagonist
10.801264,5.367274,747,O=C[C@@H]1CCCN1C(=O)[C@@H]2CCCN2C(=O)OCc3ccccc3,BRD-K60174629,O=C(C1CCCN1C(=O)OCc1ccccc1)N1CCCC1,BRD-K60174629,prolyl endopeptidase inhibitor
8.694722,5.8953586,748,NC(=O)/C(=C/c1ccc(O)c(O)c1)/C#N,BRD-K60184833,c1ccccc1,BRD-K60184833,tyrosine kinase inhibitor
1.3125051,0.49083102,749,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c5ccco5)C(=O)CCl,BRD-K60640630,O=C1C=CC2C(=C1)CCC1C2CCC2C(OC(=O)c3ccco3)CCC21,BRD-K60640630,glucocorticoid receptor agonist
11.6727705,8.433617,750,CCCN1C[C@H](CSC)C[C@H]2[C@H]1Cc3c[nH]c4cccc2c34,BRD-K60770992,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K60770992,dopamine receptor agonist
13.552667,6.1435337,751,COc1ccc(cc1OC)C(=O)O[C@H]2CC[C@@]3(C)[C@@H]4CC[C@@H]5[C@@]3(C[C@@]6(O)[C@@H]7CN8C[C@@H](C)CC[C@H]8[C@@](C)(O)[C@@]7(O)[C@@H](O)C[C@@]56O)O[C@@]42O,BRD-K60923938,O=C(OC1CCC2C3CCC4C5CCC6CC7CCCCN7CC6C5CC42OC13)c1ccccc1,BRD-K60923938,sodium channel activator
10.687668,8.031365,752,Oc1cc2[C@H](CN(CC=C)CCc2c(Br)c1O)c3ccccc3,BRD-K60932973,c1ccc(C2CNCCc3ccccc32)cc1,BRD-K60932973,dopamine receptor agonist
12.208377,6.0097623,753,CN(C)C(=O)C(CCN1CCC(O)(CC1)c2ccc(Cl)cc2)(c3ccccc3)c4ccccc4,BRD-K61250553,c1ccc(C2CCN(CCC(c3ccccc3)c3ccccc3)CC2)cc1,BRD-K61250553,opioid receptor agonist
8.644103,6.6964974,754,Oc1ccc2ccc(=O)oc2c1O,BRD-K61269089,O=c1ccc2ccccc2o1,BRD-K61269089,protein kinase inhibitor
7.238865,5.902442,755,COc1ccc2[C@H](OC(=O)c2c1OC)[C@H]3N(C)CCc4cc5OCOc5cc34,BRD-K61271364,O=C1OC(C2NCCc3cc4c(cc32)OCO4)c2ccccc21,BRD-K61271364,gaba receptor antagonist
10.632638,5.0400405,756,CC[Hg]Sc1ccccc1C(=O)O,BRD-K61443650,c1ccccc1,BRD-K61443650,antibiotic
1.4628533,0.6778754,757,C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,BRD-K61496577,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K61496577,glucocorticoid receptor agonist
11.024087,6.2812343,758,CNC(=O)c1cc2c(cn1)[nH]c3ccccc32,BRD-K61951118,c1ccc2c(c1)[nH]c1cnccc12,BRD-K61951118,gaba benzodiazepine site receptor inverse agonist
10.237559,4.3293834,759,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]4[C@@]5(CO[C@@H]5C[C@H](O)[C@@]4(C)C1=O)OC(=O)C)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7,BRD-K62008436,O=C(CC(NC(=O)c1ccccc1)c1ccccc1)OC1C=C2CC(=O)C3CCC4OCC4C3C(OC(=O)c3ccccc3)C(C2)C1,BRD-K62008436,tubulin polymerization inhibitor
1.4608221,0.762565,760,CCC(=O)O[C@@]1([C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C)C(=O)SCF,BRD-K62310379,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K62310379,glucocorticoid receptor agonist
9.522444,7.312841,761,Nc1ccc(cc1)S(=O)(=O)c2ccc(N)cc2,BRD-K62363391,O=S(=O)(c1ccccc1)c1ccccc1,BRD-K62363391,bacterial antifolate
8.944466,5.0965424,762,CCCN1CCO[C@H]2[C@H]1COc3ccc(O)cc23,BRD-K62456038,c1ccc2c(c1)OCC1NCCOC21,BRD-K62456038,dopamine receptor agonist
10.50693,9.225324,763,C[C@H]1[C@H](NC(=O)/C(=N\\OC(C)(C)C(=O)O)/c2csc(N)n2)C(=O)N1S(=O)(=O)O,BRD-K62607865,N=C(C(=O)NC1CNC1=O)c1cscn1,BRD-K62607865,bacterial cell wall synthesis inhibitor
7.290581,5.7360673,764,COc1ccc2C[C@@H]3N(CCc4cc(OC)c(O)cc34)Cc2c1O,BRD-K62609077,c1ccc2c(c1)CC1c3ccccc3CCN1C2,BRD-K62609077,adrenergic receptor antagonist|gaba receptor antagonist|serotonin receptor antagonist
11.188561,5.623338,765,C(Nc1ncnc2nc[nH]c12)c3ccccc3,BRD-K62929068,c1ccc(CNc2ncnc3nc[nH]c23)cc1,BRD-K62929068,purinergic receptor activator
12.365801,5.612574,766,Cc1cccc(C)c1NC(=O)CN2CCN(CCCC(c3ccc(F)cc3)c4ccc(F)cc4)CC2,BRD-K62996583,O=C(CN1CCN(CCCC(c2ccccc2)c2ccccc2)CC1)Nc1ccccc1,BRD-K62996583,calcium channel blocker
8.382948,3.5261958,767,CC(=CCC/C(=C/CC/C(=C/CSCC(=O)O)/C)/C)C,BRD-K63089472,,BRD-K63089472,inhibitor of methyl esterification of farnesylated proteins
12.826539,7.1532164,768,CNCCC=C1c2ccccc2C=Cc3ccccc13,BRD-K63165456,C=C1c2ccccc2C=Cc2ccccc21,BRD-K63165456,adrenergic receptor agonist
8.372756,6.5275807,769,COc1c2occc2cc3ccc(=O)oc13,BRD-K63430059,O=c1ccc2cc3ccoc3cc2o1,BRD-K63430059,dna synthesis inhibitor
10.168302,5.3378425,770,CCC(=C)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl,BRD-K63630713,c1ccccc1,BRD-K63630713,sodium/potassium/chloride transporter inhibitor
8.812417,3.9793708,771,COc1c(C)c2COC(=O)c2c(O)c1C/C=C(\\C)/CCC(=O)O,BRD-K63750851,O=C1OCc2ccccc21,BRD-K63750851,dehydrogenase inhibitor|inositol monophosphatase inhibitor
10.133383,5.1478906,772,CCOC(=O)Nc1c[n+](no1)N2CCOCC2,BRD-K63861289,c1c[n+](N2CCOCC2)no1,BRD-K63861289,guanylyl cyclase activator
8.573921,3.3766835,773,CCCCC/C=C\\C/C=C\\CCCCCCCC(=O)N,BRD-K64044582,,BRD-K64044582,acat inhibitor
11.453173,6.0695806,774,Clc1ccc2ncnc(NCc3ccc4OCOc4c3)c2c1,BRD-K64746805,c1ccc2c(NCc3ccc4c(c3)OCO4)ncnc2c1,BRD-K64746805,phosphodiesterase inhibitor
1.5347917,0.7313362,775,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)C)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]4(C)C=CC(=O)C=C14,BRD-K64862097,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K64862097,glucocorticoid receptor agonist
3.5735002,1.2526,776,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,BRD-K64994968,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K64994968,progesterone receptor agonist
10.783357,4.5066853,777,CCCNC(C)(C)COC(=O)c1ccccc1,BRD-K65417056,c1ccccc1,BRD-K65417056,local anesthetic
8.211277,6.3223844,778,COc1ccc(cc1)c2oc3c(CC=C(C)C)c(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)cc(O)c3c(=O)c2O[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O,BRD-K65639003,O=c1c(OC2CCCCO2)c(-c2ccccc2)oc2cc(OC3CCCCO3)ccc12,BRD-K65639003,phosphodiesterase inhibitor
10.988668,5.6285114,779,C(Nc1ncnc2[nH]cnc12)c3ccco3,BRD-K65667145,c1coc(CNc2ncnc3[nH]cnc23)c1,BRD-K65667145,cell division inducer
10.557503,7.0573254,780,[I+]1c2ccccc2-c3ccccc13,BRD-K65814004,c1ccc2c(c1)[I+]c1ccccc1-2,BRD-K65814004,nitric oxide synthase inhibitor|aldehyde dehydrogenase inhibitor|cytochrome p450 inhibitor|nadph oxidase inhibitor|xanthine oxidase inhibitor
12.035627,6.2897067,781,CN1[C@H](C[C@H](O)c2ccccc2)CCC[C@@H]1CC(=O)c3ccccc3,BRD-K66206289,O=C(CC1CCCC(CCc2ccccc2)N1)c1ccccc1,BRD-K66206289,acetylcholine receptor antagonist
9.9213505,6.759144,782,Nc1nc2cc(Cl)ccc2o1,BRD-K66353228,c1ccc2ocnc2c1,BRD-K66353228,myorelaxant
9.505069,6.1935763,783,O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC6CCC6)c54,BRD-K66404838,c1cc2c3c(c1)OC1CCCC4C(C2)N(CC2CCC2)CCC314,BRD-K66404838,opioid receptor agonist|opioid receptor antagonist
10.007911,6.5694203,784,Oc1cccc2cccnc12,BRD-K66808046,c1ccc2ncccc2c1,BRD-K66808046,chelating
10.894372,5.754471,785,Cc1ccc(cc1)C(=O)Cn2c3CCCCc3sc2=N,BRD-K66874953,N=c1sc2c(n1CC(=O)c1ccccc1)CCCC2,BRD-K66874953,tp53 inhibitor
10.650616,10.135898,786,CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](/N=C/N3CCCCCC3)C2=O,BRD-K67100011,O=C1C(N=CN2CCCCCC2)C2SCCN12,BRD-K67100011,bacterial cell wall synthesis inhibitor
10.796631,5.2656198,787,OC(=O)CCCc1ccccc1,BRD-K67102207,c1ccccc1,BRD-K67102207,hdac inhibitor
8.914307,5.939438,788,COP(=S)(OC)Oc1ccc(SC)c(C)c1,BRD-K67217586,c1ccccc1,BRD-K67217586,cholinesterase inhibitor
11.174728,4.3446302,789,COc1ccc(cc1C(=O)NCc2cccnc2)C(=O)NCc3cccnc3,BRD-K67277431,O=C(NCc1cccnc1)c1cccc(C(=O)NCc2cccnc2)c1,BRD-K67277431,thromboxane receptor antagonist|thromboxane synthase inhibitor
10.671332,6.0164394,790,NC(=O)c1ccc(cc1)c2nc(c([nH]2)c3ccccn3)c4ccc5OCOc5c4,BRD-K67298865,c1ccc(-c2nc(-c3ccc4c(c3)OCO4)c(-c3ccccn3)[nH]2)cc1,BRD-K67298865,tgf beta receptor inhibitor
12.515124,5.7375464,791,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3,BRD-K67783091,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1,BRD-K67783091,dopamine receptor antagonist
10.520081,5.463304,792,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CCC[C@H]2C(=O)O,BRD-K67966701,O=C(CNCCCc1ccccc1)N1CCCC1,BRD-K67966701,angiotensin converting enzyme inhibitor
10.589439,5.6675663,793,OC(=O)Cc1nn(Cc2ccc(Br)cc2F)c(=O)c3ccccc13,BRD-K68332390,O=c1c2ccccc2cnn1Cc1ccccc1,BRD-K68332390,aldose reductase inhibitor|reductase inhibitor
11.143022,5.849229,794,COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC,BRD-K68336408,c1ccc(Nc2ncnc3ccccc23)cc1,BRD-K68336408,egfr inhibitor
11.043248,7.2344613,795,Clc1cccc2c(cccc12)S(=O)(=O)N3CCCNCC3,BRD-K68402494,O=S(=O)(c1cccc2ccccc12)N1CCCNCC1,BRD-K68402494,myosin light chain kinase inhibitor
10.549266,6.156232,796,CCOC(=O)NNc1nncc2ccccc12,BRD-K68553471,c1ccc2cnncc2c1,BRD-K68553471,antihypertensive
9.161886,7.5239005,797,COc1ccc(cc1F)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)F,BRD-K68558722,c1ccc(-c2ccnn2-c2ccccc2)cc1,BRD-K68558722,cyclooxygenase inhibitor
3.466551,1.1749029,798,CC(=O)[C@H]1CC[C@H]2[C@@H]3C=CC4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]12C,BRD-K68620903,O=C1C=C2C=CC3C4CCCC4CCC3C2CC1,BRD-K68620903,progesterone receptor agonist
11.419038,3.8418853,799,COc1ccccc1N2CCN(CCCCN3C(=O)c4ccccc4C3=O)CC2,BRD-K69195780,O=C1c2ccccc2C(=O)N1CCCCN1CCN(c2ccccc2)CC1,BRD-K69195780,serotonin receptor agonist
9.206258,6.0413933,800,Cc1cc2nc3c(=O)[nH]c(=O)nc3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,BRD-K70246307,O=c1nc2[nH]c3ccccc3nc-2c(=O)[nH]1,BRD-K70246307,vitamin b
7.8475194,5.490072,801,CCCN(CCC)C1Cc2cc(OC)c(OC)cc2C1,BRD-K70281171,c1ccc2c(c1)CCC2,BRD-K70281171,dopamine receptor antagonist
12.795244,7.0247827,802,CN(C)CCC[C@]1(OCc2cc(C#N)ccc21)c3ccc(F)cc3,BRD-K70301876,c1ccc(C2OCc3ccccc32)cc1,BRD-K70301876,selective serotonin reuptake inhibitor (ssri)
12.70551,7.3857026,803,OCCN1CCN(CC/C=C\\2/c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1,BRD-K70487031,C(CCN1CCNCC1)=C1c2ccccc2Sc2ccccc21,BRD-K70487031,dopamine receptor antagonist
11.787406,7.0866356,804,Clc1cccc(c1)N2CCN(CCCn3nc4ccccn4c3=O)CC2,BRD-K70778732,O=c1n(CCCN2CCN(c3ccccc3)CC2)nc2ccccn12,BRD-K70778732,adrenergic receptor antagonist|serotonin receptor antagonist|serotonin reuptake inhibitor
4.0384207,1.5754833,805,C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)N9C[C@@H](C)CC[C@H]19,BRD-K70881766,C1=C2CC(OC3OCCC(OC4CCCCO4)C3OC3CCCCO3)CCC2C2CCC3C(CC4C3CC3CCCCN34)C2C1,BRD-K70881766,acetylcholinesterase inhibitor
9.256706,8.234703,806,Nc1ccc(cc1)S(=O)(=O)Nc2cnc3ccccc3n2,BRD-K71133585,O=S(=O)(Nc1cnc2ccccc2n1)c1ccccc1,BRD-K71133585,vitamin k antagonist
11.079069,5.506325,807,CC(C)n1cnc2c(NCc3ccccc3)nc(NCCO)nc12,BRD-K71726959,c1ccc(CNc2ncnc3[nH]cnc23)cc1,BRD-K71726959,cdk inhibitor
10.660322,4.900787,808,CC(C)c1cnc(NC(=O)Cc2ccccc2)s1,BRD-K71799778,O=C(Cc1ccccc1)Nc1nccs1,BRD-K71799778,cdk inhibitor
10.583081,6.0848775,809,NC(=O)N1c2ccccc2C=Cc3ccccc13,BRD-K71799949,C1=Cc2ccccc2Nc2ccccc21,BRD-K71799949,carboxamide antiepileptic
8.452316,6.6613936,810,COc1c(oc2cc3oc(=O)ccc3cc12)C(C)C,BRD-K72034655,O=c1ccc2cc3ccoc3cc2o1,BRD-K72034655,apoptosis inducer|antileukemic
11.892195,8.869893,811,CN1C[C@@H](C[C@H]2[C@H]1Cc3c[nH]c4cccc2c34)C(=O)N[C@]5(C)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C5=O,BRD-K72166146,O=C(NC1OC2C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O)C1CNC2Cc3c[nH]c4cccc(c34)C2C1,BRD-K72166146,serotonin receptor agonist
11.962251,5.5022087,812,CCCCOc1ccc(cc1)C(=O)CCN2CCCCC2,BRD-K72259270,O=C(CCN1CCCCC1)c1ccccc1,BRD-K72259270,sodium channel blocker
9.623709,6.410207,813,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,BRD-K72903603,O=c1ccn(C2CCCO2)c(=O)[nH]1,BRD-K72903603,reverse transcriptase inhibitor
10.570561,7.514907,814,C1CN2C[C@@H](N=C2S1)c3ccccc3,BRD-K73107279,c1ccc(C2CN3CCSC3=N2)cc1,BRD-K73107279,acetylcholine receptor agonist
10.009502,6.8252735,815,CC1=Nc2ccc(Cl)cc2S(=O)(=O)N1,BRD-K73109821,O=S1(=O)NC=Nc2ccccc21,BRD-K73109821,potassium channel activator
11.969007,4.9825635,816,CCCCc1cc2ccccc2c(OCCN(C)C)n1,BRD-K73391359,c1ccc2cnccc2c1,BRD-K73391359,local anesthetic
3.1456652,1.0426476,817,C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]2CC[C@@H]1C(=O)CO,BRD-K73589401,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K73589401,mineralocorticoid receptor agonist
11.8669815,3.6906612,818,CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC,BRD-K73642618,c1ccccc1,BRD-K73642618,dopamine receptor antagonist
9.939881,4.8792915,819,CN(C)c1cccc(c1)C(=O)Nc2ccc(C)c(NC(=O)c3ccc(O)cc3)c2,BRD-K73789395,O=C(Nc1cccc(NC(=O)c2ccccc2)c1)c1ccccc1,BRD-K73789395,raf inhibitor
10.837369,5.1723604,820,CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)c4ccccc4C(=O)O)c5nc6ccccc6n5C,BRD-K73999723,c1ccc(-c2ccc(Cn3cnc4ccc(-c5nc6ccccc6[nH]5)cc43)cc2)cc1,BRD-K73999723,angiotensin receptor antagonist
11.220568,6.567535,821,CN(C/C=C/c1ccccc1)Cc2cccc3ccccc23,BRD-K74141488,C(=Cc1ccccc1)CNCc1cccc2ccccc12,BRD-K74141488,fungal squalene epoxidase inhibitor
8.456274,5.6563735,822,COc1ccc(/C=C/C(=O)CC(=O)\\C=C\\c2cccc(O)c2OC)cc1O,BRD-K74148702,O=C(C=Cc1ccccc1)CC(=O)C=Cc1ccccc1,BRD-K74148702,cyclooxygenase inhibitor
11.877432,8.893626,823,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]7CCCN7C1=O)C(C)C,BRD-K74212935,O=C(NC1OC2C3CCCN3C(=O)CN2C1=O)C1C=C2c3cccc4[nH]cc(c34)CC2NC1,BRD-K74212935,dopamine agonist
9.202249,4.7675147,824,CCCc1c(O)c(ccc1OCCCCc2nnn[nH]2)C(=O)C,BRD-K74765201,c1ccc(OCCCCc2nnn[nH]2)cc1,BRD-K74765201,leukotriene receptor antagonist
9.323823,6.9623137,825,CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(=O)(=O)N,BRD-K74913225,O=S1(=O)NCCc2ccsc21,BRD-K74913225,carbonic anhydrase inhibitor
11.601661,4.077653,826,CCN(CC)CCNC(=O)c1ccc(N)cc1,BRD-K75089421,c1ccccc1,BRD-K75089421,sodium channel blocker
8.359159,3.5671566,827,CC(=CCC/C(=C/CC/C(=C/CC/C(=C/CSC[C@H](NC(=O)C)C(=O)O)/C)/C)/C)C,BRD-K75181824,,BRD-K75181824,inhibitor of methyl esterification of geranylgeranylated proteins
10.070135,7.5501018,828,Nc1nc2CCN(CC=C)CCc2s1,BRD-K75615183,c1nc2c(s1)CCNCC2,BRD-K75615183,adrenergic receptor agonist
11.908975,3.6806655,829,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,BRD-K75641298,c1ccccc1,BRD-K75641298,dopamine receptor antagonist|serotonin receptor antagonist
11.384642,7.274376,830,Clc1cccc(c1)N2CCNCC2,BRD-K75844781,c1ccc(N2CCNCC2)cc1,BRD-K75844781,serotonin receptor agonist
12.2081995,7.4327884,831,CN1CCC(=C2c3ccsc3CCc4ccccc24)CC1,BRD-K75958195,c1ccc2c(c1)CCc1sccc1C2=C1CCNCC1,BRD-K75958195,serotonin receptor antagonist
7.014068,5.9738603,832,CN1CCc2cccc-3c2[C@H]1Cc4ccc(O)c(O)c43,BRD-K76022557,c1ccc2c(c1)CC1NCCc3cccc-2c31,BRD-K76022557,dopamine receptor agonist
7.8734922,5.422489,833,COc1cc2ncc(nc2cc1OC)c3ccccc3,BRD-K76064317,c1ccc(-c2cnc3ccccc3n2)cc1,BRD-K76064317,flt3 inhibitor
10.368752,5.9571877,834,CCCCc1nc(Cl)c(CO)n1Cc2ccc(cc2)c3ccccc3c4nnn[nH]4,BRD-K76205745,c1ccc(-c2nnn[nH]2)c(-c2ccc(Cn3ccnc3)cc2)c1,BRD-K76205745,angiotensin receptor antagonist
9.9404545,4.0216403,835,CCCCCCCCCCCCCC(=O)N[C@H](C)[C@@H](O)c1ccccc1,BRD-K76274772,c1ccccc1,BRD-K76274772,ceramidase inhibitor
10.573836,7.2680187,836,Nc1ccc(/N=N/c2ccccc2)c(N)n1,BRD-K76304753,c1ccc(N=Nc2cccnc2)cc1,BRD-K76304753,local anesthetic
9.640471,5.733823,837,C/C(=C\\C=C\\C(=C/C(=O)O)\\C)/C=C/C1=C(C)CCCC1(C)C,BRD-K76723084,C1=CCCCC1,BRD-K76723084,retinoid receptor agonist
9.318285,6.96312,838,Oc1ccc(NC2=C(C(=O)NC2=O)c3ccccc3[N+](=O)[O-])cc1Cl,BRD-K76805682,O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1,BRD-K76805682,glycogen synthase kinase inhibitor
11.572203,8.429718,839,CO[C@@]12C[C@@H](COC(=O)c3cncc(Br)c3)CN(C)[C@@H]2Cc4cn(C)c5cccc1c45,BRD-K76810206,O=C(OCC1CNC2Cc3c[nH]c4cccc(c34)C2C1)c1cccnc1,BRD-K76810206,adrenergic receptor antagonist
10.255619,7.5096607,840,CN(CS(=O)(=O)O)c1c(C)n(C)n(c2ccccc2)c1=O,BRD-K76812510,O=c1cc[nH]n1-c1ccccc1,BRD-K76812510,cyclooxygenase inhibitor|opioid receptor agonist
9.773513,7.441248,841,[O-][N+](=O)c1ccc(/C=N/N2CC(=O)NC2=O)o1,BRD-K76927775,O=C1CN(N=Cc2ccco2)C(=O)N1,BRD-K76927775,dna inhibitor
1.3546852,0.56246054,842,C[C@@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]2C[C@@H](O)[C@]1(O)C(=O)CO,BRD-K77554836,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K77554836,glucocorticoid receptor agonist
11.18274,6.793818,843,C(C1=NCCN1)c2cccc3ccccc23,BRD-K77641333,c1ccc2c(CC3=NCCN3)cccc2c1,BRD-K77641333,adrenergic receptor agonist
10.546403,6.88091,844,c1nc(cs1)c2nc3ccccc3[nH]2,BRD-K77695569,c1ccc2[nH]c(-c3cscn3)nc2c1,BRD-K77695569,angiogenesis inhibitor
11.178006,6.9417872,845,COc1nc(C)nc(Cl)c1NC2=NCCN2,BRD-K77771411,c1ncc(NC2=NCCN2)cn1,BRD-K77771411,imidazoline receptor agonist
11.238622,7.5003033,846,C1CN(CCN1)c2ccc3ccccc3n2,BRD-K77925998,c1ccc2nc(N3CCNCC3)ccc2c1,BRD-K77925998,serotonin receptor agonist
12.708428,5.957543,847,Fc1ccc(cc1)C(CCCN2CCC3(CC2)N(CNC3=O)c4ccccc4)c5ccc(F)cc5,BRD-K77947974,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccccc1)c1ccccc1)CC2,BRD-K77947974,dopamine receptor antagonist
7.1910934,4.4684577,848,COC(=O)Nc1nc2ccc(cc2[nH]1)C(=O)c3ccccc3,BRD-K77987382,O=C(c1ccccc1)c1ccc2nc[nH]c2c1,BRD-K77987382,acetylcholinesterase inhibitor|microtubule inhibitor|tubulin inhibitor
10.879302,5.4059,849,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl,BRD-K78010432,c1ccc(NCc2ccco2)cc1,BRD-K78010432,diuretic
7.939629,9.416657,850,CCn1cc(C(=O)O)c(=O)c2cc(F)c(nc12)N3CCNCC3,BRD-K78113049,O=c1cc[nH]c2nc(N3CCNCC3)ccc12,BRD-K78113049,topoisomerase inhibitor
8.605505,3.351576,851,CCCCC/C=C\\C/C=C\\C/C=C\\CCCCCCC(=O)NCCO,BRD-K78280988,,BRD-K78280988,cannabinoid receptor agonist|potassium channel blocker|trpv agonist
8.44022,6.361269,852,COc1ccc2ccc(=O)oc2c1CC=C(C)C,BRD-K78294846,O=c1ccc2ccccc2o1,BRD-K78294846,calcium channel blocker
10.530514,9.283449,853,CO/N=C(\\C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)COC(=O)C)/c3csc(N)n3,BRD-K78364995,N=C(C(=O)NC1C(=O)N2C=CCSC12)c1cscn1,BRD-K78364995,bacterial cell wall synthesis inhibitor
9.941323,4.8400583,854,CCCC[C@@H](C)/C=C(\\C)/C=C(\\C)/C(=O)NC1=C[C@@](O)(\\C=C\\C=C\\C=C\\C(=O)NC2C(=O)CCC2=O)[C@@H]3O[C@@H]3C1=O,BRD-K78599730,O=C(C=CC=CC=CC1C=CC(=O)C2OC12)NC1C(=O)CCC1=O,BRD-K78599730,farnesyltransferase inhibitor|nfkb pathway inhibitor|ras farnesyltransferase inhibitor
12.622659,5.7435136,855,OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Br)cc3,BRD-K78643075,O=C(CCCN1CCC(c2ccccc2)CC1)c1ccccc1,BRD-K78643075,dopamine receptor antagonist
10.112558,4.702845,856,Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F,BRD-K78692225,O=C(Nc1ccccc1)c1cnoc1,BRD-K78692225,dihydroorotate dehydrogenase inhibitor|pdgfr tyrosine kinase receptor inhibitor
10.27804,5.655606,857,CCCCC1(COC(=O)CCC(=O)O)C(=O)N(N(C1=O)c2ccccc2)c3ccccc3,BRD-K78815826,O=C1CC(=O)N(c2ccccc2)N1c1ccccc1,BRD-K78815826,cyclooxygenase inhibitor
9.262235,6.478759,858,C[C@H]1[C@H]2[C@H](OC1=O)[C@@H]3C(=CC(=O)C3=C(C)C[C@@H]2O)C,BRD-K78838262,O=C1CC2CCC=C3C(=O)C=CC3C2O1,BRD-K78838262,hypolipidemic
10.537872,5.302951,859,COC(=O)c1c(C)[nH]c(C)c1C(=O)c2ccccc2Cc3ccccc3,BRD-K78959463,O=C(c1cc[nH]c1)c1ccccc1Cc1ccccc1,BRD-K78959463,calcium channel activator
9.806446,7.392417,860,NC(=O)N/N=C/c1ccc(o1)[N+](=O)[O-],BRD-K79092138,c1ccoc1,BRD-K79092138,poxb inhibitor|bacterial dna inhibitor
7.206931,4.475041,861,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,BRD-K79131256,c1ccc2[nH]cnc2c1,BRD-K79131256,tubulin polymerization inhibitor
12.62671,5.8173275,862,Fc1ccc(cc1)C(=O)CCCN2CCC(CC2)n3c(=O)[nH]c4ccccc34,BRD-K79425933,O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccccc1,BRD-K79425933,dopamine receptor antagonist
8.424879,3.4736834,863,CC(=CCC/C(=C/CC/C(=C/CSC[C@H](NC(=O)C)C(=O)O)/C)/C)C,BRD-K79437791,,BRD-K79437791,inhibitor of methylation of endogenous isoprenylated proteins
11.976622,7.0864987,864,CN1CCN(CC1)C(c2ccccc2)c3ccccc3,BRD-K79501723,c1ccc(C(c2ccccc2)N2CCNCC2)cc1,BRD-K79501723,histamine receptor modulator
9.827372,4.129049,865,CS(=O)(=O)c1ccc(cc1)[C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl,BRD-K79711234,c1ccccc1,BRD-K79711234,bacterial 50s ribosomal subunit inhibitor
9.43732,6.7390175,866,CCCc1nn(C)c2c(=O)[nH]c(nc12)c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4,BRD-K79759585,O=c1[nH]c(-c2cccc(S(=O)(=O)N3CCNCC3)c2)nc2cn[nH]c12,BRD-K79759585,phosphodiesterase inhibitor
3.961648,1.0701423,867,C[C@@]12CC[C@H]3[C@@H](CCC4=C3CCC(=O)C4)[C@@H]2CC[C@@]1(O)C#C,BRD-K80334323,O=C1CCC2=C(CCC3C2CCC2CCCC23)C1,BRD-K80334323,progestogen hormone
7.3775353,5.646799,868,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]4NCCc5cc(O)c(OC)cc45,BRD-K80348542,c1ccc2c(c1)CCNC2CC1CCN2CCc3ccccc3C2C1,BRD-K80348542,protein synthesis inhibitor
8.363964,6.569195,869,COc1c2ccoc2c(OC)c3oc(C)cc(=O)c13,BRD-K80353807,O=c1ccoc2cc3occc3cc12,BRD-K80353807,vasodilator
8.812945,8.023064,870,COc1ccc2c(c1)C(=O)N(CCc3ccc(cc3)S(=O)(=O)NC(=O)NC4CCCCC4)C(=O)C2(C)C,BRD-K80396088,O=C(NC1CCCCC1)NS(=O)(=O)c1ccc(CCN2C(=O)Cc3ccccc3C2=O)cc1,BRD-K80396088,sulfonylurea
8.652123,5.9258733,871,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,BRD-K80738081,C(=Cc1ccccc1)c1ccccc1,BRD-K80738081,cytochrome p450 inhibitor|sirt activator
8.786672,5.6343355,872,CC(=O)Oc1ccc(/C=C/c2cc(OC(=O)C)cc(OC(=O)C)c2)cc1,BRD-K80946661,C(=Cc1ccccc1)c1ccccc1,BRD-K80946661,p53 activator
12.370165,4.904576,873,COc1ccc(cc1)[C@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@H]2OC(=O)C,BRD-K81029756,O=C1CC(c2ccccc2)Sc2ccccc2N1,BRD-K81029756,l-type calcium channel blocker|calcium channel antagonist|calcium channel blocker
11.4616375,4.644419,874,CC(C)c1cc(OC(=O)C)c(C)cc1OCCN(C)C,BRD-K81144366,c1ccccc1,BRD-K81144366,adrenergic receptor antagonist
9.710103,7.3868637,875,[O-][N+](=O)c1ccc(cc1)c2ccc(/C=N/N3CC(=O)NC3=O)o2,BRD-K81272440,O=C1CN(N=Cc2ccc(-c3ccccc3)o2)C(=O)N1,BRD-K81272440,calcium channel blocker
10.632494,7.0814123,876,Nc1c2CCCCc2nc3ccccc13,BRD-K81473089,c1ccc2nc3c(cc2c1)CCCC3,BRD-K81473089,acetylcholinesterase inhibitor
1.5632572,0.60392326,877,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CCl,BRD-K81709173,O=C1C=C2CCC3C(CCC4C3CC3OCOC34)C2CC1,BRD-K81709173,glucocorticoid receptor agonist
4.355867,0.95535547,878,C[C@@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]2CCC1=O,BRD-K81839095,O=C1CCC2C1CCC1c3ccccc3CCC12,BRD-K81839095,estrogen receptor agonist
10.520145,6.634075,879,NNc1nncc2ccccc12,BRD-K82103381,c1ccc2cnncc2c1,BRD-K82103381,vasodilator
10.023447,5.999578,880,Oc1c(Cc2c(O)c3ccccc3oc2=O)c(=O)oc4ccccc14,BRD-K82236179,O=c1oc2ccccc2cc1Cc1cc2ccccc2oc1=O,BRD-K82236179,nadph inhibitor
9.503422,5.894111,881,CC(C)c1cccc(C(C)C)c1O,BRD-K82255054,c1ccccc1,BRD-K82255054,gaba receptor agonist
8.63326,6.0130053,882,COc1ccn(C)c(=O)c1C#N,BRD-K82561139,O=c1cccc[nH]1,BRD-K82561139,casein kinase inhibitor
10.630988,5.534684,883,Cc1ccc(cc1)C(=O)c2ccc(CC(=O)O)n2C,BRD-K82562631,O=C(c1ccccc1)c1ccc[nH]1,BRD-K82562631,cyclooxygenase inhibitor
8.572838,4.9531507,884,CCCN(CCC)CCc1ccc(O)c(O)c1,BRD-K82577285,c1ccccc1,BRD-K82577285,dopamine receptor agonist
12.110517,7.365632,885,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc4cccnc24)CC1,BRD-K82795137,c1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,BRD-K82795137,histamine receptor antagonist
10.578673,5.09935,886,CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(=O)O,BRD-K82846253,O=C(Cc1ccccc1)NCc1ccccc1N1CCCCC1,BRD-K82846253,insulin secretagogue
8.515207,3.2775686,887,CCCCC[C@H](O)/C=C/C1=C(C/C=C\\CCCC(=O)O)C(=O)CC1,BRD-K82865713,O=C1C=CCC1,BRD-K82865713,camp inhibitor
8.79344,6.150064,888,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,BRD-K83459933,O=C1C=CC2C3Cc4ccccc4C2(CCN3)C1,BRD-K83459933,angiogenesis inhibitor
11.602031,5.550966,889,CN(CC#C)Cc1ccccc1,BRD-K83597974,c1ccccc1,BRD-K83597974,monoamine oxidase inhibitor
10.017412,4.2064905,890,CN[C@@H](C)[C@@H](O)c1ccccc1,BRD-K84175871,c1ccccc1,BRD-K84175871,adrenergic receptor agonist
10.673919,8.085034,891,Oc1cc2[C@H](CNCCc2c(Cl)c1O)c3ccccc3,BRD-K84421793,c1ccc(C2CNCCc3ccccc32)cc1,BRD-K84421793,dopamine receptor agonist
4.0059147,1.7504383,892,C[C@@]12CC[C@H]3[C@@H](CC[C@]4(O)C[C@@H](O)CC[C@]34C=O)[C@@]2(O)CC[C@@H]1C5=CC(=O)OC5,BRD-K84595254,O=C1C=C(C2CCC3C2CCC2C4CCCCC4CCC23)CO1,BRD-K84595254,atpase inhibitor
7.715554,5.678424,893,COc1cc2CCn3c(c/c(=N\\c4c(C)cc(C)cc4C)/n(C)c3=O)-c2cc1OC,BRD-K84663978,O=c1[nH]c(=Nc2ccccc2)cc2n1CCc1ccccc1-2,BRD-K84663978,phosphodiesterase inhibitor|platelet aggregation inhibitor|potassium channel blocker
9.28222,6.3320346,894,CC[C@H]1[C@@H](Cc2cncn2C)COC1=O,BRD-K85090592,O=C1CC(Cc2cnc[nH]2)CO1,BRD-K85090592,acetylcholine receptor agonist
8.986431,7.876457,895,CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,BRD-K85119730,c1ccccc1,BRD-K85119730,atp channel blocker
11.006612,6.281856,896,CCCOC(=O)c1cc2c(cn1)[nH]c3ccccc32,BRD-K85242180,c1ccc2c(c1)[nH]c1cnccc12,BRD-K85242180,"indoleamine 2,3-dioxygenase inhibitor"
8.511585,6.2267375,897,CO[C@@H]1[C@@H](OC(=O)N)[C@@H](O)[C@H](Oc2ccc3c(O)c(NC(=O)c4ccc(O)c(CC=C(C)C)c4)c(=O)oc3c2C)OC1(C)C,BRD-K85307935,O=C(Nc1cc2ccc(OC3CCCCO3)cc2oc1=O)c1ccccc1,BRD-K85307935,bacterial dna gyrase inhibitor
10.150047,5.4714627,898,C[C@]1(Cc2cc(OCC(=O)O)c(Cl)c(Cl)c2C1=O)C3CCCC3,BRD-K85383046,O=C1c2ccccc2CC1C1CCCC1,BRD-K85383046,chloride channel blocker
2.567766,0.75810874,899,C[C@@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]2CC[C@]1(O)C(=O)CO,BRD-K85883481,O=C1C=CC2C(=C1)CCC1C3CCCC3CC(=O)C21,BRD-K85883481,glucocorticoid receptor agonist
10.954638,6.5033536,900,Cc1c2[nH]c3ccccc3c2c(C)c4cnccc14,BRD-K85985071,c1ccc2c(c1)[nH]c1cc3ccncc3cc12,BRD-K85985071,topoisomerase inhibitor
13.06875,4.0673113,901,CC(C)N1CCN(CC1)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c5ccc(Cl)cc5Cl)cc2,BRD-K86204871,c1ccc(C2(Cn3cncn3)OCC(COc3ccc(N4CCNCC4)cc3)O2)cc1,BRD-K86204871,sterol demethylase inhibitor
11.413977,5.4713078,902,C[C@H](Cc1ccccc1)N(C)CC#C,BRD-K86434416,c1ccccc1,BRD-K86434416,monoamine oxidase inhibitor
10.719212,10.088858,903,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C(=O)O)c4ccccc4)C(=O)C1=O,BRD-K86873305,O=C1NCCN(C(=O)NC(C(=O)NC2C(=O)N3CCSC23)c2ccccc2)C1=O,BRD-K86873305,bacterial cell wall synthesis inhibitor
11.777046,8.465483,904,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,BRD-K86882815,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K86882815,dopamine receptor agonist|prolactin inhibitor|prolactin secretion inhibitor
11.097083,5.6023355,905,NNCCc1ccccc1,BRD-K87024524,c1ccccc1,BRD-K87024524,monoamine oxidase inhibitor
9.227119,4.6557345,906,CCCCc1ccc(nc1)C(=O)O,BRD-K87049188,c1ccncc1,BRD-K87049188,chelating|dopamine beta hydroxylase inhibitor
9.807934,5.3442516,907,CCOC(=O)n1ccn(C)c1=S,BRD-K87156652,S=c1[nH]cc[nH]1,BRD-K87156652,antithyroid
9.508206,4.4779816,908,N[C@@H](Cc1ccc(cc1)N(CCCl)CCCl)C(=O)O,BRD-K87827419,c1ccccc1,BRD-K87827419,dna alkylating|dna inhibitor
10.148754,6.093262,909,NS(=O)(=O)c1cc(cc(N2CCCC2)c1Oc3ccccc3)C(=O)O,BRD-K87990216,c1ccc(Oc2ccccc2N2CCCC2)cc1,BRD-K87990216,glucocorticoid receptor agonist
8.395823,6.6754856,910,Oc1ccc2ccc(=O)oc2c1,BRD-K87991767,O=c1ccc2ccccc2o1,BRD-K87991767,carbonic anhydrase inhibitor|cyclooxygenase inhibitor
12.132133,7.376249,911,CN1CCC(=C2c3ccccc3Sc4ccccc24)CC1,BRD-K88090157,c1ccc2c(c1)Sc1ccccc1C2=C1CCNCC1,BRD-K88090157,antihistamine
10.35037,6.5240183,912,Cc1c(C(=O)c2cccc3ccccc23)c4cccc5OC[C@@H](CN6CCOCC6)n1c54,BRD-K88282786,O=C(c1cccc2ccccc12)c1cn2c3c(cccc13)OCC2CN1CCOCC1,BRD-K88282786,cannabinoid receptor agonist
7.638018,5.756047,913,COc1ccc(CN2CCNCC2)c(OC)c1OC,BRD-K88366685,c1ccc(CN2CCNCC2)cc1,BRD-K88366685,3-ketoacyl coa thiolase inhibitor
12.284062,4.805116,914,COc1ccc(CN(CCN(C)C)c2ncccn2)cc1,BRD-K88405679,c1ccc(CNc2ncccn2)cc1,BRD-K88405679,antihistamine
10.177135,6.455834,915,CCc1nc(N)nc(N)c1c2ccc(Cl)cc2,BRD-K88429204,c1ccc(-c2cncnc2)cc1,BRD-K88429204,dihydrofolate reductase inhibitor
10.193864,4.7963653,916,CC(C)NNC(=O)c1ccncc1,BRD-K88568253,c1ccncc1,BRD-K88568253,monoamine oxidase inhibitor
8.862907,5.588798,917,COc1ccc(cc1)C(=O)N2CCCC2=O,BRD-K88611939,O=C1CCCN1C(=O)c1ccccc1,BRD-K88611939,glutamate receptor agonist
11.2086935,6.3572826,918,CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,BRD-K88743730,c1ccc2[nH]ccc2c1,BRD-K88743730,serotonin receptor partial agonist
10.356821,6.0655336,919,N#Cc1ccc(cc1)C(c2ccc(C#N)cc2)n3cncn3,BRD-K88789588,c1ccc(C(c2ccccc2)n2cncn2)cc1,BRD-K88789588,aromatase inhibitor
10.7310505,7.5013776,920,N[C@H]1C[C@@H]1c2ccccc2,BRD-K88809146,c1ccc(C2CC2)cc1,BRD-K88809146,monoamine oxidase inhibitor
8.566909,5.2838635,921,CCCCCc1c(C(=O)O)c(O)cc2OC(=O)c3c(cc(OC)cc3Oc12)C(=O)CCCC,BRD-K88849294,O=C1Oc2ccccc2Oc2ccccc21,BRD-K88849294,tyrosine phosphatase inhibitor
11.787769,8.60979,922,CCN(CC)C(=O)N[C@H]1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,BRD-K88871508,C1=C2c3cccc4[nH]cc(c34)CC2NCC1,BRD-K88871508,dopamine receptor agonist
10.712065,10.101424,923,CC1(C)S[C@@H]2[C@H](NC(=O)C3(N)CCCCC3)C(=O)N2[C@H]1C(=O)O,BRD-K89046952,O=C(NC1C(=O)N2CCSC12)C1CCCCC1,BRD-K89046952,bacterial cell wall synthesis inhibitor
11.466103,5.0937543,924,CCN(CCCc1ccccc1)CCCc2ccccc2,BRD-K89055274,c1ccc(CCCNCCCc2ccccc2)cc1,BRD-K89055274,muscle relaxant
9.4097595,6.462598,925,CCS(=O)(=O)CCn1c(C)ncc1[N+](=O)[O-],BRD-K89125793,c1c[nH]cn1,BRD-K89125793,antiprotozoal
8.38464,3.2137923,926,OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,BRD-K89210380,O=C1NC2CSCC2N1,BRD-K89210380,vitamin b
10.70803,5.054921,927,OC(=O)c1cc(ccc1NCCCc2ccccc2)[N+](=O)[O-],BRD-K89272762,c1ccc(CCCNc2ccccc2)cc1,BRD-K89272762,chloride channel blocker
11.871611,7.3459244,928,CN1CCN(CC(=O)N2c3ccccc3C(=O)Nc4cccnc24)CC1,BRD-K89375097,O=C1Nc2cccnc2N(C(=O)CN2CCNCC2)c2ccccc21,BRD-K89375097,acetylcholine receptor antagonist
10.754265,6.5174947,929,CC[C@]1(CCCN2CCc3c4[C@@H]21)C[C@@](O)(C(=O)OC)n4c5ccccc35,BRD-K89704198,c1ccc2c(c1)c1c3n2CCC2CCCN(CC1)C32,BRD-K89704198,adrenergic receptor antagonist
12.613739,7.4136653,930,CN1CCN(CCCN2c3ccccc3Sc4ccc(cc24)C(F)(F)F)CC1,BRD-K89732114,c1ccc2c(c1)Sc1ccccc1N2CCCN1CCNCC1,BRD-K89732114,dopamine receptor antagonist
3.4997354,1.190959,931,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@]54CCC(=O)O5)[C@H]13,BRD-K90027355,O=C1C=C2CCC3C(CCC4C3CCC43CCC(=O)O3)C2CC1,BRD-K90027355,mineralocorticoid receptor antagonist
11.240023,6.8248024,932,Cc1ccc(cc1)N(CC2=NCCN2)c3cccc(O)c3,BRD-K90333595,c1ccc(N(CC2=NCCN2)c2ccccc2)cc1,BRD-K90333595,adrenergic receptor antagonist
11.115215,5.961789,933,Clc1cccc(Nc2nnc(c3ccccc3)c4ccccc24)c1,BRD-K90524085,c1ccc(Nc2nnc(-c3ccccc3)c3ccccc23)cc1,BRD-K90524085,phosphodiesterase inhibitor|platelet aggregation inhibitor
10.599799,9.36679,934,CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)c3ccccc3)C2=O)C(=O)O,BRD-K90733503,O=C(Cc1ccccc1)NC1C(=O)N2C=CCSC12,BRD-K90733503,bacterial cell wall synthesis inhibitor
8.903534,3.8311725,935,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC(=O)[C@]12C)[C@@]4(C)CCC(=O)C[C@H]4CC3=O,BRD-K90976994,O=C1CCC2C(C1)CC(=O)C1C3CCCC3C(=O)CC21,BRD-K90976994,bile acid
12.789274,7.1894426,936,CNCCC=C1c2ccccc2CCc3ccccc13,BRD-K91263825,C=C1c2ccccc2CCc2ccccc21,BRD-K91263825,tricyclic antidepressant
7.161765,5.878458,937,COc1ccc2[C@@H](OC(=O)c2c1OC)[C@@H]3N(C)CCc4cc5OCOc5c(OC)c34,BRD-K91301684,O=C1OC(C2NCCc3cc4c(cc32)OCO4)c2ccccc21,BRD-K91301684,bradykinin receptor antagonist|tubulin inhibitor
11.524417,5.73192,938,CNCCc1ccccn1,BRD-K91315211,c1ccncc1,BRD-K91315211,histamine receptor agonist|histamine receptor antagonist
11.601477,8.462313,939,CN(C)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](Cc3cn(C)c4cccc2c34)N(C)C1,BRD-K91336023,c1cc2c3c(c[nH]c3c1)CC1NCCCC21,BRD-K91336023,dopamine receptor agonist
8.764139,5.5192657,940,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(=O)C)cc1,BRD-K91370081,c1ccc(CC2CCCN2)cc1,BRD-K91370081,dna synthesis inhibitor
10.5511675,6.048085,941,Cc1c(nn(c1c2ccc(I)cc2)c3ccc(Cl)cc3Cl)C(=O)NN4CCCCC4,BRD-K92000912,O=C(NN1CCCCC1)c1cc(-c2ccccc2)n(-c2ccccc2)n1,BRD-K92000912,cannabinoid receptor antagonist
10.383844,6.4422035,942,Nc1nc(N)c2nc(c(N)nc2n1)c3ccccc3,BRD-K92049597,c1ccc(-c2cnc3ncncc3n2)cc1,BRD-K92049597,sodium channel blocker
7.92462,6.8135514,943,COc1cc(O)c2c(=O)cc(oc2c1)c3ccc(OC)c(c3)c4c(O)cc(O)c5c(=O)cc(oc45)c6ccc(O)cc6,BRD-K92123432,O=c1cc(-c2cccc(-c3cccc4c(=O)cc(-c5ccccc5)oc34)c2)oc2ccccc12,BRD-K92123432,cyclooxygenase inhibitor
11.83468,7.5700836,944,CN1CCN(CC1)C2=Cc3ccccc3Oc4ccc(Cl)cc24,BRD-K92588747,C1=C(N2CCNCC2)c2ccccc2Oc2ccccc21,BRD-K92588747,dopamine receptor antagonist
8.082184,6.7066364,945,COc1ccccc1c2coc3cc(OC)c(OC)c(OC)c3c2=O,BRD-K92678294,O=c1c(-c2ccccc2)coc2ccccc12,BRD-K92678294,isoflavone
10.260332,5.338282,946,CCC[C@H](N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@@H]21)C(=O)O)C(=O)OCC,BRD-K92731339,C1CCC2NCCC2C1,BRD-K92731339,angiotensin converting enzyme inhibitor
9.9675665,6.406862,947,C[C@]1([C@H]2[C@H](C(=O)O)[C@]3(CC(=C)[C@@]4(O)C3)[C@@H](CC4)[C@]52OC1=O)[C@@H](O)C=C5,BRD-K92758126,C=C1CC23CC1CCC2C12C=CCC(C(=O)O1)C2C3,BRD-K92758126,nfkb pathway inhibitor
10.759408,4.635741,948,Cc1cccc(Nc2ccccc2C(=O)O)c1C,BRD-K92778217,c1ccc(Nc2ccccc2)cc1,BRD-K92778217,cyclooxygenase inhibitor
10.01982,4.376088,949,C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)CCl,BRD-K93080877,c1ccccc1,BRD-K93080877,tripeptidyl peptidase inhibitor
11.114778,7.2545123,950,Ic1cccc2c(cccc12)S(=O)(=O)N3CCCNCC3,BRD-K93201660,O=S(=O)(c1cccc2ccccc12)N1CCCNCC1,BRD-K93201660,myosin light chain kinase inhibitor
10.625592,4.896814,951,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc2ccccc2,BRD-K93258693,O=C(Nc1ccccc1)c1ccccc1,BRD-K93258693,ppar receptor antagonist
8.803025,3.8094103,952,COc1ccc(cc1)c2ccc(N)[n+](CCCC(=O)O)n2,BRD-K93280214,c1ccc(-c2ccc[nH+]n2)cc1,BRD-K93280214,gaba receptor antagonist
10.911859,5.3548064,953,Cc1cc(no1)C(=O)NNCc2ccccc2,BRD-K93332168,O=C(NNCc1ccccc1)c1ccon1,BRD-K93332168,monoamine oxidase inhibitor
10.63785,5.8913207,954,C[N+]1(C)CCC(=C(c2ccccc2)c3ccccc3)CC1,BRD-K93441486,c1ccc(C(=C2CC[NH2+]CC2)c2ccccc2)cc1,BRD-K93441486,acetylcholine receptor antagonist
11.660353,6.287884,955,O=C1CC2(CCCC2)CC(=O)N1CCCCN3CCN(CC3)c4ncccn4,BRD-K93461745,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,BRD-K93461745,serotonin receptor agonist
2.848979,0.90362716,956,C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]2CC[C@]1(O)C(=O)CO,BRD-K93568044,O=C1C=C2CCC3C4CCCC4CCC3C2CC1,BRD-K93568044,glucocorticoid receptor agonist
11.830195,4.5023894,957,CC/C(=C(\\c1ccccc1)/c2ccc(OCCN(C)C)cc2)/c3ccccc3,BRD-K93754473,C(=C(c1ccccc1)c1ccccc1)c1ccccc1,BRD-K93754473,estrogen receptor antagonist|selective estrogen receptor modulator (serm)
10.711337,7.5871835,958,CN1[C@@H](CCC1=O)c2cccnc2,BRD-K94144010,O=C1CCC(c2cccnc2)N1,BRD-K94144010,nicotine metabolite
9.180192,4.7012963,959,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(NCc4ccco4)ncnc23,BRD-K94325918,c1coc(CNc2ncnc3c2ncn3C2CCCO2)c1,BRD-K94325918,apoptosis stimulant
8.904929,5.3050704,960,COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(=O)N4CCOCC4)c2c1,BRD-K94379058,O=C(Cc1cn(C(=O)c2ccccc2)c2ccccc12)N1CCOCC1,BRD-K94379058,cannabinoid receptor inverse agonist
12.717152,5.930308,961,Fc1ccc(OCCCN2CCC3(CC2)N(CNC3=O)c4ccccc4)cc1,BRD-K94512704,O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccccc1)CC2,BRD-K94512704,dopamine receptor antagonist
8.280135,7.4283895,962,Oc1cc(O)c2C(=O)C[C@H](Oc2c1)c3ccccc3,BRD-K94689771,O=C1CC(c2ccccc2)Oc2ccccc21,BRD-K94689771,cytochrome p450 inhibitor
8.714967,6.9105425,963,OC(=O)c1cc(O)c2C(=O)c3c(O)cc(O)cc3C(=O)c2c1,BRD-K94841585,O=C1c2ccccc2C(=O)c2ccccc21,BRD-K94841585,laxative|free radical generator
11.215809,7.2986865,964,FC(F)(F)c1cccc(c1)N2CCNCC2,BRD-K94887716,c1ccc(N2CCNCC2)cc1,BRD-K94887716,serotonin receptor agonist
10.180608,5.6666727,965,CCCN(CCC)S(=O)(=O)c1ccc(cc1)C(=O)O,BRD-K95237249,c1ccccc1,BRD-K95237249,uricosuric blocker
9.048076,5.740676,966,C/C=C(/C(=C/C)/c1ccc(O)cc1)\\c2ccc(O)cc2,BRD-K95309561,C=C(C(=C)c1ccccc1)c1ccccc1,BRD-K95309561,estrogen receptor agonist
9.127152,6.0398297,967,CC(C)(C)c1cc(O)c(cc1O)C(C)(C)C,BRD-K95603879,c1ccccc1,BRD-K95603879,atpase inhibitor
9.27381,5.610559,968,CCN(CC)c1cc(C)nc2ncnn12,BRD-K95763993,c1cnc2ncnn2c1,BRD-K95763993,pdgfr tyrosine kinase receptor inhibitor
8.502809,3.3685086,969,CCCCCCCC/C=C\\C/C=C\\C/C=C\\CCCC(=O)O,BRD-K96144918,,BRD-K96144918,kpl-1 tumor suppressor
10.710413,5.678521,970,OC(=O)c1nn(Cc2ccc(Cl)c(Cl)c2)c3ccccc13,BRD-K96670504,c1ccc(Cn2ncc3ccccc32)cc1,BRD-K96670504,glucokinase inhibitor
10.838458,7.352988,971,OC(C1CCNCC1)(c2ccccc2)c3ccccc3,BRD-K97061094,c1ccc(C(c2ccccc2)C2CCNCC2)cc1,BRD-K97061094,histamine receptor antagonist
12.615958,5.8124647,972,Fc1ccc(cc1)C(=O)CCCN2CCC(=CC2)n3c(=O)[nH]c4ccccc34,BRD-K97158071,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccccc1,BRD-K97158071,dopamine receptor antagonist
11.223284,5.0767956,973,NC(=N)NC(=O)c1nc(Cl)c(N)nc1N,BRD-K97181089,c1cnccn1,BRD-K97181089,sodium channel blocker
12.756411,7.3336964,974,CN(C)S(=O)(=O)c1ccc2Sc3ccccc3/C(=C\\CCN4CCN(C)CC4)/c2c1,BRD-K97309399,C(CCN1CCNCC1)=C1c2ccccc2Sc2ccccc21,BRD-K97309399,dopamine receptor antagonist
8.095297,6.7716866,975,Oc1cc(O)c2c(=O)c(O)c(oc2c1)c3ccc(O)c(O)c3,BRD-K97399794,O=c1cc(-c2ccccc2)oc2ccccc12,BRD-K97399794,polar auxin transport inhibitor
11.900729,8.895704,976,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]6(O)[C@@H]7CCCN7C(=O)[C@H](Cc8ccccc8)N6C1=O,BRD-K97440753,O=C(NC1OC2C3CCCN3C(=O)C(Cc3ccccc3)N2C1=O)C1CNC2Cc3c[nH]c4cccc(c34)C2C1,BRD-K97440753,adrenergic receptor antagonist|prolactin inhibitor
9.315991,7.0514965,977,Nc1cc(C(=C(Cl)Cl)Cl)c(cc1S(=O)(=O)N)S(=O)(=O)N,BRD-K97521363,c1ccccc1,BRD-K97521363,glycolysis inhibitor
11.175475,6.34784,978,COc1ccc2[nH]cc(CCNC(=O)C)c2c1,BRD-K97530723,c1ccc2[nH]ccc2c1,BRD-K97530723,melatonin receptor agonist|nitric oxide synthase inhibitor
12.354029,4.875705,979,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1,BRD-K97564742,c1ccc(CNc2ccccn2)cc1,BRD-K97564742,histamine receptor antagonist
11.293626,5.1052656,980,N/C(=N\\C(=O)c1nc(Cl)c(N)nc1N)/NCc2ccccc2,BRD-K97688263,O=C(N=CNCc1ccccc1)c1cnccn1,BRD-K97688263,sodium channel blocker
8.98457,7.87425,981,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,BRD-K97746869,c1ccccc1,BRD-K97746869,atp channel blocker
9.193184,6.6473856,982,Cn1c(=O)n(C)c2nc[nH]c2c1=O,BRD-K97799481,O=c1[nH]c(=O)c2[nH]cnc2[nH]1,BRD-K97799481,adenosine receptor antagonist
2.4994924,0.76610976,983,C[C@@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]2CC[C@]1(O)C(=O)CO,BRD-K98039984,O=C1C=CC2C(=C1)CCC1C3CCCC3CCC21,BRD-K98039984,glucocorticoid receptor agonist
9.960036,6.898187,984,Clc1ccc2oc(=O)[nH]c2c1,BRD-K98174813,O=c1[nH]c2ccccc2o1,BRD-K98174813,bacterial 30s ribosomal subunit inhibitor
10.929601,7.190829,985,Clc1cccc(Cl)c1N=C2NCCN2,BRD-K98530306,c1ccc(N=C2NCCN2)cc1,BRD-K98530306,adrenergic receptor agonist
10.530769,4.9243817,986,OC(=O)c1cccnc1Nc2cccc(c2)C(F)(F)F,BRD-K98763141,c1ccc(Nc2ccccn2)cc1,BRD-K98763141,cyclooxygenase inhibitor
9.976771,5.304245,987,CCOC(=O)c1ncn-2c1CN(C)C(=O)c3cc(F)ccc32,BRD-K98769987,O=C1NCc2cncn2-c2ccccc21,BRD-K98769987,benzodiazepine receptor antagonist
8.951289,5.751044,988,COc1nc(NC(C)C)nc(NC(C)C)n1,BRD-K99029477,c1ncncn1,BRD-K99029477,photosynthesis inhibitor
10.601129,4.796032,989,NC(=O)OCC(COC(=O)N)c1ccccc1,BRD-K99107520,c1ccccc1,BRD-K99107520,glutamate receptor antagonist
11.768509,3.8651936,990,CCCCOc1cc(C(=O)NCCN(CC)CC)c2ccccc2n1,BRD-K99121711,c1ccc2ncccc2c1,BRD-K99121711,sodium channel blocker
8.071472,5.626589,991,COC1=C[C@H]2[C@H](C3=C2c4c(OC)c(OC)c(OC)cc4CC[C@@H]3NC(=O)C)C1=O,BRD-K99411983,O=C1C=CC2C3=C(CCCc4ccccc43)C12,BRD-K99411983,"colchicine isomer, non-binder of microtubules"
10.527211,9.315742,992,CO/N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)O)COC(=O)C)\\c3csc(N)n3,BRD-K99586414,N=C(C(=O)NC1C(=O)N2C=CCSC12)c1cscn1,BRD-K99586414,bacterial cell wall synthesis inhibitor
9.756383,6.2824035,993,Oc1c(Cl)cc(Cl)c(Cl)c1Cc2c(O)c(Cl)cc(Cl)c2Cl,BRD-K99792991,c1ccc(Cc2ccccc2)cc1,BRD-K99792991,potassium channel activator
8.902547,5.06314,994,CCCCCCc1ccc(O)cc1O,BRD-K99946902,c1ccccc1,BRD-K99946902,local anesthetic
